carmustine and melphalan

carmustine has been researched along with melphalan in 698 studies

Research

Studies (698)

TimeframeStudies, this research(%)All Research%
pre-1990175 (25.07)18.7374
1990's179 (25.64)18.2507
2000's183 (26.22)29.6817
2010's139 (19.91)24.3611
2020's22 (3.15)2.80

Authors

AuthorsStudies
Barrows, LR; Ireland, CM; Kokoshka, JM1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Geisert, EE; Hong, SS; Kang, GS; Kirichenko, OV; Li, W; Miller, DD; Mohler, ML; Patil, R; Rakov, IM1
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J1
Lombardo, F; Obach, RS; Waters, NJ1
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM1
Benfenati, E; Raska, I; Toropov, AA; Toropova, AP1
García-Mera, X; González-Díaz, H; Prado-Prado, FJ1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Alberts, DS; Durie, BG; Hamburger, AW; Moon, TE; Salmon, SE; Soehnlen, B1
Barbatano, L; Bartolini, M; Castellani, R; Fremiotti, A; Salerno, L1
Bast, RC; Borsos, T; Greene, SL; Ohanian, SH; Rapp, HJ; Segerling, M; Zbar, B1
Carcassonne, Y; Foa, J1
Laster, WR; Schabel, FM; Trader, MW; Wheeler, GP; Witt, MH1
Buonanno, G; Cantore, N; Castaldo, C; Russolillo, S; Tortarolo, M1
McIntyre, OR1
Buonanno, G; Castaldo, C; Gonnella, F; Russolillo, S; Tortarolo, M; Valente, A1
Coleman, M; Cooper, MR; Cuttner, J; Harley, JB; Kochwa, S; McIntyre, OR; Pajak, TF1
Blom, J; Gailani, S; Holland, JF; Kyle, RA; McIntyre, OR; Pajak, TF; Seligman, BR1
Bailey, AJ; Bergsagel, DE; Langley, GR; MacDonald, RN; Miller, AB; White, DF1
Miller, S; Perrotta, AL1
Alexanian, R; Bonnet, J; Gehan, E; Haut, A; Salmon, S; Weick, J1
Case, DC; Clarkson, BD; Lee, DJ1
Solomon, A1
Durie, BG; Hamburger, AW; Salmon, SE1
Klahr, C; Presant, CA1
Emmerich, B; Maurer, R; Rastetter, J; Schmidt, G1
Hunter, JA1
Elveback, LR; Kyle, RA1
Bergsagel, DE2
Bergsagel, DE; Pruzanski, W1
Capra, JD; McLaughlin, CL; Solomon, A1
Obrecht, JP1
Brockman, RW; Laster, WR; Schabel, FM; Shaddix, SC; Trader, MW1
Goldenberg, GJ1
Adamson, RH; Sieber, SM1
Durant, JR; Ghanta, V; Hiramoto, R1
Chapman, C; Dunn, J; Kelly, K; MacLennan, IC1
Adam, M; Baruchel, A; Brice, P; Dombret, H; Gisselbrecht, C; Lepage, E; Marolleau, JP; Miclea, JM; Sitthy, X1
Egerer, G; Ehrhardt, R; Haas, R; Hohaus, S; Hunstein, W; Witt, B1
Clarke, M; Dunn, J; Gray, R; MacLennan, I1
Arya, R; Brito-Babapulle, F; Griffiths, T; Mufti, GJ; Pagliuca, A1
Guenthner, TM; Jevtović-Todorović, V1
Hernando, JC; Pais, JR; Pascual, J; Pérez Vaquero, MA; Sureda, A1
Alcalá, A; Bladé, J; Fontanillas, M; García-Conde, J; Hernández, JM; Martínez, M; Moro, J; Ortega, F; San Miguel, J; Sanz-Sanz, MA1
DeGregorio, MW; Rappeport, JM; Smith, BR; Wiebe, VJ1
Janmohammed, RM; Leyland, MJ; Long, SG; Macdonald, DF; Milligan, DW; Smith, AG1
Gore, M; Harding, M; Mansi, J; Meldrum, M; Milan, S; Perren, T; Selby, P; Treleavan, J; Viner, C; Zulian, G1
Gola, A; Kuliczkowski, K; Sedek, K1
Ara, G; Coleman, CN; Herman, TS; Holden, SA; Teicher, BA1
Azais, I; Bernard, JF; Doyen, C; Grosbois, B; Laporte, JP; Le Loet, X; Menard, JF; Michaux, JL; Monconduit, M; Pollet, JP1
Ara, G; Ha, CS; Herman, TS; Holden, SA; Northey, D; Teicher, BA1
Blair, S; Cervi, P; Chopra, R; Goldstone, AH; Kinsey, S; Linch, DC; McMillan, AK; Moir, D; Patterson, KG; Richards, JD1
Douay, L; Eugene-Jolchine, I; Fouillard, L; Gorin, NC; Isnard, F; Laporte, JP; Najman, A; Stachowiak, J1
Berger, NA; Chatterjee, S; Cheng, MF2
Bastion, Y; Coiffier, B; Tigaud, JD1
Herman, TS; Hopkins, RE; Menon, K; Teicher, BA1
Matsuzaki, M; Ono, K; Sano, M; Shimamoto, Y; Yamaguchi, M1
Brito Barroso, ML; González Brito, G; Hernández Nieto, L; Marsá Vila, L; Raya Sánchez, JM1
Kraj, M; Maj, S; Mendek-Czajkowska, E; Pogłód, R; Rostkowska, J; Sabliński, J1
Dmoszyńska, A; Kowalewski, J; Kraj, M; Kurowska, M; Maj, S; Mendek-Czajkowska, E; Pogłód, R; Rostkowska, J; Sokołowska, B; Sokołowska, U1
Bubley, G; Coleman, CN; Eder, JP; Frei, E; Herman, TS; Holden, SA; Tanaka, J; Teicher, BA1
Anderson, WK; Elliott, WL; Fry, DW; Hawkins, PA; Hook, KE; Leopold, WR; Nelson, JM1
Golenkov, AK1
Cheung, NK; Gulati, SC; Kushner, BH; LaQuaglia, M; Mandell, LR; O'Reilly, RJ1
Boyd, MA; Case, DC; Ervin, TJ; Redfield, DL1
Cuttner, J1
Erbersdobler, A; Gassmann, W; Glass, B; Löffler, H; Mueller-Ruchholtz, W; Schmitz, N; Uharek, L; Wottge, HU1
Baggio, G; Bolzonella, S; Casara, D; Chiarion-Sileni, V; De Besi, P; Favaretto, A; Frizzarin, M; Paccagnella, A; Salvagno, L; Soesan, M1
Barlogie, B; Beckord, J; Crowley, J; Pugh, RP; Salmon, SE1
Andriani, A; Avvisati, G; Barbui, T; Boccadoro, M; Cantonetti, M; Carotenuto, M; Comotti, B; Dammacco, F; Marmont, F; Tribalto, M1
Benz, CC; Ford, JM; Hait, WN; Matlin, SA1
Goldstone, A; McMillan, A1
Dezube, B; Frei, E; Herman, TS; Holden, SA; Tanaka, J; Teicher, BA1
Guenthner, TM; Jevtorić-Todorović, V; Jevtović-Todorović, V1
Bartels, H; Bartl, R; Braun, HJ; Coldewey, R; Deicher, H; Fischer, JT; Gramatzki, M; Leo, R; Peest, D; von Broen, IM1
Antman, K; Ayash, L; Begg, C; Critchlow, J; Eder, JP; Elias, A; Schryber, SM; Shea, TC; Teicher, BA; Weissman, L1
Bonnet, JD; Cheson, B; Coltman, CA; Crowley, J; Finley, P; Hutchins, LF; Milder, MS; Saeed, S; Salmon, SE; Tesh, D1
Biron, P; Cahn, JY; Colombat, P; Gorin, NC; Herve, P; Lamagnere, JP; Laporte, JP; Philip, T1
Hellquist, L; Hjorth, M; Holmberg, E; Magnusson, B; Rödjer, S; Westin, J1
Cammerer, U; Coldewey, R; Deicher, H; Hein, R; Hoffmann, L; Konyar, H; Kreuser, ED; Peest, D; Selbach, J; von Broen, IM1
Alcalá, A; Alonso, C; Besses, C; Bladé, J; García-Conde, J; Maldonado, J; Moro, MJ; San Miguel, J; Sanz Sanz, MA; Zubizarreta, A1
Factor, SM; Reed, LJ; van Hoeven, KH1
Avvisati, G; Boccadoro, M; Cantonetti, M; Cavo-Comotti, BM; Frieri, R; Gallamini, A; Gallone, G; Lauta, VM; Liberati, M; Marmont, F1
Alberts, DS; Asbury, RF; Boros, L; Goodman, TL; Hickox, DE; Peng, YM; Penn, TE1
Brandwein, JM; Callum, J; Keating, A; Scott, JG; Sutcliffe, SB1
Greenberg, CS; Hannun, YA; Panella, TJ; Peters, W; White, JG1
Ito, T; Saito, Y; Uzuka, Y1
Douay, L; Fouillard, L; Gorin, NC; Isnard, F; Laporte, JP; Najman, A1
Beschorner, J; Bitran, JD; Golick, J; Kaminer, LS; O'Brien, S; Williams, SF1
Benbunan, M; Brouet, JC; Castaigne, S; Cosset, JM; Fermand, JP; Gerota, J; Lévy, Y; Seligmann, M1
Devereaux, S; Goldstone, AH; Gribben, JG; Linch, DC; McMillan, A; Patterson, K1
Forgeson, G; Gore, M; McElwain, TJ; Milan, S; Nandi, A; Perren, TJ; Selby, P; Zulian, GB1
Bitran, JD; Williams, SF1
Ahre, A; Björeman, M; Björkholm, M; Brenning, G; Gahrton, G; Gyllenhammar, H; Järnmark, M; Johansson, B; Juliusson, G; Osterborg, A1
Havemann, K; Koeppler, H; Pflueger, KH; Seitz, R1
Barbui, T; Boccadoro, M; Comotti, B; Dammacco, F; Gallamini, A; Marmont, F; Neretto, G; Petrucci, MT; Pileri, A; Resegotti, L1
García Laraña, J; Odriozola, J; Pérez de Oteyza, J; Sureda, A1
al-Achi, A; Henner, WD; Holden, SA; Rosbe, KW; Shea, TC; Teicher, BA; Wang, YY1
Arriagada, R; Baume, D; Beaujean, F; Gouyette, A; Hayat, M; Le Chevalier, T; Ostronoff, M; Pico, JL; Rebattu, P1
Peters, W; Souhami, R1
Blaise, D; Gaspard, MH; Gastaut, JA; Maraninchi, D; Michel, G; Novakovitch, G; Rossi, JF; Stoppa, AM; Tubiana, N; Weiller, PJ1
Brunner, K; Coleman, M; Cooper, MR; Cornwell, GG; Glowienka, LP; Henderson, E; Kochwa, S; McIntyre, OR; Pajak, TF; Rafla, S1
Boyd, M; Case, DC; Dorsk, BM; Hayes, DM1
Gola, A; Niewolna, M; Weryńska, B1
Ishii, H1
Ben-Efraim, S; Berko, R; Bocian, RC; Colvin, M; Dray, S; Seissman, K1
Beaujean, F; Behard, C; Benhamou, E; Deville, A; Flamant, F; Hartmann, O; Kalifa, C; Lejars, O; Patte, C; Thyss, A2
Bury, J; Fillet, G; Salmon, J1
Antman, KH; Eder, JP; Elias, A; Frei, E; Henner, WD; Peters, WP; Schnipper, LE; Schoenfeld, DA; Schryber, S; Shea, TC1
Huijgens, PC; Ossenkoppele, GJ; Reijneke, RM; Thomas, LL; van der Lelie, J; Wijngaarden, MJ1
Cavo, M; Galieni, P; Gobbi, M; Tassi, C; Tura, S1
Deicher, H; Glück, S; Peest, D; Schedel, I; Schmoll, HJ; Schumacher, K1
Anderson, CC; Cawley, JC; Goldstone, AH; Harper, PG; Jelliffe, AM; Jones, M; Linch, DC; Machin, SJ; McLennan, KA; Souhami, RL1
Appelbaum, FR; Buckner, CD1
Antman, K; Bast, R; Eder, JP; Finberg, R; Gargone, B; Henner, WD; Peters, WP; Schoenfeld, D; Schryber, S; Wilmore, D1
Baccarani, M; Cavo, M; Gobbi, M; Ricci, P; Tura, S1
Bartolucci, AA; Cohen, HJ; Forman, WB; Silberman, HR1
Gazová, S; Hrubisko, M; Prümmerová, J; Sakalová, A; Steruská, M1
Bonnet, J; Carter, S; Costanzi, JJ; Dabich, L; Dixon, DO; Durie, BG; Files, JC; Rivkin, S; Salmon, SE; Stephens, R1
Anderson, K; Coleman, M; Cooper, MR; Kochwa, S; Kyle, RA; McIntyre, OR; Prager, D; Propert, KJ; Rafla, S; Zimmer, B1
Boll, J; Deicher, H; Essers, U; Gamm, H; Glück, S; Görg, K; Gramatzki, M; Peest, D; Schedel, I; Schmoll, HJ1
Glode, LM; Morton, N; Mughal, TI; Robinson, WA; Thomas, MR1
Aisner, J; Tait, N; Tchekmedyian, NS; Van Echo, D1
Bjark, P; Bondevik, A; Bull, O; Dehli, O; Kildahl-Andersen, O; Kvambe, V; Lamvik, J; Nordahl, E; Ytrehus, K1
Andersen, J; Antman, K; Eder, JP; Elias, A; Finberg, R; Henner, WD; Peters, WP; Schryber, S; Shea, T; Wilmore, D1
Frei, E; Griswold, DP; Laster, WR; Peters, WP; Trader, MW; Wolpert, MK1
Del Potro, E; Diaz-Mediavilla, J; Krsnik, I; Peñalver, MA1
Milas, L; Tofilon, PJ; Vines, CM1
Rosin, A; Sonnenblick, M; van Dijk, JM; Weissberg, N1
Ho, AD; Hunstein, W; Keilholz, U; Theml, H; Wittkamp, S1
Becherer, C; Busch, FW; Ostendorf, P; Steinke, B; Waller, HD1
Blanco, L; Montalbán, C; Sabán, J; Serrano Ríos, M; Serrano, M; Sevilla, F; Zapatero, A1
Bove, L; Carroll, RJ; Case, DC; Dorsk, BM; Hayes, DM; Paul, SD; Sonneborn, HL1
Bosanquet, AG1
Bayle, C; Beaujean, F; Benhamou, E; Hartmann, O; Kalifa, C; Lemerle, J1
Ozhiganov, EL; Platinskiĭ, LV; Sokolova, VD1
Bartolucci, A; Cohen, HJ1
Amadori, S; Boccadoro, M; Cantonetti, M; Centurioni, R; Dammacco, F; Franchi, A; Papa, G; Pileri, A; Tribalto, M; Vacca, A1
Clausen, NA; Drivsholm, A; Hansen, OP; Laursen, B1
Chen, XW; Lin, TB; Lu, SF1
Gouyette, A; Hartmann, O; Pico, JL1
Adams, K; Peacock, JH; Stephens, TC1
Cornwell, GG; Kyle, RA; Leone, L; McIntyre, OR; Pajak, TF1
Basic, I; Milas, L; Tofilon, PJ1
Valeriote, F; Vietti, T1
Bleehen, NM; Honess, DJ1
Case, DC; Fanning, JP; Porensky, RS1
Frei, E; Goldin, A; Schabel, FM1
Luce, JK1
Favre, E; Martz, G; Sonntag, R1
Carter, SK1
Azam, L; Delamore, IW2
Clarkson, BD; Krakoff, IH; Lee, BJ; Sahakian, G1
Collis, CH1
Salmon, SE1
Larson, A; Lindström, M; Pontén, J1
D'Incalci, M; Damia, G; Erba, E; Garattini, S; Morasca, L; Torti, L1
Alexanian, R; Dreicer, R1
Lohrmann, HP1
Knight, WA1
Gartenhaus, W; Jagathambal, K; Phillips, E; Rai, KR; Sawitsky, A1
Arrick, BA; Nathan, CF1
Klastersky, J; Sculier, JP1
Bunn, PA; Carney, DN; Cohen, MH; Eddy, JL; Ihde, DC; Minna, JD; Morstyn, G; Schechter, GP1
Cornbleet, MA; Leonard, RC; Smyth, JF1
Adelstein, DJ; Herzig, RH; Lazarus, HM; Smith, MC1
McLeod, BC; Sassetti, RJ; Viernes, AL1
Bartolucci, AA; Cohen, HJ; Silberman, HR; Tornyos, K1
Grussendorf, M; Ritz, E; Seelig, HP; Waldherr, R1
Cohen, GI; Greenberger, JS; Sakakeeny, MA1
Ducore, JM; Rosenstein, BS1
Case, DC3
Busch, FW; Ostendorf, P; Stapelfeld, S; Steinke, B; Waller, HD1
Bauer, K; Bettelheim, P; Gössinger, H; Hinterberger, W; Korninger, K; Lechner, K; Neumann, E; Niessner, H; Pabinger-Fasching, I1
Iwata, Y; Kageyama, S; Kamio, N; Karitani, Y; Kataoka, Y; Katayama, N; Kobayashi, T; Ohno, T; Ohota, C; Tanaka, I1
Blanco, L; García Laraña, J; Montalbán, C; Odriozola, J; Sevilla, F; Zapatero, A1
Bartolucci, A; Presant, CA1
Bolzonella, S; Cartei, G; Chiarion Sileni, V; Fiorentino, MV; Fosser, V; Paccagnella, A; Salvagno, L1
Al-Mondhiry, H; Arlin, Z; Clarkson, B; Dowling, M; Gee, T; Hecht, S; Kempin, S; Koziner, B; Lee, BJ; Little, C; Mayer, K; Phillips, E; Reich, L; Straus, D; Thaler, HT1
Kaye, SB1
Dantas, ME; Glode, LM; Koeppler, H; Morton, N; Robinson, WA; Sutherland, J; Thomas, MR1
Atassi, G; Dumont, P; Tagnon, HJ1
Carbone, A; Crivellari, D; Galligioni, E; Grigoletto, E; Tirelli, U; Trovò, MG; Tumolo, S; Veronesi, A1
Kilian, Z; Kołakowski, L; Kraj, M; Maj, S; Mariańska, B; Mendek, E; Rostkowska, J; Roszkowski, S; Snigurowicz, J1
Arcese, W; Colombo, R; Franchii, A; Pastore, S; Tribalto, M1
Abramson, N; Bennett, JM; Horton, J; Lurie, P; Mietlowski, WL; Schilling, A1
Brunner, K; Henderson, ES; Henry, PH; Holland, JF; Kyle, RA; McIntyre, OR; Nawabi, IU; Pajak, TF1
Benckhuysen, C; van der Steen, J; van Wichen, BH1
Clutterbuck, RD; McElwain, TJ; Millar, JL1
Brunner, K; Cooper, MR; Cornwell, GG; Cuttner, J; Glowienka, LP; Haurani, FI; Henderson, E; Kochwa, S; Kyle, RA; McIntyre, OR; Pajak, TF; Rafla, S; Silver, RT1
Beer, RW; Bosanquet, AG; Gilby, ED; Martin, AD1
Durie, BG; Hofmann, V; Salmon, SE1
Bataille, R; Blotman, F; Bussière, JL; Ciurana, AJ; Lopitaux, R; Morlock, G; Rampon, S; Rosenberg, F; Sany, J; Serre, H; Simon, L1
Horton, JK; Srivastava, DK; Wilson, SH; Zmudzka, BZ1
Alonso, C; Badia, JM; Brunet, J; Delgado, E; Fuentes, J; Lacasta, A; Llanos, M; Mendoza, LA; Ojeda, B1
Daguenel, A; Gorin, NC; Laporte, JP; Lesage, S; Najman, A; Parlier, Y; Woler, M1
Antman, K; Ayash, L; Elias, A; Frei, E; Mazanet, R; Schnipper, LE; Schwartz, G; Tepler, I; Wheeler, C1
Bassan, R; Bellavita, P; Borleri, GM; Buelli, M; Comotti, B; Cortelazzo, S; Marziali, S; Rambaldi, A; Rossi, A; Viero, P1
Chapman, CS; Ghosh, K; Murphy, P; Sivakumaran, M; Wood, JK1
Dercksen, MW; Dirkson, MK; Gerritsen, WR; Pinedo, HM; Rodenhuis, S; Schaasberg, WP; Slaper-Cortenbach, IC; van der Schoot, CE; von dem Borne, AE1
Dranitsaris, G; Sutcliffe, SB1
Fernández, P; García, MC; Gil, MT; Rivas, C; Roldán, V1
Dreger, P; Haferlach, T; Klöss, M; Loeffler, M; Löffler, H; Petersen, B; Schmitz, N1
Bastion, Y; Brice, P; Coiffier, B; Espinouse, D; Gisselbrecht, C; Haioun, C; Marolleau, JP; Reyes, F; Salles, G; Sonet, A1
Allen, PD; Castenskiold, EC; Coldwell, RD; Collins, PW; Goldstone, AH; Kelsey, SM; Makin, HL; Newland, AC; Side, LE1
Crowther, D; Ghielmini, M; Morgenstern, GR; Pettengell, R; Radford, JA; Scheid, C; Stern, PL1
Feugier, P; Guerci, AP; Guerci, O; Guillemin, F; Péré, P; Pourel, J1
Dreger, P; Eckstein, V; Haferlach, T; Jacobs, S; Löffler, H; Marquardt, P; Müller-Ruchholtz, W; Mülverstedt, T; Schmitz, N; Suttorp, M1
Chatterjee, R; Goldstone, AH; Katz, M; McGarrigle, HH; Mills, W2
Bartels, H; Bartl, R; Braun, HJ; Coldewey, R; Deicher, H; Fett, W; Fischer, JT; Göbel, B; Leo, R; Peest, D1
Bout, M; Brémond, JL; Dayan, A; Delain, M; Domenech, J; Gihana, E; Linassier, C; Petit, A; Petitdidier, C; Truglio, D1
Goldstone, AH; Khwaja, A; Linch, DC1
Phillips, GL; Reece, DE1
Brandwein, JM; Colwill, R; Couture, F; Crump, M; Danish, R; Keating, A; Scott, JG; Stewart, AK; Sutcliffe, SB; Sutton, DM1
Kaddurah-Daouk, R; Kufe, DW; Liu, J; Menon, K; Northey, D; Teicher, BA1
Chopra, R; Goldstone, AH; Linch, DC; McMillan, A; Mills, W; Pearce, R1
Colović, MD; Janković, GM; Miletić, VD; Nikolov, VS; Suvajdzić, ND1
Brice, P; Castaigne, S; Gisselbrecht, C; Marolleau, JP; Pautier, P1
Ara, G; Chen, YN; Holden, SA; Korbut, TT; Northey, D; Teicher, BA1
Bender-Götze, C; Burdach, S; Ebell, W; Friedrich, W; Herrmann, F; Klingebiel, T; Koscielniak, E; Kremens, B; Schmid, H; Siegert, W1
Barlogie, B; Crowley, JJ; Finley, P; Grogan, TM; Pugh, RP; Salmon, SE1
Barbot, C; Jazwiec, B; Mahon, FX; Reiffers, J; Rice, A; Vanès, I1
Ali-Osman, F; Bigner, DD; Colvin, OM; Dolan, ME; Friedman, HS; Griffith, OW; Kaufmann, SH; Moschel, RC; Schold, SC1
Chopra, R; Goldstone, AH; Hancock, B; Hudson, GV; Linch, DC; McMillan, A; Milligan, D; Moir, D; Winfield, D1
Dreger, P; Gassmann, W; Glass, B; Haferlach, T; Horst, HA; Löffler, H; Ollech-Chwoyka, J; Schmitz, N; Suttorp, M1
Brosteanu, O; Haas, R; Hasenclever, D; Kirchner, H; Koch, P; Kuse, R; Lathan, B; Pfreundschuh, MG; Rueffer, U; Schmitz, N1
Ardiet, C; Lind, MJ1
Bonilla, MA; Canete, A; Cheung, IY; Cheung, NK; Heller, G; Kushner, B; Larson, SM; Yeh, SJ1
Gola, A; Kotlarek-Haus, S; Urbaniak-Kujda, D; Usnarska-Zubkiewicz, L; Wołowiec, D1
Ashkenazi, Y; Gottschalk-Sabag, S; Hershko, C; Meerkin, D1
Bernard, JL; Bouffet, E; Coze, C; Frappaz, D; Ladenstein, R; Louis, D; Philip, T; Pinkerton, R; Siegert, W; Zucker, JM1
Chopra, R; Goldstone, AH; Linch, DC; McMillan, AK; Patterson, KG; Pearce, R; Taghipour, G; Yuklea, S1
Alcalá, A; Alonso, C; Besalduch, J; Bladé, J; García-Conde, J; Maldonado, J; Moro, MJ; San Miguel, JF; Sanz, MA; Zubizarreta, A1
Dupuis, NP; Emi, Y; Goff, DA; Robinson, MF; Teicher, BA1
Smith, RJ; Sweetenham, JW1
Baczyński, S; Kuliszkiewicz-Janus, M1
Goldstone, AH; Linch, DC; Mills, W; Strang, J1
Barge, A; Boogaerts, MA; Demuynck, HM; Dreger, P; Ferrant, A; Goldstone, AH; Linch, DC; Link, H; Schmitz, N; Zander, A1
Crowley, J; Modiano, MR; Salmon, SE; Villar-Werstler, P1
Döhner, H; Flentje, M; Goldschmidt, H; Haas, R; Hunstein, W; Möhle, R; Moos, M; Murea, S; Wannenmacher, M; Witt, B1
Attal, M; Bataille, R; Casassus, P; Facon, T; Fuzibet, JG; Harousseau, JL; Ifrah, N; Maisonneuve, H; Payen, C; Rossi, JF; Sotto, JJ; Stoppa, AM1
Ali-Osman, F; Bigner, DD; Elion, GB; Friedman, HS; Keir, S; Marcelli, S; Moynihan, K1
Ager, S; Baglin, TP; Bass, G; Mahendra, P; Marcus, RE; Richards, EM1
Billingham, LJ; Knechtli, CJ; Long, SG; Lumley, MA; McDonald, DF; Milligan, DW1
Ager, S; Baglin, TP; Barker, P; Bass, G; Bloxham, DM; Boraks, PA; Hood, IM; Jestice, HK; Johnson, D; Mahendra, P; Marcus, RE; Scott, MA1
Barbui, T; Bassan, R; Bellavita, P; Buelli, M; Comotti, B; Cortelazzo, S; Fracassetti, D; Marchioli, R; Marfisi, RM; Rambaldi, A; Rossi, A; Viero, P1
Doll, K; Harstrick, A; Hoffmann, B; Seeber, S; Strumberg, D1
Bonini, A; Carotenuto, M; Cascavilla, N; D'Arena, G; Di Mauro, L; Greco, MM; Melillo, L; Minervini, MM; Musto, P; Sajeva, MR; Scalzulli, P1
Haynes, AP; Iqbal, A; McQuaker, IG; Russell, NH1
Gregory, SA; Greipp, PR; Kay, NE; Kyle, RA; O'Connell M, J; Oken, MM; Spiegel R, J; Tsiatis, A1
Billadeau, D; Greipp, P; Kay, NE; Kyle, RA; Leong, T; Liu, P; Oken, MM; Quam, L; Van Ness, B1
de Kreuk, AM; Dräger, AM; Huijgens, PC; Jonkhoff, AR; Legdeur, MC; Oberink, JW; Ossenkoppele, GJ; Schuurhuis, GJ; Westra, G; Zweegman, S1
Mahendra, P; Marcus, RE; Nacheva, E; Richards, EM; Sinclair, P1
Gaarsdal, E; Jensen, L; Johnsen, HE; Knudsen, LM; Nielsen, KJ; Nikolaisen, K1
Fielding, AK; Goldstone, AH; Jamieson, E; Linch, DC; Sullivan, AM; Watts, MJ1
Alcalá, A; Besses, C; Bladé, J; Estapé, J; Fontanillas, M; García-Conde, J; Maldonado, J; Montserrat, E; Moro, MJ; Muñoz, M; Rozman, C; San Miguel, J1
Argentino, C; Avvisati, G; Boccadoro, M; Comotti, B; Dominietto, A; Frieri, R; Lauta, VM; Liberati, M; Marmont, F; Musto, P; Palumbo, A; Pileri, A; Tribalto, M1
Berdel, WE; Hoppe, B; Knauf, WU; Koenigsmann, MP; Notter, M; Oberberg, D; Reufi, B; Thiel, E1
Behringer, D; Fetscher, S; Finke, J; Kanz, L; Lange, W; Lübbert, M; Mertelsmann, R1
Barbui, T; Bertini, M; Botto, B; Cinieri, S; Cortellazzo, S; Falda, M; Freilone, R; Grignani, F; Levis, A; Liberati, AM; Locatelli, F; Lovisone, E; Marmont, F; Pizzuti, M; Resegotti, L; Rossi, A; Viero, P; Vitolo, U1
Barbui, T; Bassan, R; Bellavita, P; Comotti, B; Cortelazzo, S; Marchioli, R; Marfisi, RM; Rambaldi, A; Rossi, A; Viero, P1
Amigo, ML; Caballero, MD; del Cañizo, C; García, R; Gonzalez, M; Hernández, JM; San Miguel, JF; Vazquez, L1
Attal, M; Harousseau, JL2
Keimowitz, RM1
Abramson, N; Glick, JH; Harrington, DP; Knospe, W; Kyle, RA; Oken, MM1
Betts, E; Goebel, ME; Honegger, H; Jost, LM; Nagler, A; Stahel, RA1
Antonijevic, N; Colovic, M; Jovanovic, V; Radosevic-Radojkovic, N; Rolovic, Z1
Anderson, L; Linch, DC; Vaughan Hudson, B; Vaughan Hudson, G1
Bartels, H; Dreger, P; Glass, B; Kuse, R; Löffler, H; Schmitz, N; Sonnen, R; Uharek, L; von Neuhoff, N1
Batan, ZE; Milanovich, NF; Skriagin, AE; Snegir', VM; Uss, AL; Zmachinskiĭ, VA1
Brandwein, J; Crump, M; Dufresne, J; Girouard, C; Imrie, K; Keating, A; Pantolony, D; Prince, HM; Stewart, AK1
Caballero, MD; Corral, M; del Cañizo, MC; García-Sanz, R; Gonzalez, M; Heras, I; Jean-Paul, E; León, A; Moraleda, JM; Rifon, J; Rocha, E; Rubio, V; San Miguel, JF; Vázquez, L; Vidriales, B1
Geisler, C; Myhre, J; Pedersen, M; Pedersen-Bjergaard, J1
Abella, E; Adams, PT; al-Katib, A; Dragovic, J; Du, W; Janakiraman, N; Karanes, C; Raman, SB; Ratanatharathorn, V; Sensenbrenner, L; Silver, SM; Uberti, J; Varterasian, M1
Belfi, CA; Berger, NA; Berger, SJ; Chatterjee, S; Hirota, H1
Barbui, T; Bellavita, P; Cortelazzo, S; Marchioli, R; Marfisi, RM; Rambaldi, A; Rossi, A; Viero, P1
Caballero, D; del Cañizo, C; García-Sanz, R; González, M; Heras, I; Jean-Paul, E; León, A; Pérez-Simón, JA; Rifon, J; Rocha, E; Rubio, V; San Miguel, JF; Vicente, V; Vidriales, B1
Andreeva, LA; Batan, ZE; Chervonobab, IuV; Chimishkian, KL; Demina, EA; Kondrat'eva, NE; Larionova, VB; Milanovich, NF; Mkheidze, DM; Ptuskin, VV; Snegir', VM; Tupitsyn, NN; Uss, AL; Zmachinskiĭ, VA1
Dmoszyńska, A; Sokołowska, B; Walter-Croneck, A; Wojtaszko, M1
Chen, PM; Chiou, TJ; Fang, FS; Hsieh, RK; Liu, JH; Tung, SL; Tzeng, CH; Wang, WS; Yen, CC1
Devereux, S; Goldstone, AH; Leverett, D; Linch, DC; Peniket, AJ; Perry, AR; Sullivan, AM; Watts, MJ; Williams, CD1
Cooper, DL; D'Andrea, E; Hu, GL; Jillella, AP; Nadkarni, R; Salloum, E; Seropian, S; Zelterman, D1
Azaceta, G; Palomera, L; Soria, J; Varo, MJ1
Diehl, V; Engert, A; Josting, A; Kàtay, I; Rueffer, U; Tesch, H; Wickramanayake, PD; Winter, S1
Aurlien, E; Holte, H; Jakobsen, E; Kvalheim, G; Kvaløy, S; Pharo, A; Smeland, EB1
Buckner, CD; Weaver, CH; Zhen, B1
Dreger, P; Glass, B; Kuse, R; Löffler, H; Schmitz, N; Schoch, R; Sonnen, R; Uharek, L; von Neuhoff, N1
Arias, J; Besalduch, J; Bladé, J; Carnero, M; Escudero, ML; Estapé, J; Fontanillas, M; García-Conde, J; Gardella, S; Marti, JM; Montserrat, E; Rozman, C; San Miguel, JF1
Bulabois, CE; Colombat, P; Dupas, B; Harousseau, JL; Juge-Morineau, N; Mahé, B; Milpied, N; Moreau, A; Moreau, P; Rapp, MJ; Voillat, L1
Cunningham, D; Popescu, RA; Wotherspoon, AC1
al-Bassam, M; Buzaid, AC; Dasgupta, C; Fruehauf, JP; Kyshtoobayeva, A; Milovanovic, T; Parker, RJ; Zonis, S1
Ackermann, J; DeSantis, M; Drach, J; Fiegl, M; Fritz, E; Gisslinger, H; Heinz, R; Huber, H; Krömer, E; Ludwig, H; Roka, S; Schuster, J; Schuster, R; Zojer, N1
Usnarska-Zubkiewicz, L1
Blumenstengel, K; Fricke, HJ; Höffken, K; Kath, R; Kunert, C; Sayer, HG; Vogel, W1
Andreu, G; Aoudjhane, M; Bauters, F; Belkacemi, Y; Cheron, N; Douay, L; Fenaux, P; Fouillard, L; Gorin, NC; Isnard, F; Jouet, JP; Labopin, M; Laporte, JP; Lemonnier, MP; Lesage, S; Lopez, M; Morel, P; Najman, A; Noël-Walter, MP; Stachowiak, J; Zunic, P1
Anusevicius, Z; Cènas, N; Didziapetrienè, J; Kersienè, R; Kliukienè, R; Marozienè, A1
Fehse, N; Gutensohn, K; Hassan, HT; Kröger, N; Krüger, W; Lölliger, C; Zander, AR; Zeller, W1
Amigo, ML; del Cañizo, MC; Gonzalez, MB; Gutiérrez, N; Hernández, JM; Mateos, MV; San Miguel, JF1
Brammer, CG; Clark, RE1
Azais, I; Bernard, JF; De Gramont, A; Doyen, C; Euller-Ziegler, L; Grosbois, B; Laporte, JP; Le Loët, X; Ménard, JF; Michaux, JL; Mineur, P; Monconduit, M; Peny, AM; Pollet, JP; Wetterwald, M1
Barta, A; Batai, A; Kelemen, E; Lengyel, L; Paloczi, K; Petranyi, GG; Sipos, A; Torbagyi, E1
Colović, MD; Colović, RB; Janković, GM; Martinović-Cemerikić, VM1
Bass, G; Bloxham, D; Gandhi, MK; Jestice, K; Marcus, RE; Scott, MA1
Chen, MG; Gastineau, DA; Gertz, MA; Greipp, PR; Inwards, DJ; Kyle, RA; Lacy, MQ; Litzow, MR; Lust, JA; Pineda, AA; Tefferi, A; Witzig, TE1
Bamborschke, S; Diehl, V; Feiden, W; Lehrke, R; Re, D; Schröder, R; Tesch, H1
Belfi, CA; Berger, NA; Berger, SJ; Chatterjee, S; Gosky, DM1
Burtness, B; Cooper, DL; Hu, GL; Jillella, AP; Nadkarni, R; Salloum, E; Seropian, S; Zelterman, D1
Dias Wickramanayake, P; Diehl, V; Draube, A; Engert, A; Josting, A; Reiser, M; Scheid, C; Tesch, H; Wolf, J1
Dispenzieri, A; Gertz, MA; Lacy, MQ1
Anderlini, P; Andersson, B; Braunschweig, I; Champlin, R; Claxton, D; Cleary, K; Donato, M; Folloder, J; Gajewski, J; Giralt, S; Hagemeister, F; Khouri, I; Körbling, M; Mehra, R; Molldrem, J; Przepiorka, D; Samuels, B; Ueno, NT; van Besien, K1
Gertz, MA; Greipp, PR; Kyle, RA; Lacy, MQ; Lust, JA; Witzig, TE1
Biriukova, LS; Fetisova, EV; Margolin, OV; Pivnik, AV; Volodiaeva, EB1
Bearman, S; Cagnoni, P; Jones, R; Nieto, Y; Peters, W; Ross, M; Shpall, E; Vredenburgh, J1
Greipp, PR; Kay, NE; Keimowitz, RM; Kyle, RA; Lenhard, RE; Leong, T; Oken, MM; Van Ness, B1
Devereux, S; Goldstone, AH; Gregory, W; Hancock, B; Harrison, CN; Hoskin, P; Hudson, GV; Linch, DC; MacMillan, AK; Milligan, D; Newland, AC; Winfield, D1
Aguado, MJ; Canales, MA; de Bustos, JG; Fernández-Jiménez, MC; Hernández-Navarro, F; Ojeda, E1
Foss, HD; Keilholz, U; Knauf, W; Siehl, J; Szelényi, H; Thiel, E1
Buijt, I; Huijgens, PC; Ossenkoppele, GJ; Uyl-de Groot, CA1
Ara, G; Bunnell, C; Elias, A; Frei, E; Richardson, P; Teicher, B; Tew, K; Wheeler, C1
Bourhis, JH; Brice, P; Brousse, N; Decaudin, D; Gisselbrecht, C; Haioun, C; Morel, P; Quesnel, B; Souleau, B; Van Hoof, A1
Alessandrino, EP; Bernasconi, C; Bernasconi, P; Caldera, D; Colombo, A; Klersy, C; Malcovati, L; Martinelli, G; Nascimbene, C; Varettoni, M; Vitulo, P; Volpini, E1
Ma, DQ; Rajewski, RA; Stella, VJ; Vander Velde, D1
Blume, KG; Chao, NJ; Feiner, RH; Hu, WW; Johnston, LJ; Long, GD; Negrin, RS; Shizuru, JA; Stockerl-Goldstein, K; Wong, RM1
Gregora, E; Havrdová, E; Kobylka, P; Kozák, T; Maaloufová, J; Marecková, H; Pit'ha, J; Pytlík, R; Vodvárková, S1
Bhagwati, N; Horton, C; Kulkarni, S; Mainwaring, P; Mehta, J; Pandha, H; Powles, R; Singhal, S; Sirohi, B; Treleaven, J1
Diehl, V; Draube, A; Engert, A; Josting, A; Reiser, M; Rueffer, U; Söhngen, D; Tesch, H; Wickramanayake, PD; Wolf, J2
Byrne, JL; Carter, GI; Cull, GM; Hale, G; Haynes, AP; Miflin, G; Rebello, P; Russell, NH; Waldmann, H1
Abdallah, A; Haas, R; Ho, AD; Hohaus, S; Martin, S; Schlenk, RF; Voso, MT1
Bruty, SJ; Duncombe, AS; George, P; Sweetenham, JW; Wyre, RM1
Buthmann, U; Freund, M; Kleine, HD; Volk, J1
Brion, A; Casassus, P; Colombat, P; Deconinck, E; Delwail, V; Foussard, C; Gaillard, F; Lamy, T; Lemevel, A; Milpied, N1
Argiris, A; Cooper, DL; Seropian, S1
Björkholm, M; Gruber, A; Hansson, M; Steingrimsdottir, H; Svensson, A1
Bertz, H; Engelhardt, M; Finke, J; Hahn, J; Holler, E; Kunzmann, R; Reisser, S; Veelken, H; Wäsch, R1
Dzhumabaeva, BT; Efimov, IV; Kaplanskaia, IB; Margolin, OV; Moiseeva, TN; Pivnik, AV; Rasstrigin, NA; Roshchina, LS; Shavlokhov, VS; Sotnikov, VM; Stroiakovskiĭ, DL1
Clark, RE; Durham, BH; Flory, AJ; Fraser, WD; Ion, EM; Woodcock, BE1
Carreras, E; Esteve, J; Fernández, F; Martínez, C; Montserrat, E; Perales, M; Rovira, M; Urbano-Ispizua, A1
Jantunen, E; Mahlamäki, E; Nousiainen, T1
Berger, M; Boiret, N; Deméocq, F; Halle, P; Kanold, J; Malpuech, G; Paillard, C; Rapatel, C; Yakouben, K1
Avigdor, A; Ben-Bassat, I; Grotto, I; Hardan, I; Raanani, P; Shpilberg, O1
Blaise, D; Caraux, J; Chabannon, C; Faucher, C; Maraninchi, D; Vey, N1
Carella, AM; Cavaliere, M; Corsetti, MT; De Stefano, F; Ferrara, R; Lambelet, P; Lerma, E; Loni, C; Pinotti, G; Romanelli, A; Tedeschi, L; Valbonesi, M; Verdiani, S; Vinci, M1
Dobie, D; Hastings, M; Mahendra, P; Richardson, G; Tauro, S1
Klener, P; Procházka, B; Slabý, J; Trnený, M1
Anagnostopoulos, N; Barbarousi, D; Bourantas, K; Dimopoulos, MA; Gregoraki, B; Maniatis, A; Pouli, A; Tzilianos, M; Venetis, E; Vyniou, N; Zervas, K1
Bouafia, F; Coiffier, B; Dumontet, C; Espinouse, D; Hequet, O; Salles, G; Thieblemont, C1
Beham-Schmid, C; Hoefler, G; Linkesch, W; Neumeister, P; Sill, H1
Aleĭnikova, OV; Batan, ZE; Dziuba, EV; Milanovich, NF; Mitskevich, PB; Skriagin, AE; Solov'eva, NS; Uss, AL; Vlasenkova, SV; Zavgorodniaia, IL; Zhavrid, EA; Zmachinskiĭ, VA1
Caballero, MD; Canales, MA; Fernández-Jiménez, MC; García de Bustos, J; Hernández-Navarro, F; Martín, A; Pérez-Simón, JA; San Miguel, JF; Vázquez, L1
Gregora, E; Havrdová, E; Kobylka, P; Kozák, T; Maaloufová, J; Pit'ha, J; Pytlík, R; Vodvárková, S1
Diehl, V; Ehninger, G; Franklin, J; Hasenclever, D; Kirchner, H; Koch, P; Lathan, B; Loeffler, M; Pfreundschuh, M; Rueffer, U; Schmitz, N; Sextro, M; Tesch, H1
Filippi, M; Gualandi, F; Inglese, M; Lugaresi, A; Mancardi, GL; Marmont, A; Marrosu, MG; Massacesi, L; Meucci, G; Murialdo, A; Pagliai, F; Saccardi, R; Sardanelli, F; Sormani, MP1
Dreger, P; Glass, B; Kuse, R; Schmitz, N; Seyfarth, B; Sonnen, R1
Kashyap, A; Snowden, J1
Ansén, S; Bischoff, S; Bohlen, H; Diehl, V; Dietlein, M; Re, D; Scheidhauer, K; Schicha, H; Tesch, H; Weihrauch, MR; Wolf, J1
Inwards, DJ; Lacy, MQ; Markovic, SN; Porrata, LF1
Blystad, AK; Delabie, J; Holte, H; Kvalheim, G; Kvaløy, S; Smeland, E1
Bethe, U; Cornely, OA; Pels, H; Ritzkowsky, A; Seibold, M; Soehngen, D; Toepelt, K1
Berger, F; Brice, P; Colin, P; Diviné, M; Fermé, C; Jaubert, J; Lederlin, P; Mounier, N; Reman, O; Salles, G; Stamatoullas, A; Voillat, L1
Becherer, A; Dudczak, R; Greinix, HT; Jaeger, U; Kalhs, P; Karanikas, G; Kletter, K; Mitterbauer, M; Pötzi, C; Raderer, M1
Ariatti, C; Bertini, M; Boccomini, C; Botto, B; Calvi, R; Capello, D; Carbone, A; Freilone, R; Gaidano, G; Gallo, E; Gloghini, A; Milan, I; Novero, D; Orsucci, L; Palestro, G; Parvis, G; Pregno, P; Saglio, G; Vitolo, U; Vivenza, D; Zagonel, V1
Dreger, P; Glass, B; Haas, R; Kneba, M; Kröger, N; Kuse, R; Martin, S; Parwaresch, R; Schmitz, N; Sonnen, R1
Barbui, T; Bassan, R; Carter, M; Casula, P; Di Bona, E; Fabris, P; Lambertenghi-Deliliers, G; Lerede, T; Lister, TA; Morandi, S; Pogliani, E; Rambaldi, A; Rohatiner, AZ; Rossi, G1
Alcalá, A; Besalduch, J; Besses, C; Bladé, J; Brunet, S; Carbonell, F; Carnero, M; Conde, E; Escudero, ML; Estapé, J; Esteve, J; Fernández-Calvo, J; Font, L; Fontanillas, M; García-Conde, J; Gardella, S; Hernández-Martín, J; Maldonado, J; Martí, JM; Montserrat, E; Moro, MJ; Ortega, F; Ribera, JM; Rozman, C; San Miguel, JF; Trujillo, J1
Boissevain, F; Carella, AM; Decker, S; Diehl, V; Goldstone, AH; Haenel, M; Hasenclever, D; Kirchner, H; Koch, B; Lohri, A; Müller, P; Pfistner, B; Schmitz, N; Sextro, M; Sieber, M; Zschaber, R1
Buerger, T; Gebauer, T; Halloul, Z; Meyer, F1
Clemente González, C; García Parés, D; García-Bragado Dalmau, F; Guardia Sánchez, R; Pérez Ayuso, MJ; Porcar Ramells, C1
Elonen, E; Franssila, K; Itälä, M; Jantunen, E; Kuittinen, O; Lehtinen, T; Oinonen, R; Wiklund, T1
Byrne, J; Carter, GI; Craddock, CF; Cull, GM; Garg, M; Haynes, AP; Lui Yin, JA; Lush, RJ; Mahendra, P; Mufti, G; Pagliuca, A; Parker, JE; Potter, MN; Prentice, HG; Russell, NH1
Bataille, R; Harousseau, JL; Mahé, B; Milpied, N; Misbahi, R; Moreau, P; Morineau, N; Rapp, MJ; Vigier, M1
Gallet, B; Genet, P; Jondeau, K; Laribi, K; Lionnet, F; Pulik, M; Touahri, T1
Engert, A; Glossmann, JP; Josting, A; Paulus, U; Pfistner, B1
Cavenagh, J; Chopra, R; Clark, FJ; Culligan, D; Davies, A; Fuller, S; Hunt, L; Hunter, A; Littlewood, T; Lush, R; Marks, DI; Marsh, J; Milligan, DW; Parker, A; Schey, S; Smith, GM; Towlson, K; Vandenberghe, E; Williams, CD; Yin, J1
Cook, SD; Ropner, JE; Shuttleworth, GN1
Carella, A; de Elvira, CR; Goldstone, AH; Mackinnon, S; Robinson, SP; Russell, N; Schmitz, N; Taghipour, G1
Abel, U; Baudis, M; Birkmann, J; Bischoff, HG; Franke, A; Grundeis, M; Havemann, K; Hossfeld, DK; Kaiser, U; Karakas, T; Kneba, M; Köppler, H; Krahl, D; Mantovani, L; Mesters, RM; Metzner, B; Müller, P; Parwaresch, R; Pfab, R; Pfreundschuh, M; Reiser, M; Rothmann, F; Schmalenberg, H; Schmitz, N; Schumacher, K; Steinhauer, EU; Trümper, L; Uebelacker, I; von Seydewitz, CU1
Aleĭnikova, OV; Pochetukhin, KV; Strongin, IuS1
Albó, C; Arranz, R; Caballero, MD; Cabrera, R; Carreras, E; Conde, E; Fernández de Sevilla, A; Gandarillas, M; García Ruíz, JC; García-Conde, J; García-Laraña, J; Grande, C; Iriondo, A; Lahuerta, JJ; Marín, J; Moraleda, JM; Pérez-Equiza, C; Pérez-Simón, JA; Rifón, J; Rubio, V; San Miguel, JF; Sierra, J; Sureda, A; Varela, R; Vidal, MJ; Zuazu, J1
Afanas'ev, BV; Alekseeva, IuA; Medvedeva, NV; Mikhaĭlova, NB; Zaritskiĭ, AIu; Zubarovskaia, LS3
García, J; Lahuerta, JJ; Lizasoain, M; Sanz, F1
del Palacio, A; Garau, M; Molina, L; Relaño, MT1
Cooney, JP; Parthasarathy, M; Stiff, PJ; Toor, AA1
Bertz, H; Finke, J; Potthoff, K1
Bell, SE; Brown, J; Child, JA; Davies, FE; Drayson, MT; Hawkins, K; Morgan, GJ; Owen, RG; Selby, PJ1
Apostoli, P; Beggiolin, G; Beretta, GL; Carenini, N; Colangelo, D; Corna, E; Dal Bo, L; Gatti, L; Leone, R; Lombardi, L; Perego, P; Piazzoni, L; Righetti, SC; Tinelli, S; Zunino, F1
Adamson, PJ; Allan, JM; Ashcroft, AJ; Child, JA; Dasgupta, RK; Davies, FE; Dring, AM; Fenton, JA; Morgan, GJ; Roddam, PL; Rollinson, S1
Jaffrey, I; Pashaei, S; Ryder, J; Sun, T1
Dai, MS; Hou, TY; Kao, WY1
Grøttum, P; Kvalheim, G; Rusten, LS; Østby, I1
Jantunen, E; Kuittinen, T; Nousiainen, T1
NEU, JT1
AMALRIC, R; CLEMENT, R1
GIAUX, G; SWYNGEDAUW, J; TOISON, G1
BOWMAN, DE1
BACHMAN, CH; DAVIS, HW; GELORMINI, OJ1
FETZER, H; KELLER, L1
FRANKE, H1
FETZER, H1
QUICK, D; RICHMOND, JD1
FLATBY, J; MAUDAL, S1
RAMIOUL, H1
SMITH, IH1
ARDRAN, GM; CROOKS, HE1
KAHR, E1
MARX, P1
DE VULPIAN, P1
BERENS, A1
KOHN, HI1
VUORINEN, P1
PIGNATARO, E1
CHAUNDY, CJ1
EBERL, J1
ECKER, A1
HENCEK, M; ZACHAR, J1
LOCHMAN, DJ1
MAHFOUZ, MM1
Au, WY; Chan, EC; Kwong, YL; Leung, AY; Liang, R; Lie, AK; Ooi, GC; Siu, LL1
Abrey, LE; Anderson, ND; Caron, D; Correa, DD; Crump, M; DeAngelis, LM; Forsyth, P; Mason, WP; Moskowitz, CH; Nimer, SD; Paleologos, N; Stewart, D; Zelenetz, A1
Arranz, R; Caballero, MD; Carreras, E; Conde, E; Fernández de Sevilla, A; Gandarillas, M; García-Laraña, J; Gutiérrez, A; Lahuerta, JJ; León, A; Marín, J; Rifon, J; Rodríguez, J; SanMiguel, J; Sureda, A; Varela, R; Zuazu, J1
ROSWIT, B1
Blystad, AK; Delabie, J; Holte, H; Ikonomou, I; Kvalheim, G; Kvaløy, S; Vålerhaugen, H1
Ball, ED; Bashey, A; Carrier, E; Chen, YA; Corringham, S; Holman, P; Wang, EH1
Cailliot, C; Fouillard, L; Gorin, NC; Isnard, F; Labopin, M; Laporte, JP; Lesage, S; Najman, A; Yeshurun, M1
Caballero, MD; Cañizo, MC; López-Holgado, N; Martín, A; Mateos, MV; Miguel, JF; Pérez-Simón, JA1
Assari, S; Bennaceur, AL; Boccaccio, C; Bonnet, ML; Bourhis, JH; Decaudin, D; Farace, F; Greissenger, N; Guillier, M; Marracho, MC; Michon, J; Némati, F; Turhan, AG; Vantelon, JM1
Ardito, R; Cammarota, A; Di Renzo, N; Gallucci, G; Romano, G; Tartarone, A1
Armitage, JO; Bierman, PJ; Bociek, G; Enke, C; Hankins, J; Lynch, JC; Vose, JM1
Bosi, A; Bruzzi, P; Di Bartolomeo, P; Donelli, A; Filippi, M; Gualandi, F; Guerrasio, A; La Nasa, G; Mancardi, GL; Marmont, AM; Murialdo, A; Pagliai, F; Papineschi, F; Saccardi, R; Scappini, B; Solari, A1
Berdel, WE; Diehl, V; Dörken, B; Engert, A; Glossmann, JP; Hossfeld, DK; Josting, A; Kirchner, HH; Kisro, J; Mapara, M; Metzner, B; Rudolph, C; Sieber, M; Sienawski, M; Sieniawski, M1
Caballero, MD; del Cañizo, MC; López-Holgado, N; Martín, A; Pérez-Simón, JA; San Miguel, JF; Vázquez, L1
Boruczkowski, D; Choma, M; Chybicka, A; Drabko, K; Gorczyńska, E; Kałwak, K; Kowalczyk, JR; Pieczonka, A; Toporski, J; Turkiewicz, D; Wachowiak, J; Wójcik, B; Zaucha-Prazmo, A1
Abboud, CN; Bernstein, SH; Chapman, M; Friedberg, JW; Ifthikharuddin, JJ; Johnson, V; Lancet, JE; Liesveld, JL; Phillips, GL; Spreng, E; Vesole, DH1
Bocková, J; Bystrická, E; Koza, V; Misaniová, L; Pavlicová, V; Scudlová, J; Valentová, D; Vokurka, S1
Acholonu, S; Anderlini, P; Champlin, RE; Couriel, D; De Lima, M; Donato, ML; Fayad, L; Giralt, S; Hosing, C; Jones, R; Khouri, IF; Korbling, M; Maadani, F; Manning, JT; McLaughlin, P; Okoroji, GJ; Pro, B; Saliba, RM; Shpall, E; Younes, A1
Alapetite, C; Anract, P; Babinet, A; Barthier, S; de Pinieux, G; Laurence, V; Palangié, T; Pierga, JY; Pouillart, P1
Diehl, V; Dörken, B; Engert, A; Glossmann, JP; Josting, A; Kisro, J; Ko, Y; Mapara, M; Metzner, B; Nogova, L; Peters, N; Sieniawski, M; Staak, O1
Abboud, CN; Felgar, R; Komrokji, RS; Oliva, JL; Zand, M1
Belford, D; Gates, P; Jablonskis, L; Januszewicz, H; Lillie, K; Prince, HM; Regester, G; Seymour, JF; West, R; Wolf, M1
Arnaud, P; Bocaccio, C; Bourhis, JH; Carde, P; Ferme, C; Jabbour, E; Koscielny, S; Peslin, N; Ribrag, V; Vantelon, JM1
Barez, A; Bladé, J; Callís, M; Carbonell, F; Díaz-Mediavilla, J; Fernández-Calvo, J; Font, L; Fontanillas, M; García-Laraña, J; Gardella, S; Giraldo, P; Martí, JM; Mateos, MV; Moro, MJ; Palomera, L; Ribera, JM; Rosiñol, L; San Miguel, J; Soler, A; Sureda, A; Trujillo, J1
Bauchmüller, K; Engelhardt, M; Schmitt-Gräff, A; Strobel, ES1
Albarello, A; Ballerini, F; Balocco, M; Canepa, L; Canepa, P; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Varaldo, R1
Brevet, M; Damaj, G; Garidi, R; Gruson, B; Royer, B; Vaida, I1
Bakshi, A; Bhagwat, R; Biswas, G; Khadwal, A; Narayanan, P; Parikh, P; Sastry, P1
Antonenas, V; Bradstock, K; Collins, D; Crowther, H; Gottlieb, D; Kerridge, I; McGurgan, M1
Comenzo, RL; Dhodapkar, M; Filippa, D; Fleisher, M; Hassoun, H; Kewalramani, T; Klimek, V; Nimer, SD; Reich, L; Teruya-Feldstein, J1
Crump, M; Keating, A; Kuruvilla, J; Nagy, T; Pintilie, M; Tsang, R1
Bauchmüller, K; Engelhardt, M; Finke, J; Haas, PS; Ihorst, G; Kühnemund, A1
Brambilla, G; Castagna, L; Magagnoli, M; Masci, G; Morenghi, E; Pedicini, V; Poretti, D; Santoro, A1
Anderson, KC; Barlogie, B; Chapman, RA; Cromer, JN; Crowley, JC; Dakhil, SR; Durie, B; Greipp, PR; Hurd, DD; Kyle, RA; Lanier, KS; Lazarus, HM; McCoy, J; Moore, DF; Salmon, SE1
Bahlis, N; Balogh, A; Brown, C; Jones, A; Morris, DG; Russell, JA; Savoie, L; Stewart, DA; Valentine, K1
Bystrická, E; Koza, V; Misaniová, L; Pavlicová, V; Scudlová, J; Valentová, D; Visokaiová, M; Vokurka, S1
Greipp, PR; Kay, NE; Kyle, RA; Leong, T; Li, S; Oken, MM; Van Ness, B1
Drayson, M; Hock, BD; Kerr, L; McKenzie, JL; Patton, WN; Taylor, K1
Alcalá, A; Alegre, A; Besalduch, J; Bladé, J; Carrera, D; Casado, LF; de Arriba, F; de la Rubia, J; Fernández, P; García Boyero, R; García, PR; García-Laraña, J; Hernández, MT; Lahuerta, JJ; Martínez, R; Palomera Bernal, L; Pérez-Calvo, J; Ribera, JM; San Miguel, J; Sureda, A1
Gisselbrecht, C; Hagberg, H1
Goh, YT; Hwang, WY; Koh, BC; Koh, LP; Linn, YC; Loh, SM; Ratnagopal, P; Tan, HC1
Horvath, N; Keefe, D; Lees, J1
Atkins, H; Bence-Bruckler, I; Bredeson, C; Huebsch, L; Leger, C; McDiarmid, S; Sabloff, M; Zhang, H1
Caballero, D; Canales, MA; Hernandez-Navarro, F; Martin, A1
Blechschmidt, M; Bornhäuser, M; Ehninger, G; Hänel, M; Hölig, K; Kroschinsky, F; Oelschlaegel, U; Ordemann, R; Platzbecker, U; Poppe-Thiede, K; Schaich, M1
Aldouri, M; Devereux, S; Milojković, D; Mufti, GJ; Pagliuca, A1
Cupelli, L; de la Rubia, J; Jarque, I; Jiménez, C; Lorenzo, I; Martín, G; Martínez, JA; Puig, N; Remigia, MJ; Sanz, GF; Sanz, J; Sanz, MA1
Balzarotti, M; Bramanti, S; Castagna, L; Magagnoli, M; Mazza, R; Nozza, A; Russo, F; Santoro, A; Sarina, B; Siracusano, L; Timofeeva, I; Todisco, E1
Dong, HQ; Ji, BX; Lu, CY; Lu, DP; Su, L; Wan, SG; Xu, J; Yu, YY1
Dörken, B; Dreyling, M; Forstpointner, R; Freund, M; Ganser, A; Hiddemann, W; Hoster, E; Huber, C; Ludwig, WD; Nickenig, C; Trümper, L; Unterhalt, M1
Bishton, MJ; Haynes, AP1
Delgado-Lamas, JL; García-Ruiz-Esparza, MA; Gómez-Almaguer, D; Gómez-Rangel, D; Gutiérrez-Aguirre, CH; Morales-Toquero, A; Padilla-González, Y; Ruiz-Argüelles, GJ; Ruiz-Delgado, GJ; Vela-Ojeda, J1
Bertz, H; Bley, TA; Feuerhake, F; Finke, J; Mielke, S; Potthoff, K; Windfuhr, M1
Cağirgan, S; Ergene, U; Pehlivan, M; Tombuloğlu, M; Yilmaz, M1
Bühlmann, M; Bükki, J; Ernst, S; Stanga, Z; Stucki, A1
Arceci, RJ; Chen, AR; Colombani, P; Higman, MA; Schwartz, CL; Wharam, M; Williams, KM1
Atta, J; Chow, KU; Hoelzer, D; Martin, H; Mitrou, PS; Weidmann, E1
Huijgens, PC; Keijzer, A; van de Loosdrecht, AA1
Arber, C; Bucher, C; Buser, AS; Ghielmini, M; Gratwohl, A; Halter, J; Heim, D; Lohri, A; Meyer-Monard, S; Passweg, JR; Stern, M; Stussi, G; Tichelli, A1
Avigdor, A; Ben-Bassat, I; Hardan, I; Nagler, A; Oksman, Y; Shem-Tov, N; Shimoni, A; Yerushalmi, R; Zwas, ST1
Abdelkefi, A; Ben Abdeladhim, A; Ben Othman, T; Ladeb, S; Lakhal, A; Torjman, L1
Bu, Q; Cai, QQ; Gao, Y; Huang, HQ; Lin, XB; Peng, YL; Wang, BF1
Blundell, E; Goldstone, AH; Linch, DC; Peggs, KS; Thomson, KJ1
Ades, L; Attal, M; Bernard, M; Blaise, D; Bordigoni, P; Bourhis, JH; Cassuto, JP; Chevalier, P; Deconinck, E; Facon, T; Garban, F; Ifrah, N; Kuentz, M; Lioure, B; Michallet, M; Milpied, N; Porcher, R; Renaud, M; Socié, G; Tabrizi, R; Tilly, H; Vernant, JP; Vigouroux, S1
Meng, H; Qian, W; Shao, K; Yang, C; Yang, X; Ye, X; Zhou, Y1
Abdelsalam, M; Akhtar, S; El Weshi, A; Hussaini, H; Janabi, I; Maghfoor, I; Rahal, M1
Huh, J; Jang, G; Jo, JC; Kang, BW; Kim, JW; Kim, S; Koo, JE; Lee, SS; Suh, C; Sym, SJ1
Al-Ali, HK; Niederwieser, D; Wittekind, C1
Brand, R; Dreger, P; Michallet, M1
Bauchmüller, K; Engelhardt, M; Ihorst, G; Strobel, ES1
Falk, P; Forman, SJ; Fung, HC; Krishnan, A; Molina, A; Nademanee, A; Palmer, JM; Raubitschek, AA; Rodriguez, R; Spielberger, RT; Yamauchi, D1
Albo, C; Alonso, N; Arranz, R; Caballero, D; Conde, E; Fernández-Rañada, JM; Gandarillas, M; García Vela, JA; Garzón, S; Grande, C; Hernández, MT; Lahuerta, JJ; Mateos, MV; Rodríguez, J1
Caballero, D; Canals, C; Finke, J; Goldstone, A; Hunter, A; Kienast, J; Kobbe, G; Kolb, HJ; Kyriakou, C; Metzner, B; Oberg, G; Reimer, P; Schmitz, N; Sureda, A; Theorin, N1
Baker, N; Barker, P; Boogaerts, M; Canizo, CD; Johnsen, HE; Mesters, R; Russell, N; Schmitz, N; Schubert, J; Skacel, T1
Bacon, P; Blijlevens, N; D'Addio, A; Einsele, H; Maertens, J; McCann, S; Niederwieser, D; Quinn, B; Rabitsch, W; Roosaar, A; Ruutu, T; Schouten, H; Schwenkglenks, M; Stone, R; Vokurka, S1
Briones, J; Camós, M; Colomo, L; Escoda, L; Espinosa, I; Estany, C; Gutiérrez-García, G; López-Guillermo, A; Martínez, S; Martino, R; Mercadal, S; Montserrat, E; Pedro, C; Ribera, JM; Xicoy, B1
Barada, WM; Bazarbachi, A; Beydoun, A; Hourani, R; Masroujeh, R; Otrock, ZK1
Byrne, JL; Das-Gupta, EP; Devereux, S; Gonzalez, J; Haynes, AP; Ho, A; Ingram, W; McMillan, A; Mufti, GJ; Pagliuca, A; Russell, NH; Shaw, BE1
Arkenau, T; Cunningham, D; Horwich, A; Murphy, F; Norman, A; Oates, J; Powles, R; Sirohi, B; Wotherspoon, A1
Bertz, H; Finke, JM; Hahn, J; Holler, E; Ihorst, G; Marks, R; Potthoff, K; Spyridonidis, A1
Augustin, KM; Devine, SM; Dipersio, JF; Sempek, D; Vij, R; Wildes, TM; Zhang, QJ1
Chondropoulos, S; Dervenoulas, J; Economopoulos, T; Giannopoulou, V; Girkas, K; Ioannidou, E; Kalli, T; Ladas, SD; Papageorgiou, E; Papaxoinis, G; Pappa, V; Triantafyllou, K; Tsirigotis, P1
Benhattar, J; Bernasconi, CC; Bricod, C; Gros, S; Janzer, RC; Juillerat-Jeanneret, L; Trepey, S1
Licci, S; Narciso, P1
Ansell, SM; Costa, LJ; Inwards, DJ; Johnston, PB; Litzow, MR; Micallef, IN; Porrata, LF1
Bacon, P; Blijlevens, N; D'Addio, A; Einsele, H; Maertens, J; McCann, S; Niederwieser, D; Quinn, B; Rabitsch, W; Roosaar, A; Ruutu, T; Schouten, H; Schwenkglenks, M; Stone, R; Vorkurka, S1
Gil, L; Komarnicki, M; Kozlowska-Skrzypczak, M; Mol, A; Poplawski, D; Styczynski, J1
Alinari, L; Baccarani, M; Derenzini, E; Fanti, S; Gandolfi, L; Musuraca, G; Stefoni, V; Tani, M; Venturini, F; Zinzani, PL1
SEASHORE, HG1
Bensinger, WI; Gooley, T; Gopal, AK; Holmberg, L; Maloney, D; Press, O; Zaucha, R1
Cook, G; Crawley, C; Fields, P; Hickling, R; Hunter, A; Mahendra, P; Marcus, R; Peniket, A; Wilson, K1
Brault, P; Decaudin, D; Escande, MC; Girodet, J; Mariani, P; Mathiot, C; Precupanu, CM; Zanni, M1
Benvegnú, DM; Bonfanti, G; Frediani, AV; Gonçalves, TL; Rocha, JB1
Cooks, RG; Gao, L; Ouyang, Z; Smith, SA; Song, Q; Volný, M; Xu, W1
Arpaci, F; Ataergin, S; Kilic, S; Komurcu, S; Kuzhan, O; Ozet, A; Ozturk, B; Ozturk, M1
Friedenberg, WR; Greipp, PR; Jacobus, S; Kyle, RA; Rajkumar, SV; Slabber, CF1
Erwin, W; Evens, AM; Gordon, LI; Inwards, DJ; Mehta, J; Micallef, I; Molina, A; Patton, D; Rademaker, AW; Singhal, S; Spies, S; Tallman, MS; Weitner, BB; White, CA; Williams, SF; Winter, JN; Wiseman, G; Zimmer, M1
Crump, M; Keating, A; Kuruvilla, J; Pintilie, M; Seshadri, T; Tsang, R; Zadeh, S1
Adam, Z; Bolcák, K; Cerný, J; Fakan, F; Hájek, R; Krejcí, M; Kren, L; Mayer, J; Neubauer, J; Pour, L; Smardová, L; Soumarová, R; Vanícek, J; Veselý, K1
Martin, R; Schippling, S1
Bahlis, N; Mansoor, A; Stewart, DA1
Barreira, AA; Barros, GM; Barros, JC; Brum, DG; Burt, RK; Hamerschlak, N; Kutner, JM; Madeira, MI; Mastropietro, AP; Moraes, DA; Neto, JZ; Oliveira, EA; Oliveira, MC; Paes, AT; Pieroni, F; Porto, PP; Ribeiro, AA; Rodrigues, M; Santana, CL; Santos, AC; Simões, BP; Stracieri, AB; Tylberi, CP; Voltarelli, JC1
Cerno, M; Damiani, D; Fanin, R; Geromin, A; Patriarca, F; Rinaldi, C; Skert, C; Sperotto, A; Stocchi, R; Tiribelli, M; Zaja, F1
García-Sanz, R; González-López, TJ; Graciani, IF; Hermida, G; San Miguel, JF; Vázquez, L1
Kuruvilla, J1
Barosi, G; Fanti, S; Gianni, AM; Martelli, M; Petrini, M; Tura, S; Vitolo, U; Zinzani, PL1
Qiao, W; Wang, C; Wang, T; Xing, Y; Zhao, J1
Aureli, V; Balduino, G; Caniglia, M; Cometa, AM; Isacchi, G; Landi, F; Miele, MJ; Pinto, RM; Rana, I; Scerpa, MC; Zinno, F1
Butler, JB; Cooke, A; Demers, A; Liu, HW; Nugent, Z; Rubinger, M; Schroeder, G; Seftel, MD; Szwajcer, D1
Boesen, AM; Browett, P; Cunningham, D; Grigg, A; Hancock, B; Holte, H; Hoskin, P; Jack, A; Linch, DC; Maclennan, K; Qian, W; Smith, P; Trneny, M; Yung, L1
BRAESTRUP, CB; SINGER, G; WYCKOFF, HO2
HERSCHER, LW; WRIGHT, N1
Havrdová, E; Kemlink, D; Kobylka, P; Kovárová, I; Kozák, T; Krasulová, E; Lhotáková, P; Pohlreich, D; Trneny, M; Vacková, B1
Asmar, L; Beveridge, R; Boehm, KA; Mandanas, R; McGaughey, D; Orloff, G; Rifkin, R; Spitzer, G; Zhan, F1
Schneider, AE; Talmon, GA1
Cornely, OA; Keulertz, C; Lövenich, H; Rüping, MJ; Söhngen, D; Vehreschild, JJ; Wieland, U1
Huh, J; Kim, JE; Kim, S; Kim, SW; Lee, DH; Lee, JS; Park, CJ; Suh, C; Yoo, C1
Dong, HQ; Ji, BX; Liu, CY; Liu, YO; Su, L; Sun, WL; Wan, SG; Xu, J; Zhang, P1
TOLANSKY, S1
Abboud, CN; Becker, MW; Bernstein, SH; Constine, LS; Friedberg, JW; Ifthikharuddin, JJ; Liesveld, JL; Loughner, JE; Milner, LA; Phillips, GL; Vesole, DH1
Buset, EM; Haile, SR; Honegger, H; Knuth, A; Mischo, A; Pestalozzi, BC; Petrausch, U; Renner, C; Samaras, P; Schanz, U; Siciliano, RD; Stahel, RA; Stenner-Liewen, F; Stussi, G1
Choma, M; Chybicka, A; Cornish, J; Gorczyńska, E; Grund, G; Kowalczyk, JR; Peters, C; Sykora, KW; Wachowiak, J1
Bockova, J; Brandejsova, R; Bystricka, E; Chvojkova, I; Mazur, E; Mjartanova, D; Scudlova, J; Streinerova, K; Vasilieva, E; Visokaiova, M; Vitkova, J; Vodickova, M; Vokurka, S; Vrabcova, M1
Cai, JL; Delioukina, M; Forman, SJ; Gaal, K; Kogut, N; Nademanee, A; Palmer, JM; Popplewell, L; Tsai, NC1
Glass, B; Griesinger, F; Hasenkamp, J; Hohloch, K; Lakhani, VJ; Meller, J; Riggert, J; Sahlmann, CO; Trümper, L; Wulf, G1
Bologna, S; Bosly, A; Bouabdallah, K; Brière, J; Coiffier, B; Decaudin, D; Delarue, R; Ghesquières, H; Gisselbrecht, C; Huynh, A; Le Gouill, S; Morschhauser, F; Mounier, N; Ribrag, V; Tilly, H1
Arai, S; Chen, AI; Johnston, LJ; Laport, GG; Lowsky, R; McMillan, A; Miklos, DB; Negrin, RS; Shizuru, JA; Stockerl-Goldstein, K; Weng, WK1
Bartlett, NL; Cashen, AF; Foyil, KV; Grove, LE; Kennedy, DA1
Dib, M; Gagnadoux, F; Paris, A; Rousselet, MC; Tazi, A; Urban, T1
Barzal, J; Gawronski, K; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P; Wasko-Grabowska, A1
Barzał, J; Gawroński, K; Młot, B; Oborska, S; Rzepecki, P; Szczylik, C; Waśko-Grabowska, A1
Crump, M; Keating, A; Kuruvilla, J; Massey, C; Puig, N; Seshadri, T; Tsang, R; Villa, D1
de Rooij, M; Huijgens, PC; Visser, OJ; Wondergem, MJ; Zijlstra, JM; Zweegman, S1
Avigdor, A; Avivi, I; Levi, I; Nagler, A; Or, R; Patachenko, P; Rowe, JM; Shimoni, A; Yeshurun, M; Zwas, T1
Bruno, A; Cantoni, F; Cupelli, L; Datturi, T; De Angelis, V; de Fabritiis, P; De Meis, I; Dentamaro, T; Niscola, P; Tendas, A1
Briere, J; Bron, D; Cogliatti, S; Cuccuini, W; Gaulard, P; Gisselbrecht, C; Hirchaud, E; Houlgatte, R; Mounier, N; Rosenwald, A; Soulier, J; Sundstrom, C; Thieblemont, C; Voelker, HU; Ysebaert, L1
Ardeshna, K; Kayani, I; Linch, DC; Lowry, L; Moore, S; Peggs, K; Qian, W; Thomson, K1
Adam, Z; Adamová, Z; Brejcha, M; Hájek, R; Kodet, R; Koukalová, R; Krejčí, M; Mayer, J; Moulis, M; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L1
Ma, X; Ren, C; Sheng, Z; Wang, B; Xia, B; Zhang, W1
Aznar Oroval, E; García-Lozano, T; Juan Bañón, JL; Lorente Alegre, P1
Andersen, NS; Bentzen, H; Brown, P; Delabie, J; Ehinger, M; Elonen, E; Eriksson, M; Geisler, CH; Jerkeman, M; Karjalainen-Lindsberg, ML; Kimby, E; Kolstad, A; Kuittinen, O; Laurell, A; Lauritzsen, GF; Nilsson-Ehle, H; Nordström, M; Pedersen, LB; Ralfkiaer, E; Räty, R; Sundström, C1
Beuthien-Baumann, B; Bornhäuser, M; Ehninger, G; Kroschinsky, F; Middeke, JM; Ordemann, R; Platzbecker, U; Platzek, I; Stöhlmacher, J; van den Hoff, J; Zietz, C1
Bucher, C; Buser, A; Gerull, S; Halter, J; Heim, D; O'Meara, A; Passweg, J; Stern, M1
Bruno Ventre, M; Caligaris-Cappio, F; Cattaneo, C; Di Nicola, M; Donadoni, G; Ferreri, AJ; Foppoli, M; Fumagalli, L; Govi, S; Mappa, S; Re, A; Rossi, G; Spina, M; Tirelli, U1
Armitage, JO; Bierman, PJ; Bociek, RG; Chan, WC; Enke, C; Hankins, J; Loberiza, FR; Vose, JM; Weisenburger, DD1
Cooney, JP; Kruger, PC; Turner, JH1
Anderson, D; Greaves, P; Gribben, JG; Lillington, D; Lister, TA; Matthews, J; Montoto, S1
Casper, J; Gebauer, W; Köhne, CH; Kraemer, D; Metzner, B; Müller, TH; Pott, C; Rosien, B; Schumann-Binarsch, S; Thole, R1
Ambinder, R; Ayala, E; Burns, LJ; Carter, S; Fenske, T; Fisher, R; Horowitz, M; Mineshi, S; Moskowitz, CH; Press, OW; Stadtmauer, EA; Tomblyn, M; Vose, JM1
Berdel, WE; Demant, A; Evers, G; Kessler, T; Köhler, G; Krug, U; Kuhlmann, M; Mesters, R; Mikesch, JH; Mohr, M; Müller-Tidow, C; Pohlen, M; Schliemann, C; Schmidt, E; Thoennissen, GB; Thoennissen, NH; Wessling, J1
Aslan, D; Cetin, M; Eroglu, C; Eser, B; Kaynar, L; Keklik, M; Kurnaz, F; Mentes, S; Orhan, O; Sahin, C; Sivgin, S; Soyuer, S; Unal, A; Yildiz, OG1
Adams, RH; Betcher, JA; Dueck, AC; Fauble, VD; Khera, N; Klein, JL; Leis, JF; Noel, P; Reeder, CB; Slack, JL; Sproat, LO1
Bembnista, E; Czyz, A; Dytfeld, D; Gil, L; Kazmierczak, M; Komarnicki, M; Kozlowska-Skrzypczak, M; Lojko-Dankowska, A; Matuszak, M; Nowicki, A1
Armitage, JO; Bierman, PJ; Bociek, RG; Loberiza, FR; Vose, JM; Whalen, V; William, BM1
Czajczynska, A; Gramatzki, M; Günther, A; Humpe, A; Kneba, M; Nickelsen, M; Raff, T; Repp, R; Schrappe, M; Schrauder, A; Schub, N1
Blijlevens, NM; de Haan, AF; Donnelly, JP; Herbers, AH; van der Velden, WJ1
Go, A; Guo, R; Parthasarathy, M; Rodriguez, T; Smith, S; Sobol, U; Stiff, P; Vimr, R1
Calandrelli, M; Capelli, D; Chiarucci, M; Gini, G; Inglese, E; Leoni, P; Mancini, G; Mancini, S; Montanari, M; Offidani, M; Olivieri, A; Poloni, A; Raggetti, G; Scortechini, I1
Bernal, T; Briones, J; Caballero, D; Canales, MA; García-Marco, JA; González-Barca, E; Grande, C; Hernández, M; Jarque, I; López, D; Moraleda, JM; Novelli, S; Palmero, F; Panizo, C; Tomás, JF; Torres, A1
Boyce, TG; Burnette, BL; Jentoft, MA; Porrata, LF; Witzig, TE1
Chung, JS; Kim, H; Kim, JS; Lee, GW; Lee, HS; Lee, WS; Shin, HJ; Song, MK; Yhim, HY1
Allen, MS; Armitage, JO; Bierman, PJ; Bociek, RG; Loberiza, FR; Vose, JM; William, BM1
Ardeshna, KM; Bird, A; Goldstone, AH; Kothari, J; Lambert, J; Linch, DC; Morris, E; Peggs, KS; Thomson, KJ; Virchis, AE1
Buck, A; Duell, J; Einsele, H; Knop, S; Maeder, U; Rasche, L; Rosenwald, A; Strifler, S1
WOOD, CA1
CHARTERIS, AA1
BATHO, HF; EVANS, AM; MIBUS, SA; MOFFAT, RG; NASH, RD1
Belada, D; Berková, A; Bolomská, I; Burešová, L; Campr, V; Klener, P; Kozák, T; Kubáčková, K; Matuška, M; Pirnos, J; Přibylová, J; Pytlík, R; Sýkorová, A; Trněný, M; Vášová, I1
Bentzen, H; Bogsrud, TV; Brown, Pde N; Delabie, J; Ehinger, M; Elonen, E; Fagerli, UM; Frederiksen, H; Geisler, CH; Grønbæk, K; Hansen, PB; Jerkeman, M; Karjalainen-Lindsberg, ML; Kimby, E; Kolstad, A; Kostova-Aherdan, K; Laurell, A; Lauritzsen, GF; Lehmann, AK; Loft, A; Nilsson-Ehle, H; Pedersen, LB; Ralfkiaer, E; Räty, R; Schildt, J; Sundstrom, C1
Auger-Quittet, S; Daures, JP; Duny, Y; Quittet, P1
Daw, S; Hayward, J; Hewitt, M; Kirkwood, A; McCarthy, K; Morland, B; Shankar, A1
Caballero, MD; Cabrero-Calvo, M; García-Sanz, R; Labrador, J; Mateos, MV; Pérez-López, E; Vázquez, L1
D'Sa, S; Dorman, J; Marzolini, MA; Thomson, KJ1
Berritta, D; Cupri, A; Fauci, AL; Leotta, S; Milone, G; Parisi, M; Spina, P; Tripepi, G1
Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A1
Arranz, R; Bargay, J; Bello, JL; Caballero, MD; Conde, E; Coronado, M; González-Barca, E; Grande, C; Hernández, MT; Marín-Niebla, A; Martín, A; Montes-Moreno, S; Panizo, C; Pardal, E; Pérez-Ceballos, E1
Abboud, CN; Cashen, AF; DiPersio, JF; Fiala, MA; Fletcher, T; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Wang, TF; Westervelt, P; Wu, N1
Bordessoule, D; Bouabdallah, R; Bouteloup, M; Briere, J; Casasnovas, RO; Ciappuccini, R; Delmer, A; Fermé, C; Fruchart, C; Ghesquières, H; Gisselbrecht, C; Morschhauser, F; Tilly, H; Van Den Neste, E; Ysebaert, L1
Forman, SJ; Hasenkamp, J; Krishnan, AY; Mei, M; Nademanee, A; Palmer, JM; Raubitschek, A; Shimoni, A; Simpson, J; Tsai, NC; Wondergem, MJ1
Bates, A; Cooke, R; Cunningham, D; Falk, SJ; Gilson, D; Hancock, BW; Harris, SJ; Horwich, A; Hoskin, PJ; Linch, DC; Lister, A; Lucraft, HH; Radford, J; Stevens, AM; Swerdlow, AJ; Syndikus, I; Williams, MV1
Biron, P; Bouabdallah, R; Boumendil, A; Cahn, JY; Colombat, P; Cook, G; Cordonnier, C; Dreger, P; El-Najjar, I; Ferrant, A; Finel, H; Gribben, J; Haynes, AP; Luan, JJ; Mohty, M; Montoto, S; Pfreundschuh, M; Sureda, A; Thomson, K; Tilly, H; Vernant, JP1
Argnani, L; Maglie, R; Pellegrini, C; Pileri, S; Zinzani, PL1
Nagai, H1
Cook, G; Fox, C; Johnson, P; Kirkland, K; McQuaker, G; Pagliuca, A; Pearce, R; Perry, J; Robinson, S; Russell, N; Truelove, E1
Banat, A; Basara, N; Derigs, G; Flohr, T; Frickhofen, N; Gramatzki, M; Hess, G; Kirschey, S; Kolbe, K; Link, H; Meyer, RG; Peter, N; Schmitz, N; Schulz, A; Theobald, M; Weidmann, E; Wolf, HH1
Barriere, J; Borchiellini, D; Boscagli, A; Coso, D; Garnier, G; Gastaud, L; Gutnecht, J; Martin, N; Naman, H; Petit, E; Peyrade, F; Re, D; Rossignol, B; Saudes, L; Thyss, A1
Akpek, G; Aljurf, M; Artz, A; Bredeson, CN; Chen, YB; Cooke, KR; Ho, VT; Lane, AA; Lazarus, HM; Logan, B; McCarthy, P; Olsson, R; Pasquini, MC; Saber, W; Zhu, X1
Banz, Y; Berger, MD; Branger, G; Klaeser, B; Mueller, BU; Novak, U; Pabst, T; Taleghani, BM1
Abela, EM; Anagnostopoulos, A; Apostolou, C; Baliakas, P; Batsis, I; Douka, V; Iskas, M; Kaloyannidis, P; Karypidis, K; Konstantinou, V; Kouvatseas, G; Mallouri, D; Marvaki, A; Sakellari, I; Smias, C; Sotiropoulos, D; Yannaki, E1
Ford, PA; Grant, SJ; Keck, G; Mick, R1
Clark, SM; Clemmons, AB; DeRemer, DL; Garren, J; Kota, VK; Schaack, L1
Caimi, PF; Campagnaro, EL; Cooper, BW; Creger, RJ; de Lima, M; Fox, R; Fu, P; Gerson, SL; Lazarus, HM; Reese-Koc, J; Silva Rondon, CH; William, BM1
Abidi, MH; Ayash, L; Bhutani, D; Deol, A; Dyson, G; Jain, T; Kim, S; Lum, LG; Ratanatharathorn, V; Uberti, JP; Veeraputhiran, M1
Bachy, E; Casasnovas, O; Freyer, G; Guitton, J; Hénin, E; Ribrag, V; Salles, G; Sebban, C; Tilly, H; Tod, M; You, B1
Brozova, J; Dobrovolny, J; Kozak, T; Novak, J; Novakova, L1
Amorim, S; Bouabdallah, R; Boumendil, A; Choquet, S; de Rosa, G; Delmer, A; Dreger, P; Faber, E; Facchini, L; Falzetti, F; Ferrara, F; Finel, H; Finke, J; Kobbe, G; Nicolas-Virelizier, E; Salles, G; Sayer, H; Scime, R; Sellner, L; Sureda, A; Vallisa, D; Yakoub-Agha, I; Zuffa, E1
Gore, A; Gupta, A; Jain, R; Jeevangi, N; Kannan, S; Khattry, N; Nair, R; Saikia, T; Thippeswamy, R1
Agresta, F; Ayton, R; Bennett, A; Bhattacharyya, P; Cooke, RE; Grigg, A; Lasica, M; Stern, C; Taylor, E1
Chwieduk, A; Fidyk, W; Giebel, S; Głowala-Kosińska, M; Mitrus, I; Najda, J; Smagur, A1
Chen, S; Lei, X; Tang, C; Xiong, YL; Xu, WJ; Zhao, KW; Zhou, Q1
Bojic, M; Greinix, H; Hermann, A; Jäger, U; Kalhs, P; Lamm, W; Leiner, M; Mitterbauer, M; Rabitsch, W; Schörgenhofer, C; Schulenburg, A; Sillaber, C; Skrabs, K; Sperr, WR; Wohlfarth, P1
Ai, W; Bence-Bruckler, I; Bierman, P; Braunschweig, I; Chen, AI; Comeau, T; Costa, LJ; Craig, M; Fay, JW; Flinn, I; Flowers, CR; Freytes, CO; Horwitz, ME; Kato, K; Laneuville, P; Le-Rademacher, J; Lill, M; Mason, J; Mineishi, S; Pasquini, MC; Pulsipher, MA; Rodriguez, TE; Rondelli, D; Shea, TC; Shore, TB; Smith, AJ; Vaughan, W; Waller, EK; Wang, Y; Xu, C; Yeager, AM; Yeh, RF1
Boulahdour, H; Daguindau, E; Deconinck, E; Helias, P; Philippe, L; Puyraveau, M1
Chapuy, B; Feller, AC; Hasenclever, D; Hohloch, K; Loeffler, M; Pfreundschuh, M; Schmitz, N; Trümper, L; Wulf, G; Zeynalova, S; Ziepert, M1
Ardeshna, KM; Foley, M; Kothari, J; Lambert, J; Linch, DC; Mackenzie, S; Morris, E; Peggs, KS; Thomson, K; Virchis, AE1
Christofides, A; Isidori, A; Visani, G1
Ammari, S; Canova, C; Dercle, L; Deutsch, E; Levy, A; Marabelle, A; Mazeron, R; Michot, JM; Ribrag, V; Rose, S; Rubin, E; Soria, JC1
Abboud, C; Cashen, AF; Ceriotti, C; DiPersio, J; Fletcher, T; Gao, F; Ghobadi, A; Stockerl-Goldstein, K; Vij, R1
Baran, A; Barr, PM; Becker, MW; Friedberg, JW; Liesveld, JL; Milner, LA; Phillips, GL; Reid, RM; Wedow, L1
Bachanova, V; Brunstein, CG; Fair, C; Lazaryan, A; McClune, B; Rogosheske, J; Shanley, R1
Bhat, V; Khattry, N; Toshniwal, M; Vira, H1
Bouabdallah, K; Cornillon, J; Damaj, G; Gastinne, T; Ghésquières, H; Gressin, R; Gyan, E; Ranchon, F; Salles, G; Vigouroux, S; Yakoub-Agha, I1
Butcher, B; Chong, G; Cull, G; Fay, K; Filshie, R; Gandhi, MK; Gill, D; Grigg, A; Hahn, U; Hertzberg, M; Hicks, RJ; Ho, SJ; Hofman, MS; Johnston, A; Kannourakis, G; Lewis, ID; Milliken, S; Renwick, W; Seymour, JF; Taper, J; Trotman, J; Warburton, P; Watson, AM; Wirth, A1
Amorim, S; Bachy, E; Bay, JO; Bento, L; Bonifazi, F; Bouabdallah, R; Boumendil, A; Ceballos, P; Crawley, C; Damaj, G; Dreger, P; Finel, H; Gribben, J; Guilhot, F; Haenel, A; Huynh, A; Johnson, R; Le Gouill, S; Malladi, R; McQuaker, G; Metzner, B; Monjanel, H; Montoto, S; Nicolas-Virelizier, E; Orchard, K; Pohlreich, D; Poiré, X; Rambaldi, A; Rossi, G; Russell, NH; Thomson, K; Tilly, H1
Billett, AL; Dahmoush, HM; Grant, FD; LaCasce, AS; Lehmann, LE; Margossian, SP; Ozuah, NW1
Cassaday, RD; Cowan, A; Ermoian, R; Gopal, AK; Graf, SA; Holmberg, LA; Press, OW; Shadman, M; Smith, SD; Stevenson, PA; Till, BG; Tseng, YD1
Bacon, W; Chao, NJ; Gasparetto, C; Horwitz, ME; Kang, Y; Li, Z; Long, GD; Rizzieri, DA; Sivaraj, D; Sullivan, KM1
Bentz, M; Binnenhei, M; Bohl, SR; Bullinger, L; Bunjes, D; Döhner, H; Döhner, K; Drognitz, K; Kuchenbauer, F; Kündgen, L; Moulin, JC; Nguyen, TM; Ringhoffer, M; Schlenk, RF; Teleanu, V; von Harsdorf, S; Wais, V1
Alenxandrova, K; Arfi-Rouche, J; Bourhis, JH; Castilla-Llorente, C; Danu, A; Ghez, D; Khalife-Saleh, N; Koscielny, S; Lapierre, V; Lazarovici, J; Legoupil, C; Michot, JM; Pilorge, S; Ribrag, V; Saleh, K1
Lavolé, J; Le Goff, M; Mallet, V; Oudjit, A; Sogni, P1
Braziel, RM; Chansky, K; Chen, AI; Dunlap, JB; Fan, G; Gay, ND; Leonard, JT; Maziarz, RT; Okada, CY; Raess, PW; Stentz, A1
Baars, JW; Brouwer, R; Chamuleau, MED; de Jong, D; de Wreede, LC; Demandt, AMP; Doorduijn, JK; Hardi, L; Kersten, MJ; Kluin, PM; Nijland, M; Oosten, LEM; Siemes, C; Smeekes, OS; Stevens, WBC; Thielen, FW; Uyl-de Groot, CA; van Imhoff, GW; Veelken, H1
Ansuinelli, M; Canfora, M; Cantonetti, M; Capria, S; Caputo, MD; Di Rocco, A; Giannarelli, D; Gumenyuk, S; Marchesi, F; Mengarelli, A; Palombi, F; Papa, E; Pisani, F; Provenzano, I; Pupo, L; Renzi, D; Romano, A; Serrao, A; Spadea, A; Trisolini, SM1
Akhtar, S; Elhassan, TAM; Elshenawy, MA; Maghfoor, I; Shahzad Rauf, M1
Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hosing, C; Jones, RB; Kebriaei, P; Ma, J; Milgrom, S; Myers, A; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shpall, EJ; Thall, PF; Timmons, M; Valdez, BC1
Bellò, M; Benevolo, G; Bisi, G; Boccomini, C; Botto, B; Castellino, A; Chiappella, A; Ciochetto, C; Freilone, R; Nicolosi, M; Orsucci, L; Passera, R; Pecoraro, C; Pregno, P; Vitolo, U1
Fornecker, LM; Guffroy, A; Korganow, AS; Martin, M; Meyer, A1
Dünweber, A; Fridthjof, KS; Friis, LS; Gørløv, JS; Kampmann, P; Kjeldsen, L; Moser, C; Møller, T; Nexø, C; Nørskov, KH; Welinder, PC1
Fauble, V; Hogan, WJ; Jain, T; Khera, N; Kunze, KL; Leis, JF; Mesa, RA; Noel, P; Palmer, J; Partain, DK; Patnaik, MS; Roy, V; Slack, JL; Sproat, LZ; Temkit, M1
Boehm, A; Keil, F; Koller, E; Menschel, E; Moestl, M; Noesslinger, T; Panny, M; Simanek, R1
Billio, A; Borghero, C; Calimeri, T; Carli, G; Cascavilla, N; Centurioni, R; Chiusolo, P; Codeluppi, K; Fama, A; Fanin, R; Federici, I; Ferrero, S; Finotto, S; Gherlinzoni, F; Ghione, P; Giannoccaro, M; Lanza, F; Loseto, G; Marino, D; Matera, R; Mazzone, AM; Mosna, F; Olivieri, A; Olivieri, J; Orciuolo, E; Pelosini, M; Perali, G; Rattotti, S; Saraceni, F; Sgherza, N; Sica, S; Stefani, PM; Tisi, MC; Tomei, G; Zaja, F1
Andrick, B; Clemmons, AB; DeRemer, D; Gandhi, A; Orr, J; Sportes, C1
Abou Mourad, Y; Clissa, C; Connors, JM; Gerrie, AS; Guiducci, B; Isidori, A; Loscocco, F; Nantel, SH; Power, M; Sanford, D; Savage, KJ; Scott, DW; Sehn, LH; Song, K; Sutherland, H; Toze, C; Tsang, ES; Villa, D; Visani, G1
Ali, H; Budde, E; Chen, R; Forman, SJ; Herrera, AF; Mei, M; Mokhtari, S; Nademanee, A; Nakamura, R; Popplewell, L; Salhotra, A; Sandhu, K; Stiller, T; Zain, J1
Barnett, MH; Barnett, Y; Ford, CD; Hendrawan, K; Khoo, ML; Kyle, KA; Ma, DDF; Ma, KC; Massey, JC; Milliken, ST; Moore, JJ; Sutton, IJ; Zaunders, JJ; Zivadinov, R1
Bando-Polaino, I; Cabezas-Camarero, S; de la Orden García, V; Díaz-Rubio, E; García-Barberán, V; Llovet García, P; Mediero-Valeros, B; Merino Menéndez, S; Pérez-Segura, P; Subhi-Issa, AI1
Abounader, D; Andritsos, L; Benson, DM; Bolwell, B; Dean, R; Devine, SM; Efebera, YA; Elder, P; Hill, B; Hofmeister, CC; Jagadeesh, D; Jaglowski, S; Kalaycio, M; Majhail, NS; Penza, S; Pohlman, B; Rosko, A; Sharma, N; Singer, S; Sobecks, R; Vasu, S; William, BM; Zhao, Q2
Arcani, R; Colle, J; Costello, RT; Fanciullino, R; Farnault, L; Ivanov, V; Jourde-Chiche, N; Mercier, C; Pourroy, B; Roche, P; Venton, G1
Bishton, M; Campbell, R; Cheah, CY; Cochrane, T; De Mel Widanalage, S; Gilbertson, M; Hapgood, G; Hawkes, E; Hill, K; Johnston, A; Lee, HP; Manos, K; Nelson, N; Ng, M; Ng, ZY; Opat, S; Poon, M; Purtill, D; Ratnasingam, S; Ritchie, D; Schwarer, A; Seymour, J; Shorten, S; Sunny, T; Tam, C; Xin, L1
Hagiwara, S; Ishiyama, M; Izuka, Y; Kazama, H; Osanai, S; Ryuzaki, M; Shinohara, A; Shiseki, M; Tanaka, J; Tanaka, N; Watanabe, A; Yoshinaga, K1
Bashir, Q; Champlin, RE; Delgado, R; Hosing, C; Kebriaei, P; Lee, HC; Manasanch, EE; Mukherjee, A; Nieto, Y; Orlowski, RZ; Patel, KK; Patel, RD; Popat, U; Qazilbash, MH; Rondon, G; Saini, NY; Thomas, SK; Varma, A; Weber, DM1
Barbon Gauro, J; Heng, MS; Thomas, J; Yaxley, A1
Bañuelos-Ávila, AJ; Barrera-Chairez, E; Fernandez-Vargas, OE; Ron-Guerrero, CS; Ron-Magaña, AL1
Barlogie, B; Mouhieddine, TH; Teruya-Feldstein, J1
Arora, R; Hildebrandt, GC; Munker, R; Qasrawi, A; Ramlal, R1
Abraham, J; Borel, C; Bouabdallah, K; Bouabdallah, R; Casasnovas, RO; Chantepie, S; Damaj, G; Delapierre, B; Delette, C; Durot, E; Fornecker, LM; Garciaz, S; Gastinne, T; Gressin, R; Gyan, E; Houot, R; Hueso, T; Ibrahim, A; Le Gouill, S; Lemal, R; Malak, S; Morello, R; Peyrade, F; Tchernonog, E; Tessoulin, B; Tournilhac, O1
Ahmed, S; Ahn, KW; Aljurf, M; Bacher, U; Badawy, SM; Bejanyan, N; Cairo, M; Cerny, J; Epperla, N; Farhadfar, N; Fenske, TS; Freytes, CO; Gale, RP; Hamadani, M; Haverkos, B; He, Y; Hossain, N; Inwards, D; Jagadeesh, D; Kamble, RT; Kenkre, VP; Kharfan-Dabaja, MA; Lazarus, HM; Lazaryan, A; Lekakis, L; Litovich, C; Majhail, NS; Mei, M; Murthy, HS; Mussetti, A; Nathan, S; Nishihori, T; Olsson, RF; Ramakrishnan Geethakumari, P; Savani, BN; Sureda, A; Yared, JA1
Böhmer, LH; Chitu, DA; de Jong, D; de Jongh, E; de Weerdt, O; Doorduijn, JK; Hoogendoorn, M; Kersten, MJ; Kibbelaar, RE; Kluin-Nelemans, HC; Leys, RBL; Lugtenburg, PJ; MacKenzie, MA; Minnema, MC; Snijders, TJF; van Gelder, M; van Marwijk Kooij, R; Van't Veer, MB; Zijlstra, JM1
Bazarbachi, A; Bou Akl, I; El-Cheikh, J; Ghaoui, N; Karout, L; Khalil, PB; Massoud, R; Matar, M; Zahreddine, A1
Charifa, A; Ko, CJ; Lee, A; Levy, L; McNiff, JM; Paulson, N; Perincheri, S1
Ballotta, L; Capria, S; Celentano, M; Ferrara, F; Marchesi, F; Mengarelli, A; Papa, E; Pedata, M; Picardi, A; Regazzo, G; Riccardi, C; Riemma, C; Terrenato, I; Trisolini, S1
Bertz, H; Duque-Afonso, J; Finke, J; Ihorst, G; Köhler, T; Marks, R; Müller-Quernheim, J; Wäsch, R; Waterhouse, M; Yücel, M; Zeiser, R1
Kelsey, P; Kirkland, K; Lambert, J; Malladi, R; Morley, N; Paul, R; Pearce, R; Peniket, A; Perry, J; Snowden, JA1
Allione, B; Calimeri, T; Cattaneo, C; Donadoni, G; Facchetti, F; Ferrari, D; Ferreri, AJM; Foppoli, M; Fumagalli, L; Lleshi, A; Pecciarini, L; Ponzoni, M; Re, A; Rigacci, L; Rossi, G; Sassone, M; Spina, M; Verga, L1
Akkurt, DM; Cinli, TA; Demir, I; Durusoy, SS; Gunes, AK; Ince, I; Ozkan, G; Pehlivan, M; Sarifakiogullari, S; Serin, I1
Dahi, PB; Devlin, SM; Giralt, SA; Hamlin, PA; Jakubowski, AA; Lee, J; Maloy, M; Matasar, MJ; Moskowitz, CH; Papadopoulos, E; Perales, MA; Petrlik, E; Rondon-Clavo, C; Ruiz, J; Sauter, CS; Scordo, M; Shah, G; Tamari, R1
Birkmann, J; Blaudszun, AR; Bornhäuser, M; Ehninger, G; Fiedler, F; Fricke, S; Hänel, A; Hänel, M; Herbst, R; Kroschinsky, F; Kürzel, S; Schaefer-Eckart, K; Stahl, L1
Bosch, M; Danyluk, P; Dusyk, T; Elemary, M; Hahn, L; Lim, H; Sabry, W; Stakiw, J1
Bhar, S; Carrum, G; Craddock, J; Doherty, EE; Friend, BD; Heslop, HE; Hill, LC; John, TD; Kamble, RT; Krance, RA; Lulla, P; Martinez, C; Muhsen, IN; Patel, S; Pingali, SR; Ramos, CA; Salem, B; Sasa, G; Wang, T; Wu, M1
Bouabdallah, K; Casasnovas, RO; Costes-Tertrais, D; Damaj, G; Dartigeas, C; Delette, C; Fogarty, P; Fornecker, LM; Garciaz, S; Gastinne, T; Gressin, R; Houot, R; Hueso, T; Le Gouill, S; Malak, S; Oberic, L; Ribrag, V; Tchernonog, E; Thieblemont, C1
Ghraichy, M; Jelcic, I; Martin, R; Müller, AM; Ruder, J; Schanz, U; Trück, J; von Niederhäusern, V1
Ahmad, I; Bambace, N; Bernard, L; Boisjoly, JA; Bouchard, P; Bourguignon, A; Chagnon, M; Cohen, S; Delisle, JS; Fleury, I; Kiss, T; Lachance, S; Mollica, L; Roy, DC; Roy, J; Sauvageau, G; Veilleux, O; Zehr, J1
Chari, A; Cho, HJ; Jakubowski, R; Moshier, E; Mouhieddine, TH; Parekh, S; Puliafito, B; Rattu, M; Richard, S; Richter, J; Rodriguez, C; Rossi, A; Sanchez, L; Steinberg, A; Thibaud, S1
Avni, B; Cohen, YI; Grisariu, S; Lebel, E; Shaulov, A; Stepensky, P; Zimran, E1

Reviews

46 review(s) available for carmustine and melphalan

ArticleYear
[Treatment of Kahler's disease].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1976, Jan-16, Volume: 52, Issue:3

    Topics: Bone Neoplasms; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Humans; Melphalan; Multiple Myeloma; Prednisone; Procarbazine; Urethane; Vincristine

1976
Patterns of resistance and therapeutic synergism among alkylating agents.
    Antibiotics and chemotherapy, 1978, Volume: 23

    Topics: Alkylating Agents; Animals; Carmustine; Cell Survival; Cyclophosphamide; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Leukemia L1210; Melphalan; Mice; Neoplasms, Experimental

1978
[Recent progress in chemotherapy of multiple myeloma].
    Recenti progressi in medicina, 1978, Volume: 65, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Procarbazine

1978
Current concepts in cancer. Multiple myeloma.
    The New England journal of medicine, 1979, Jul-26, Volume: 301, Issue:4

    Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Humans; Immunoglobulins; Lomustine; Melphalan; Multiple Myeloma; Neoplasm Staging; Plasmapheresis; Prednisone; Risk; Sodium Fluoride; Uremia

1979
Cutaneous malignant melanoma.
    International journal of dermatology, 1976, Volume: 15, Issue:9

    Topics: Adult; Aged; Biopsy; Carmustine; Cyclophosphamide; Dactinomycin; Female; Humans; Hydroxyurea; Male; Melanoma; Melphalan; Microscopy, Electron; Middle Aged; Prognosis; Skin Neoplasms; Sunlight; Wounds and Injuries

1976
The treatment of plasma cell myeloma.
    British journal of haematology, 1976, Volume: 33, Issue:4

    Topics: Animals; Carmustine; Cytarabine; Doxorubicin; Drug Evaluation, Preclinical; Fluorouracil; Humans; Melphalan; Methotrexate; Mice; Mice, Inbred BALB C; Multiple Myeloma; Myeloma Proteins; Prednisone; Procarbazine; Remission, Spontaneous

1976
Pharmacology of agents used in bone marrow transplant conditioning regimens.
    Critical reviews in oncology/hematology, 1992, Volume: 13, Issue:3

    Topics: Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Carmustine; Hematopoiesis; Humans; Immunosuppressive Agents; Melphalan; Whole-Body Irradiation

1992
[Treatment of relapses and failures in disseminated Hodgkin's disease].
    Presse medicale (Paris, France : 1983), 1991, Nov-02, Volume: 20, Issue:35

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dacarbazine; Doxorubicin; Epirubicin; Etoposide; Hodgkin Disease; Humans; Ifosfamide; Mechlorethamine; Melphalan; Methotrexate; Mitoguazone; Prednisone; Procarbazine; Remission Induction; Transplantation, Autologous; Transplantation, Homologous; Vinblastine; Vincristine

1991
[Chemotherapy of multiple myeloma].
    Sovetskaia meditsina, 1991, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Drug Evaluation; Humans; Melphalan; Multiple Myeloma; Prednisone; Remission Induction; Vincristine

1991
What is the value of autologous bone marrow transplantation in the treatment of relapsed or resistant Hodgkin's disease?
    Leukemia research, 1991, Volume: 15, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Cytarabine; Drug Resistance; Etoposide; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Melphalan; Neutropenia; Pilot Projects; Randomized Controlled Trials as Topic; Registries; Time Factors; Transplantation, Autologous

1991
The role of high-dose therapy and autologous bone marrow reinfusion in the treatment of Hodgkin's disease.
    Hematology/oncology clinics of North America, 1989, Volume: 3, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Dose-Response Relationship, Drug; Hodgkin Disease; Humans; Melphalan; Remission Induction; Transplantation, Autologous; Whole-Body Irradiation

1989
High dose chemotherapy in solid tumours in adults.
    Clinics in haematology, 1986, Volume: 15, Issue:1

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Breast Neoplasms; Carcinoma, Small Cell; Carmustine; Cell Separation; Cisplatin; Colonic Neoplasms; Cyclophosphamide; Etoposide; Glioma; Humans; Lung Neoplasms; Male; Melanoma; Melphalan; Neoplasms; Testicular Neoplasms; Whole-Body Irradiation

1986
Overview of the clinical relevance of autologous bone marrow transplantation.
    Clinics in haematology, 1986, Volume: 15, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Evaluation; Drug Resistance; Etoposide; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Melphalan; Neoplasm Recurrence, Local; Neoplasms; Thioguanine; Transplantation, Autologous

1986
Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. General considerations, the nitrosoureas and alkylating agents.
    Cancer chemotherapy and pharmacology, 1985, Volume: 14, Issue:2

    Topics: Alkylation; Antineoplastic Agents; Carmustine; Chlorambucil; Colony-Forming Units Assay; Cyclophosphamide; Drug Storage; Hydrogen-Ion Concentration; Lomustine; Mathematics; Melphalan; Nimustine; Nitrosourea Compounds; Solutions; Temperature; Tumor Stem Cell Assay

1985
[Chemotherapy of cancer of the large intestine].
    Sovetskaia meditsina, 1985, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colonic Neoplasms; Drug Evaluation; Fluorouracil; Humans; Lomustine; Melphalan; Methotrexate; Rectal Neoplasms; Semustine; Vincristine

1985
Plasma cell myeloma. An interpretive review.
    Cancer, 1972, Volume: 30, Issue:6

    Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Carmustine; Cell Division; Cyclophosphamide; Drug Resistance; Humans; Melphalan; Multiple Myeloma; Nitrosourea Compounds; Prednisone; Procarbazine; Prognosis; Remission, Spontaneous

1972
Chemotherapy of malignant melanoma.
    Cancer, 1972, Volume: 30, Issue:6

    Topics: Alkylating Agents; Amides; Animals; Antigen-Antibody Reactions; Antimetabolites; Antineoplastic Agents; Carmustine; Humans; Imidazoles; Immunity, Cellular; Immunotherapy; Ketosteroids; Lymphocyte Transfusion; Melanoma; Melphalan; Mice; Nitrosourea Compounds; Perfusion; Pregnenes; Procarbazine; Prognosis; Sex Factors; Skin Neoplasms; Triazenes; Vaccination; Vinca Alkaloids; Vincristine

1972
An overview of the status of the nitrosoureas in other tumors.
    Cancer chemotherapy reports. Part 3, 1973, Volume: 4, Issue:3

    Topics: Adenocarcinoma; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Carcinoma, Bronchogenic; Carmustine; Cyclohexanes; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Hodgkin Disease; Humans; Hydroxyurea; Leukemia, Lymphoid; Leukemia, Myeloid; Lymphoma; Melanoma; Melphalan; Multiple Myeloma; Nitrosourea Compounds; Prednisone; Vincristine

1973
Lung damage from cytotoxic drugs.
    Cancer chemotherapy and pharmacology, 1980, Volume: 4, Issue:1

    Topics: Antineoplastic Agents; Azathioprine; Bleomycin; Busulfan; Carmustine; Chlorambucil; Cyclophosphamide; Drug Therapy, Combination; Humans; Lung; Melphalan; Mercaptopurine; Methotrexate; Mitomycins; Oxygen Inhalation Therapy; Pneumonia; Procarbazine; Radiation Injuries

1980
The problem of permanent bone marrow damage after cytotoxic drug treatment.
    Oncology, 1984, Volume: 41, Issue:3

    Topics: Animals; Antineoplastic Agents; Bone Marrow Diseases; Busulfan; Carmustine; Cell Division; Cell Survival; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Hematopoiesis; Hematopoietic Stem Cells; Humans; Melphalan; Semustine; Time Factors

1984
Chronic lymphocytic leukemia.
    The Medical clinics of North America, 1984, Volume: 68, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Carmustine; Chromosomes, Human, 6-12 and X; Cyclophosphamide; Doxorubicin; Female; Humans; Leukemia, Lymphoid; Male; Melphalan; Middle Aged; Neoplasm Staging; Prednisone; T-Lymphocytes; Trisomy; Vincristine

1984
Glutathione metabolism as a determinant of therapeutic efficacy: a review.
    Cancer research, 1984, Volume: 44, Issue:10

    Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Biological Transport; Carmustine; Cyclophosphamide; Cytochrome P-450 Enzyme System; Glutathione; Humans; Mechlorethamine; Melphalan; Mercaptopurine; Mice; Neoplasms; Neoplasms, Experimental

1984
High-dose alkylating agent therapy: a review of clinical experiences.
    Cancer drug delivery, 1984,Summer, Volume: 1, Issue:3

    Topics: Alkylating Agents; Busulfan; Carcinoma, Bronchogenic; Carmustine; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Mechlorethamine; Melphalan; Neoplasms; Ovarian Neoplasms; Testicular Neoplasms

1984
Combination chemotherapy of advanced chronic lymphocytic leukemia: the M-2 protocol (vincristine, BCNU, cyclophosphamide, melphalan, and prednisone).
    Blood, 1982, Volume: 60, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Female; Femur Head Necrosis; Humans; Hypercalcemia; Leukemia, Lymphoid; Male; Melphalan; Neoplasms, Multiple Primary; Paresthesia; Prednisone; Prognosis; Thrombocytopenia; Vincristine

1982
Intensive chemotherapy for solid tumours--current clinical applications.
    Cancer chemotherapy and pharmacology, 1982, Volume: 9, Issue:3

    Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combination; Etoposide; Forecasting; Humans; Melphalan; Neoplasms

1982
[Chemotherapy of multiple myeloma. Review of the recent trials].
    Recenti progressi in medicina, 1981, Volume: 71, Issue:2

    Topics: Antineoplastic Agents; Azathioprine; Carmustine; Chlorambucil; Cyclophosphamide; Drug Therapy, Combination; Humans; Melphalan; Multiple Myeloma; Prednisone; Procarbazine; Vincristine

1981
Intensive therapy and autotransplantation in Hodgkin's disease.
    Stem cells (Dayton, Ohio), 1994, Volume: 12, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Digestive System Diseases; Etoposide; Heart Diseases; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lung Diseases; Melphalan; Multicenter Studies as Topic; Podophyllotoxin; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome; Whole-Body Irradiation

1994
Pharmacokinetics of alkylating agents.
    Cancer surveys, 1993, Volume: 17

    Topics: Alkylating Agents; Carmustine; Chlorambucil; Cyclophosphamide; Humans; Ifosfamide; Lomustine; Melphalan; Neoplasms; Nitrosourea Compounds; Organophosphorus Compounds; Thiotepa

1993
Plasma cell dyscrasia with marrow fibrosis. A reversible syndrome mimicking agnogenic myeloid metaplasia.
    Cancer, 1994, Feb-01, Volume: 73, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Diagnosis, Differential; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Paraproteinemias; Prednisone; Primary Myelofibrosis; Splenomegaly; Vincristine

1994
Peripheral blood progenitor cell transplantation: a single centre experience comparing two mobilisation regimens in 67 patients.
    Bone marrow transplantation, 1996, Volume: 17, Issue:4

    Topics: Adolescent; Adult; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Cell Movement; Colony-Forming Units Assay; Cyclophosphamide; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Kidney Diseases; Leukapheresis; Leukocyte Count; Male; Melphalan; Middle Aged; Neoplasms; Podophyllotoxin; Retrospective Studies; Thiotepa; Transplantation Conditioning

1996
Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy.
    Bone marrow transplantation, 1999, Volume: 23, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Encephalitis; Etoposide; Female; Humans; Immunoglobulins, Intravenous; Immunosuppression Therapy; Injections, Spinal; Interferon-alpha; Interleukin-12; Leukoencephalopathy, Progressive Multifocal; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Melphalan; Memory Disorders; Middle Aged; Podophyllotoxin; Transplantation Conditioning; Transplantation, Autologous; Vincristine

1999
Considerations in the selection of an appropriate conditioning regimen for the treatment of rheumatoid arthritis by autologous peripheral blood stem cell transplantation.
    The Journal of rheumatology. Supplement, 2001, Volume: 64

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Melphalan; Podophyllotoxin; Radiotherapy, Adjuvant; Transplantation Conditioning; Transplantation, Autologous; Vidarabine

2001
[Primary cardiac lymphoma: cytological diagnosis and treatment with response to polychemotherapy and hematopoietic precursor autotransplant. Presentation of a case a review of the literature].
    Anales de medicina interna (Madrid, Spain : 1984), 2002, Volume: 19, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Atrial Flutter; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Echocardiography, Transesophageal; Etoposide; Heart Failure; Heart Neoplasms; Heart Septum; Hematopoietic Stem Cell Transplantation; Humans; Hydrocortisone; Immunocompetence; Injections, Spinal; Lymphoma, Large B-Cell, Diffuse; Magnetic Resonance Imaging; Male; Melphalan; Methotrexate; Middle Aged; Pleural Effusion; Prednisone; Remission Induction; Tomography, X-Ray Computed; Transplantation Conditioning; Transplantation, Autologous; Vincristine

2002
Autologous stem cell transplantation in patients with mantle cell lymphoma.
    Leukemia & lymphoma, 2002, Volume: 43, Issue:6

    Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Finland; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Life Tables; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prednisone; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine

2002
Long-term follow up of high-dose chemotherapy with autologous stem cell rescue in adults with Ewing tumor.
    American journal of clinical oncology, 2005, Volume: 28, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Carmustine; Cisplatin; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Life Tables; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prognosis; Retrospective Studies; Risk Factors; Sarcoma, Ewing; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine

2005
Autologous stem cell transplantation for chronic lymphocytic leukemia.
    Seminars in hematology, 2007, Volume: 44, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Etoposide; Evidence-Based Medicine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Melphalan; Neoplasm, Residual; Neoplasms, Second Primary; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation

2007
Frequency, severity and risk factors for oral mucositis after BEAM conditioning and autologous peripheral blood stem cell transplantation: a single center analysis and review of the literature.
    Leukemia & lymphoma, 2007, Volume: 48, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Humans; Incidence; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Prognosis; Risk Factors; Stomatitis; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous

2007
[Interdigitating dendritic cell sarcoma of lower extremities resistant to high dose chemotherapy BEAM with peripheral blood stem cell transplantation].
    Vnitrni lekarstvi, 2009, Volume: 55, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carmustine; Cytarabine; Dendritic Cell Sarcoma, Interdigitating; Drug Resistance, Neoplasm; Etoposide; Humans; Leg; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Positron-Emission Tomography; Soft Tissue Neoplasms; Tibia; Tomography, X-Ray Computed

2009
[Stem cell therapy in multiple sclerosis: a clinical update].
    Zeitschrift fur Rheumatologie, 2009, Volume: 68, Issue:3

    Topics: Animals; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Carmustine; Central Nervous System; Clinical Trials, Phase II as Topic; Controlled Clinical Trials as Topic; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Melphalan; Mitoxantrone; Multicenter Studies as Topic; Multiple Sclerosis; Podophyllotoxin; Risk Assessment; Survival Rate; Treatment Outcome

2009
Standard therapy of advanced Hodgkin lymphoma.
    Hematology. American Society of Hematology. Education Program, 2009

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Mechlorethamine; Melphalan; Methylprednisolone; Positron-Emission Tomography; Prednisone; Procarbazine; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Salvage Therapy; Transplantation, Autologous; Treatment Outcome; Vinblastine; Vincristine; Vindesine

2009
Intensified therapy followed by autologous stem-cell transplantation (ASCT) versus conventional therapy as first-line treatment of follicular lymphoma: a meta-analysis.
    Hematological oncology, 2013, Volume: 31, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Interferon alpha-2; Interferon-alpha; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Neoplasms, Second Primary; Prednisone; Recombinant Proteins; Remission Induction; Survival Analysis; Teniposide; Transplantation, Autologous; Treatment Outcome; Vincristine; Whole-Body Irradiation

2013
Outcomes after (90) Yttrium-ibritumomab tiuxetan-BEAM in diffuse large B-cell lymphoma: a meta-analysis.
    Cancer medicine, 2014, Volume: 3, Issue:4

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemoradiotherapy; Cytarabine; Disease-Free Survival; Etoposide; Humans; Lymphoma, Large B-Cell, Diffuse; Melphalan; Radiopharmaceuticals; Treatment Outcome

2014
[Treatment strategy of Hodgkin lymphoma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brentuximab Vedotin; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Immunoconjugates; Mechlorethamine; Melphalan; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prednisone; Procarbazine; Prognosis; Radiotherapy, Adjuvant; Rituximab; Vinblastine; Vincristine

2014
Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning.
    Leukemia & lymphoma, 2016, Volume: 57, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Melphalan; Podophyllotoxin; Recurrence; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2016
Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review.
    Bone marrow transplantation, 2017, Volume: 52, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cytarabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Melphalan; Podophyllotoxin

2017
[Sinusoidal obstruction syndrome after BeAM conditioning regiment for autologous stem cell transplantation: Imputability of bendamustine? Report of two cases and literature review].
    La Revue de medecine interne, 2018, Volume: 39, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Autologous

2018

Trials

206 trial(s) available for carmustine and melphalan

ArticleYear
Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB.
    Blood, 1979, Volume: 54, Issue:1

    Topics: Alkylating Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Humans; Leukopenia; Melphalan; Multiple Myeloma; Prednisone; Prognosis

1979
Multiple myeloma resistant to melphalan: treatment with cyclophosphamide, prednisone, and BCNU.
    Cancer treatment reports, 1979, Volume: 63, Issue:8

    Topics: Carmustine; Cyclophosphamide; Drug Resistance; Drug Therapy, Combination; Humans; Melphalan; Multiple Myeloma; Prednisone

1979
The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia.
    The New England journal of medicine, 1979, 10-04, Volume: 301, Issue:14

    Topics: Acute Disease; Adult; Aged; Alkylating Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Immunoglobulins; Leukemia; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Prospective Studies; Risk

1979
Combination therapy for multiple myeloma.
    Cancer, 1977, Volume: 40, Issue:6

    Topics: Antineoplastic Agents; Azathioprine; Carmustine; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Remission, Spontaneous; Time Factors; Vincristine

1977
Remission maintenance therapy for multiple myeloma.
    Archives of internal medicine, 1975, Volume: 135, Issue:1

    Topics: Bone Neoplasms; Carmustine; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Procarbazine; Recurrence; Remission, Spontaneous; Time Factors; Vincristine

1975
Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults.
    Lancet (London, England), 1992, Jan-25, Volume: 339, Issue:8787

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Carmustine; Cause of Death; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Follow-Up Studies; Humans; Melphalan; Multiple Myeloma; Prognosis; Survival Analysis

1992
Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest.
    Bone marrow transplantation, 1992, Volume: 9, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukapheresis; Male; Melphalan; Middle Aged; Recombinant Proteins; Recurrence; Transplantation, Autologous

1992
BEAM autografting in lymphoma--experience at one centre.
    Leukemia & lymphoma, 1992, Volume: 7 Suppl

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Humans; Lymphoma; Male; Melphalan; Middle Aged; Survival Rate; Transplantation, Autologous

1992
VAD or VMBCP in severe multiple myeloma. The Groupe d'Etudes et de Recherche sur le Myélome (GERM).
    British journal of haematology, 1992, Volume: 80, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Vincristine

1992
GM-CSF instead of autologous bone-marrow transplantation after the BEAM regimen.
    Lancet (London, England), 1991, Sep-07, Volume: 338, Issue:8767

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Drug Evaluation; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Hematopoietic System; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Transplantation, Autologous

1991
[Therapeutic plasmapheresis in patients with multiple myeloma].
    Acta haematologica Polonica, 1991, Volume: 22, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Female; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Plasmapheresis; Prednisone; Vincristine

1991
[Chemotherapy and immunomodulating treatment of patients with multiple myeloma].
    Acta haematologica Polonica, 1991, Volume: 22, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Female; Humans; Interferon-alpha; Levamisole; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Remission Induction; Thymus Extracts; Vincristine

1991
Waldenström's macroglobulinemia: long-term results with the M-2 protocol.
    Cancer investigation, 1991, Volume: 9, Issue:1

    Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Drug Administration Schedule; Humans; Leukopenia; Melphalan; Nausea; Prednisone; Vincristine; Vomiting; Waldenstrom Macroglobulinemia

1991
Second and third responses to the same induction regimen in relapsing patients with multiple myeloma.
    Cancer, 1991, Sep-01, Volume: 68, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Vincristine

1991
alpha-Interferon for remission maintenance: preliminary report on the Southwest Oncology Group Study.
    Seminars in oncology, 1991, Volume: 18, Issue:5 Suppl 7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Humans; Interferon-alpha; Melphalan; Multiple Myeloma; Prednisone; Remission Induction; Vincristine

1991
Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Carmustine; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Vincristine

1991
Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Treatmen
    Onkologie, 1990, Volume: 13, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Dexamethasone; Doxorubicin; Female; Humans; Interferon Type I; Male; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Recombinant Proteins; Vincristine

1990
Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Carmustine; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Randomized Controlled Trials as Topic; Remission Induction; Vincristine

1990
Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden.
    British journal of haematology, 1990, Volume: 74, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Female; Humans; Male; Melphalan; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Prednisone; Prospective Studies; Randomized Controlled Trials as Topic; Vincristine

1990
Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) therapy for multiple myeloma. Early results of a multicenter trial. The German Myeloma Treatment Group.
    Onkologie, 1990, Volume: 13, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Melphalan; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Staging; Prednisone; Vincristine

1990
A randomized multicentric study comparing alternating combination chemotherapy (VCMP/VBAP) and melphalan-prednisone in multiple myeloma.
    Blut, 1990, Volume: 60, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Male; Melphalan; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Prednisone; Prospective Studies; Randomized Controlled Trials as Topic; Vincristine

1990
GM-CSF accelerates neutrophil recovery after autologous bone marrow transplantation for Hodgkin's disease.
    Bone marrow transplantation, 1989, Volume: 4, Issue:1

    Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Colony-Stimulating Factors; Combined Modality Therapy; Cytarabine; Drug Evaluation; Etoposide; Granulocytes; Hodgkin Disease; Humans; Leukocyte Count; Macrophages; Melphalan; Neutropenia; Neutrophils; Postoperative Complications; Recombinant Proteins; Transplantation, Autologous

1989
The role of high-dose therapy and autologous bone marrow reinfusion in the treatment of Hodgkin's disease.
    Hematology/oncology clinics of North America, 1989, Volume: 3, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Dose-Response Relationship, Drug; Hodgkin Disease; Humans; Melphalan; Remission Induction; Transplantation, Autologous; Whole-Body Irradiation

1989
Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III--a randomized study from MGCS.
    European journal of haematology, 1989, Volume: 43, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prospective Studies; Random Allocation; Sweden; Vincristine

1989
Cell kinetics and therapy in multiple myeloma: an update of the M83 protocol.
    Bone marrow transplantation, 1989, Volume: 4 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Cell Cycle; Cyclophosphamide; Diagnosis, Differential; Doxorubicin; Drug Evaluation; Humans; Melphalan; Multiple Myeloma; Paraproteinemias; Plasma Cells; Prednisone; Prognosis; Random Allocation; Vincristine

1989
Vincristine and prednisone prolong the survival of patients receiving intravenous or oral melphalan for multiple myeloma: Cancer and Leukemia Group B experience.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1988, Volume: 6, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; Lomustine; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Random Allocation; Vincristine

1988
[Results of the combined treatment of advanced multiple myeloma by the M-2 protocol: cyclophosphamide, vincristine, melphalan, nitrosourea and prednisone].
    Polskie Archiwum Medycyny Wewnetrznej, 1987, Volume: 77, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Female; Humans; Male; Melphalan; Middle Aged; Multiple Sclerosis; Prednisone; Vincristine

1987
Overview of the clinical relevance of autologous bone marrow transplantation.
    Clinics in haematology, 1986, Volume: 15, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Evaluation; Drug Resistance; Etoposide; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Melphalan; Neoplasm Recurrence, Local; Neoplasms; Thioguanine; Transplantation, Autologous

1986
Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Azathioprine; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Humans; Melphalan; Multiple Myeloma; Prednisone; Random Allocation; Risk; Time Factors; Vincristine

1986
Results and further perspectives of plasmocytoma chemotherapy.
    Neoplasma, 1986, Volume: 33, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Humans; Melphalan; Multiple Myeloma; Prednisone; Vincristine

1986
Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:8

    Topics: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Hematologic Diseases; Humans; Levamisole; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Prognosis; Random Allocation; Vincristine

1986
Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Hypersensitivity; Female; Humans; Leukocyte Count; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Platelet Count

1986
Current results of a multicenter trial in multiple myeloma.
    Onkologie, 1986, Volume: 9, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Random Allocation; Vincristine

1986
Multiple myeloma in central Norway 1981-1982: a randomized clinical trial of 5-drug combination therapy versus standard therapy.
    Scandinavian journal of haematology, 1986, Volume: 37, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Humans; Melphalan; Multiple Myeloma; Prednisone; Random Allocation; Vincristine

1986
Age and the treatment of multiple myeloma. Southeastern Cancer Study Group experience.
    The American journal of medicine, 1985, Volume: 79, Issue:3

    Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis

1985
Treatment of multiple myeloma: a randomized study of three different regimens.
    Leukemia research, 1985, Volume: 9, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Immunoglobulin A; Immunoglobulin D; Leukopenia; Male; Melphalan; Middle Aged; Multiple Myeloma; Peptichemio; Prednisone; Prognosis; Random Allocation; Vincristine

1985
Phase III study of intermittent 5-drug regimen (VBCMP) versus intermittent 3-drug regimen (VMP) versus intermittent melphalan and prednisone (MP) in myelomatosis.
    Scandinavian journal of haematology, 1985, Volume: 35, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Drug Resistance; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Vincristine

1985
Response rate and survival in myeloma patients receiving prednisone alone.
    Medical and pediatric oncology, 1985, Volume: 13, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Random Allocation; Recurrence

1985
[Therapeutic experiences in multiple myeloma].
    Schweizerische medizinische Wochenschrift, 1972, Nov-04, Volume: 102, Issue:44

    Topics: Aniline Compounds; Antineoplastic Agents; Blood Sedimentation; Carmustine; Clinical Trials as Topic; Drug Synergism; Hemoglobinometry; Humans; Melphalan; Multiple Myeloma; Mustard Compounds; Prednisone; Procarbazine; Prognosis; Remission, Spontaneous

1972
Combination therapy for myelomatosis.
    British medical journal, 1974, Dec-07, Volume: 4, Issue:5944

    Topics: Bone Marrow Examination; Calcium; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Hemoglobins; Humans; Immunoglobulin Fragments; Immunoglobulins; Kidney Function Tests; Melphalan; Multiple Myeloma; Myeloma Proteins; Plasmacytoma; Prednisolone; Serum Albumin

1974
Chemotherapy for multiple myeloma.
    Cancer, 1984, Feb-01, Volume: 53, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Humans; Levamisole; Melphalan; Multiple Myeloma; Prednisone; Prognosis; Random Allocation; Vincristine

1984
Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
    Cancer treatment reports, 1984, Volume: 68, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Resistance; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Neoplasm Staging; Prednisone; Vincristine

1984
Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma.
    Blood, 1984, Volume: 63, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Calcium Gluconate; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Drug Resistance; Drug Therapy, Combination; Fluoxymesterone; Humans; Long-Term Care; Melphalan; Multiple Myeloma; Prednisone; Radiography; Sodium Fluoride; United States; Vitamin D

1984
[Treatment of multiple myeloma in stages I and II. Comparative study of an M-2 protocol and melphalan-prednisone].
    Sangre, 1984, Volume: 29, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Vincristine

1984
Chemotherapy of plasma-cell myeloma.
    The New England journal of medicine, 1980, Feb-14, Volume: 302, Issue:7

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Humans; Melphalan; Multiple Myeloma; Prednisone; Vincristine

1980
Effectiveness of two-stage treatment of multiple myeloma with melphalan and with melphalan in combination with cyclophosphamide, carmustine, vincristine and prednisone.
    Archivum immunologiae et therapiae experimentalis, 1981, Volume: 29, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Vincristine

1981
Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.
    Cancer treatment reports, 1982, Volume: 66, Issue:6

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Prospective Studies; Random Allocation

1982
Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone.
    Cancer treatment reports, 1982, Volume: 66, Issue:3

    Topics: Aged; Antineoplastic Agents; Carmustine; Cyclophosphamide; Doxorubicin; Drug Resistance; Drug Therapy, Combination; Female; Humans; Leukopenia; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Random Allocation; Thrombocytopenia

1982
Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience.
    Cancer, 1982, Nov-01, Volume: 50, Issue:9

    Topics: Antineoplastic Agents; Carmustine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leukopenia; Lomustine; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Random Allocation; Thrombocytopenia; Vincristine

1982
Chemotherapy and radiotherapy in locally advanced cervical cancer.
    Acta oncologica (Stockholm, Sweden), 1995, Volume: 34, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carmustine; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Melphalan; Middle Aged; Prednisone; Survival Rate; Uterine Cervical Neoplasms

1995
High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age.
    Journal of the National Cancer Institute. Monographs, 1994, Issue:16

    Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Breast Neoplasms; Carboplatin; Carmustine; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Melphalan; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Survival Analysis; Thiotepa; Treatment Outcome

1994
Granulocyte colony-stimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:4

    Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Combined Modality Therapy; Cytarabine; Etoposide; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Platelet Count

1995
Economic analysis of prophylactic G-CSF after mini-BEAM salvage chemotherapy for Hodgkin's and non-Hodgkin's lymphoma.
    Leukemia & lymphoma, 1995, Volume: 17, Issue:1-2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Fever; Granulocyte Colony-Stimulating Factor; Hodgkin Disease; Humans; Length of Stay; Lymphoma, Non-Hodgkin; Melphalan; Neutropenia; Retrospective Studies; Salvage Therapy

1995
Development of a criterion for response to therapy at 6 months in multiple myeloma.
    European journal of haematology, 1995, Volume: 55, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Immunoglobulin A; Immunoglobulin G; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisolone; Prednisone; Prognosis; Survival Rate; Vincristine

1995
A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group.
    European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dexamethasone; Doxorubicin; Female; Humans; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prospective Studies; Remission Induction; Survival Rate; Vincristine

1995
Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Confidence Intervals; Critical Care; Cytarabine; Erythrocyte Transfusion; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Neutropenia; Platelet Transfusion; Podophyllotoxin; Preoperative Care; Prognosis; Recurrence; Salvage Therapy; Time Factors

1995
BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multivariate Analysis; Prognosis; Recurrence; Remission Induction; Survival Rate; Transplantation, Autologous

1995
High-dose consolidation with local radiation and bone marrow rescue in patients with advanced neuroblastoma.
    Medical and pediatric oncology, 1994, Volume: 23, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Carmustine; Child; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Follow-Up Studies; Humans; Infant; Melphalan; Neoplasm Recurrence, Local; Neuroblastoma; Radiotherapy, High-Energy; Remission Induction; Survival Rate

1994
Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:11

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Glucocorticoids; Humans; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Remission Induction; Survival Analysis; Vincristine

1994
Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.
    Lancet (London, England), 1993, Apr-24, Volume: 341, Issue:8852

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Survival Rate

1993
Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etoposide; Female; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Prospective Studies; Survival Analysis; Treatment Outcome

1994
Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: the LMCE2 study.
    British journal of cancer, 1993, Volume: 67, Issue:1

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Carmustine; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Infant; Male; Melphalan; Neuroblastoma; Pilot Projects; Teniposide; Vincristine

1993
The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients.
    Blood, 1993, Mar-01, Volume: 81, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Prognosis; Risk; Survival Rate; Transplantation, Autologous

1993
Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Survival Rate; Vincristine

1993
Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma.
    Leukemia & lymphoma, 1995, Volume: 17, Issue:3-4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma; Male; Melphalan; Middle Aged

1995
Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients.
    Lancet (London, England), 1996, Feb-10, Volume: 347, Issue:8998

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukocytes, Mononuclear; Lymphoma, Non-Hodgkin; Male; Melphalan; Platelet Transfusion; Podophyllotoxin; Prospective Studies; Recombinant Proteins; Survival Analysis; Time Factors; Transplantation, Autologous

1996
Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Black People; Carmustine; Cohort Studies; Cyclophosphamide; Doxorubicin; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Retrospective Studies; Survival Analysis; Vincristine; White People

1996
High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
    Bone marrow transplantation, 1996, Volume: 17, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow Diseases; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Life Tables; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Polymerase Chain Reaction; Recombinant Proteins; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation

1996
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
    The New England journal of medicine, 1996, Jul-11, Volume: 335, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Prednisone; Prospective Studies; Salvage Therapy; Survival Analysis; Vincristine

1996
High lactate dehydrogenase level is associated with an adverse outlook in autografting for Hodgkin's disease.
    Bone marrow transplantation, 1996, Volume: 17, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; L-Lactate Dehydrogenase; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Recurrence; Survival Rate; Transplantation, Autologous; Treatment Outcome

1996
Peripheral blood progenitor cell transplantation: a single centre experience comparing two mobilisation regimens in 67 patients.
    Bone marrow transplantation, 1996, Volume: 17, Issue:4

    Topics: Adolescent; Adult; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Cell Movement; Colony-Forming Units Assay; Cyclophosphamide; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Kidney Diseases; Leukapheresis; Leukocyte Count; Male; Melphalan; Middle Aged; Neoplasms; Podophyllotoxin; Retrospective Studies; Thiotepa; Transplantation Conditioning

1996
Factors for rapid and sustained hematopoietic reconstitution by circulating progenitor-cell transplantation in non-Hodgkin's lymphoma.
    Cancer chemotherapy and pharmacology, 1996, Volume: 38 Suppl

    Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prognosis

1996
Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
    Leukemia & lymphoma, 1996, Volume: 20, Issue:5-6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Life Tables; Male; Melphalan; Middle Aged; Multiple Myeloma; Myocardial Infarction; Neutropenia; Prednisone; Recombinant Proteins; Remission Induction; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vincristine

1996
Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial.
    Blood, 1996, Oct-01, Volume: 88, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Clone Cells; Codon; Combined Modality Therapy; Cyclophosphamide; Disease Progression; DNA Mutational Analysis; DNA, Neoplasm; Female; Genes, ras; Humans; Immunologic Factors; Interferon-alpha; Life Tables; Male; Melphalan; Middle Aged; Multiple Myeloma; Polymorphism, Restriction Fragment Length; Prednisone; Prognosis; Survival Analysis; Vincristine

1996
Treatment of multiple myeloma in elderly people: long-term results in 178 patients.
    Age and ageing, 1996, Volume: 25, Issue:5

    Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cause of Death; Cyclophosphamide; Doxorubicin; Female; Geriatric Assessment; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Prognosis; Survival Rate; Vincristine

1996
Peripheral blood progenitor cell mobilization with Dexa-Beam/G-CSF, ether lipid purging, and autologous transplantation after high-dose CBV treatment: a safe and effective regimen in patients with poor risk malignant lymphomas.
    Leukemia & lymphoma, 1996, Volume: 23, Issue:3-4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Cell Movement; Cyclophosphamide; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukapheresis; Lymphoma; Melphalan; Middle Aged; Phospholipid Ethers; Risk Factors; Transplantation Conditioning

1996
Standard therapy versus autologous transplantation in multiple myeloma.
    Hematology/oncology clinics of North America, 1997, Volume: 11, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Doxorubicin; Female; Humans; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Prospective Studies; Vincristine

1997
Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Cancer, 1997, Apr-15, Volume: 79, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cross-Over Studies; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Prednisone; Remission Induction; Survival Analysis; Treatment Outcome; Vincristine

1997
Randomized trial showing equivalent efficacy of filgrastim 5 micrograms/kg/d and 10 micrograms/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Mesna; Middle Aged; Neutropenia; Patient Selection; Recombinant Proteins; Thiotepa

1997
Impact of high-dose salvage therapy (BEAM) on overall survival in younger patients with advanced large-cell lymphomas entered into BNLI trials.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8 Suppl 1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Staging; Podophyllotoxin; Prednisone; Salvage Therapy; Treatment Outcome; Vincristine

1997
Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Staging; Prospective Studies; Transplantation, Autologous

1997
High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure.
    Leukemia, 1997, Volume: 11, Issue:10

    Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Podophyllotoxin; Risk Factors

1997
Transplantation in patients with multiple myeloma: a multicenter comparative analysis of peripheral blood stem cell and allogeneic transplant.
    American journal of clinical oncology, 1997, Volume: 20, Issue:5

    Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Carmustine; Cause of Death; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Whole-Body Irradiation

1997
Navoban (tropisetron, ICS 205-930) and dexamethasone combination in the prevention of vomiting for patients receiving preconditioning high-dose chemotherapy before marrow transplantation.
    Japanese journal of clinical oncology, 1998, Volume: 28, Issue:2

    Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Carmustine; Child; Cyclophosphamide; Cytarabine; Dexamethasone; Dizziness; Drug Therapy, Combination; Female; Headache; Heartburn; Humans; Indoles; Leukemia; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Transplantation Conditioning; Tropisetron; Vomiting; Whole-Body Irradiation

1998
Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate; Treatment Outcome

1998
Treatment of patients with malignant lymphoma with Mini-BEAM reduces the yield of CD34+ peripheral blood stem cells.
    Bone marrow transplantation, 1998, Volume: 21, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Melphalan

1998
Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure?
    British journal of cancer, 1998, Volume: 77, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chlorambucil; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Fluorouracil; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Hydrocortisone; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Melphalan; Methotrexate; Methylprednisolone; Middle Aged; Mitomycins; Prednisone; Prospective Studies; Treatment Outcome; Vincristine

1998
Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology).
    Leukemia, 1998, Volume: 12, Issue:7

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Prospective Studies; Recombinant Proteins; Remission Induction; Therapeutics; Vincristine

1998
[Level of interleukin-6 (IL-6), soluble interleukin-6 receptors (sIL-6R) and tumor necrosis factor alpha (TNF-alpha) in untreated and progressing multiple myeloma].
    Polskie Archiwum Medycyny Wewnetrznej, 1998, Volume: 99, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Disease Progression; Female; Humans; Interleukin-6; Kidney Failure, Chronic; Male; Melphalan; Methylprednisolone; Middle Aged; Multiple Myeloma; Prednisone; Receptors, Interleukin; Receptors, Interleukin-6; Recombinant Fusion Proteins; Survival Rate; Tumor Necrosis Factor-alpha; Vincristine

1998
Correlation between granulocyte/macrophage-colony-forming units and CD34+ cells in apheresis products from patients treated with different chemotherapy regimens and granulocyte-colony-stimulating factor to mobilize peripheral blood progenitor cells.
    Journal of cancer research and clinical oncology, 1998, Volume: 124, Issue:6

    Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Carmustine; Cell Separation; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Epirubicin; Etoposide; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Granulocytes; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Ifosfamide; Macrophages; Male; Melphalan; Neoplasms; Prednisolone; Vincristine

1998
VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85).
    British journal of haematology, 1998, Volume: 103, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Salvage Therapy; Survival Rate; Treatment Outcome; Vincristine

1998
Dexa-BEAM is not effective in patients with relapsed or resistant aggressive high-grade non-Hodgkin's lymphoma.
    Leukemia & lymphoma, 1999, Volume: 33, Issue:3-4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Drug Resistance, Multiple; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Staging; Recurrence; Survival Analysis; Time Factors

1999
Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Alkylating Agents; Amyloidosis; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Prednisone; Prospective Studies; Survival Rate; Vincristine

1999
The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Cancer, 1999, Sep-15, Volume: 86, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Carmustine; Cyclophosphamide; Hematologic Diseases; Humans; Infections; Interferon Type I; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recombinant Proteins; Survival Analysis; Vincristine

1999
Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
    Haematologica, 1999, Volume: 84, Issue:11

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carmustine; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Podophyllotoxin; Recurrence; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

1999
Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study.
    Bone marrow transplantation, 2000, Volume: 25, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Neoplasms, Second Primary; Recurrence; Survival Rate; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation

2000
Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies.
    Bone marrow transplantation, 2000, Volume: 25, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infections; Lung Diseases; Male; Melphalan; Middle Aged; Retrospective Studies; Transplantation, Autologous

2000
High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis.
    Bone marrow transplantation, 2000, Volume: 25, Issue:5

    Topics: Adolescent; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Carmustine; CD4-CD8 Ratio; Cytarabine; Etoposide; Female; Fever; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infections; Leukapheresis; Lymphocyte Subsets; Magnetic Resonance Imaging; Male; Melphalan; Middle Aged; Multiple Sclerosis; Neutropenia; Prognosis; Severity of Illness Index

2000
The role of autologous transplantation in patients with multiple myeloma aged 65 years and over.
    Bone marrow transplantation, 2000, Volume: 25, Issue:5

    Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Chemical and Drug Induced Liver Injury; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Graft Survival; Heart Diseases; Hematopoietic Stem Cell Mobilization; Hospitalization; Humans; Interferons; Kidney Diseases; Male; Matched-Pair Analysis; Melphalan; Methylprednisolone; Middle Aged; Multiple Myeloma; Neutropenia; Neutrophils; Platelet Count; Recurrence; Sepsis; Survival Rate; Thrombocytopenia; Transplantation, Autologous; Vincristine

2000
Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.
    Leukemia & lymphoma, 2000, Volume: 37, Issue:1-2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous

2000
Dexa-BEAM: an effective regimen for cytoreduction prior to high-dose chemotherapy with autologous stem cell support for patients with relapsed/refractory mantle-cell lymphoma.
    Leukemia & lymphoma, 2000, Volume: 37, Issue:1-2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Autologous

2000
Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial.
    British journal of haematology, 2000, Volume: 109, Issue:4

    Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Prospective Studies; Survival Rate; Transplantation, Autologous

2000
Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation.
    Bone marrow transplantation, 2000, Volume: 26, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclosporine; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukapheresis; Male; Melphalan; Methotrexate; Middle Aged; Neoplasms; Prospective Studies; Survival Analysis; T-Lymphocytes; Transplantation Chimera; Transplantation Conditioning; Transplantation Tolerance; Vidarabine

2000
Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Dec-01, Volume: 18, Issue:23

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cyclosporine; Cytarabine; Etoposide; Female; Graft vs Tumor Effect; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Pilot Projects; Risk Factors; Survival Rate; Transplantation Chimera; Vidarabine

2000
Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
    Neoplasma, 2000, Volume: 47, Issue:5

    Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Granisetron; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lymphoma; Male; Melphalan; Nausea; Ondansetron; Serotonin Antagonists; Transplantation, Autologous; Tropisetron; Vomiting

2000
Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized stud
    European journal of haematology, 2001, Volume: 66, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Greece; Humans; Interferon alpha-2; Interferon-alpha; Life Tables; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Prospective Studies; Recombinant Proteins; Remission Induction; Survival Analysis; Treatment Outcome; Vincristine

2001
A prospective study of intensive induction therapy with high-dose consolidation in patients with aggressive non-Hodgkin's lymphoma and two or three adverse prognostic factors.
    Leukemia, 2000, Volume: 14, Issue:12

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Feasibility Studies; Female; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prognosis; Prospective Studies; Treatment Outcome

2000
Immunoablative therapy with autologous stem cell transplantation in the treatment of poor risk multiple sclerosis.
    Transplantation proceedings, 2001, Volume: 33, Issue:3

    Topics: Adrenal Cortex Hormones; Adult; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphocyte Depletion; Magnetic Resonance Imaging; Melphalan; Middle Aged; Multiple Sclerosis; Patient Selection; T-Lymphocytes

2001
Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSF.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Double-Blind Method; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hodgkin Disease; Humans; Leukocyte Count; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Neoplasm Staging; Treatment Outcome

2001
Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS.
    Neurology, 2001, Jul-10, Volume: 57, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Gadolinium; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Melphalan; Middle Aged; Multiple Sclerosis, Chronic Progressive; Preoperative Care; Transplantation, Autologous; Treatment Outcome

2001
Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jan-15, Volume: 20, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Male; Melphalan; Middle Aged; Mitoguazone; Recurrence; Salvage Therapy; Transplantation, Autologous; Vinblastine; Vinorelbine

2002
The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients.
    The hematology journal : the official journal of the European Haematology Association, 2000, Volume: 1, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Neoplasm Staging; Prednisolone; Prednisone; Prognosis; Survival Rate; Time Factors; Transplantation, Autologous; Treatment Outcome; Vincristine; Whole-Body Irradiation

2000
Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients.
    The hematology journal : the official journal of the European Haematology Association, 2001, Volume: 2, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cause of Death; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Remission Induction; Survival Analysis; Survival Rate; Vincristine

2001
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.
    Lancet (London, England), 2002, Jun-15, Volume: 359, Issue:9323

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cause of Death; Cytarabine; Dexamethasone; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Recurrence; Salvage Therapy

2002
Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.
    Cytotherapy, 2001, Volume: 3, Issue:3

    Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Blood Donors; Carmustine; Cytarabine; Disease Progression; Etoposide; Female; Graft Survival; Graft vs Host Disease; Humans; Immunosuppression Therapy; Lymphocyte Transfusion; Lymphoproliferative Disorders; Male; Melphalan; Middle Aged; Monitoring, Physiologic; Secondary Prevention; Stem Cell Transplantation; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome

2001
A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's diseas
    Annals of hematology, 2002, Volume: 81, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Hodgkin Disease; Humans; Melphalan; Prognosis; Recurrence; Stem Cell Transplantation; Transplantation, Autologous

2002
Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Nov-15, Volume: 20, Issue:22

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Germany; Humans; L-Lactate Dehydrogenase; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prednisolone; Prognosis; Prospective Studies; Radiotherapy, Adjuvant; Risk; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vincristine

2002
[Effectiveness of high-dose polychemotherapy and autologous hemopoietic cell transplantation in patients with low-grade non-Hodgkin lymphoma].
    Voprosy onkologii, 2002, Volume: 48, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prednisone; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vincristine

2002
Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Apr-15, Volume: 21, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Female; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid; Living Donors; Male; Melphalan; Middle Aged; Prognosis; Siblings; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vidarabine

2003
[Effectiveness of dose-intensive polychemotherapy with autologous hemopoietic cell transplantation for high-grade non-Hodgkin lymphoma].
    Voprosy onkologii, 2003, Volume: 49, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prednisone; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vincristine

2003
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
    The New England journal of medicine, 2003, May-08, Volume: 348, Issue:19

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cause of Death; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prognosis; Survival Analysis

2003
Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma.
    Blood, 2003, Oct-01, Volume: 102, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Case-Control Studies; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Genetic Variation; Genotype; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Incidence; Isoenzymes; Male; Melphalan; Middle Aged; Multiple Myeloma; Polymorphism, Genetic; Prednisolone; Survival Rate; Treatment Outcome; Vincristine

2003
BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy.
    Leukemia & lymphoma, 2003, Volume: 44, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Survival Rate; Transplantation, Autologous

2003
High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:12

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma, T-Cell, Peripheral; Male; Melphalan; Middle Aged; Neoplasm Staging; Peripheral Blood Stem Cell Transplantation; Prognosis; Retrospective Studies; Risk Factors; Salvage Therapy; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation

2003
Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study.
    Bone marrow transplantation, 2004, Volume: 34, Issue:8

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Cytarabine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Male; Melphalan; Middle Aged; Multivariate Analysis; Retrospective Studies; Time Factors; Transplantation Conditioning; Transplantation, Autologous

2004
Ex vivo expansion of megakaryocyte precursor cells in autologous stem cell transplantation for relapsed malignant lymphoma.
    Bone marrow transplantation, 2004, Volume: 34, Issue:12

    Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cell Culture Techniques; Cells, Cultured; Cyclophosphamide; Cytarabine; Erythroid Precursor Cells; Humans; Integrin beta3; Lymphoma; Megakaryocytes; Melphalan; Peripheral Blood Stem Cell Transplantation; Platelet Membrane Glycoprotein IIb; Platelet Transfusion; Salvage Therapy; Thrombocytopenia; Thrombopoietin; Transplantation, Autologous; Treatment Outcome

2004
Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jan-20, Volume: 23, Issue:3

    Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Iodine Radioisotopes; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Radioimmunotherapy; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome

2005
Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hodgkin Disease; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Melphalan; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recurrence; Treatment Outcome; Vincristine

2005
Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report.
    Seminars in oncology, 2004, Volume: 31, Issue:6 Suppl 18

    Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Cytoprotection; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Middle Aged; Radiation-Protective Agents; Transplantation, Autologous

2004
The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT--results of a randomized multicentre study.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2005, Volume: 13, Issue:7

    Topics: Adult; Aged; Anti-Infective Agents, Local; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Humans; Male; Melphalan; Middle Aged; Mouth Mucosa; Mouthwashes; Peripheral Blood Stem Cell Transplantation; Povidone-Iodine; Sex Factors; Sodium Chloride; Stomatitis; Transplantation, Autologous

2005
Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Apr-01, Volume: 23, Issue:10

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Lymphoma, B-Cell; Male; Melphalan; Middle Aged; Rituximab; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome

2005
High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:8

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cytarabine; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Feasibility Studies; Female; Hodgkin Disease; Humans; Infusions, Intravenous; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Treatment Outcome

2005
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
    Blood, 2005, Dec-01, Volume: 106, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Remission Induction; Spain; Survival Analysis; Treatment Outcome; Vincristine

2005
First-line autologous stem cell transplantation in primary CNS lymphoma.
    European journal of haematology, 2005, Volume: 75, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunocompetence; Lymphoma; Male; Melphalan; Middle Aged; Neurotoxicity Syndromes; Radiotherapy, Adjuvant; Recurrence; Remission Induction; Survival Rate; Transplantation, Autologous

2005
Trial of amifostine in autologous stem cell transplant.
    Bone marrow transplantation, 2006, Volume: 37, Issue:1

    Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cytarabine; Female; Graft Survival; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Radiation-Protective Agents; Stem Cell Transplantation; Transplantation, Homologous

2006
Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation.
    Leukemia, 2006, Volume: 20, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Lung Diseases; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Recurrence; Survival Analysis; Transplantation, Autologous

2006
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Feb-20, Volume: 24, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Chemotherapy, Adjuvant; Clinical Protocols; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Interferons; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prospective Studies; Radiotherapy, Adjuvant; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Transplantation, Homologous; Treatment Failure; Treatment Outcome; United States; Vincristine; Whole-Body Irradiation

2006
Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma.
    Blood, 2006, Jun-15, Volume: 107, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; L-Lactate Dehydrogenase; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Prednisone; Prognosis; Prospective Studies; Recurrence; Remission Induction; Risk Factors; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Vincristine

2006
Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation.
    Cancer, 2006, May-01, Volume: 106, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Vincristine

2006
Circulating levels and clinical significance of soluble CD86 in myeloma patients.
    British journal of haematology, 2006, Volume: 133, Issue:2

    Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; B7-2 Antigen; Biomarkers, Tumor; Carmustine; Cyclophosphamide; Doxorubicin; Enzyme-Linked Immunosorbent Assay; Epidemiologic Methods; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Prognosis; Treatment Outcome

2006
Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
    Haematologica, 2006, Volume: 91, Issue:5

    Topics: Adult; Age Factors; Aged; Antigens, CD34; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carmustine; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisone; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine

2006
Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17 Suppl 4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cisplatin; Combined Modality Therapy; Cytarabine; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Remission Induction; Rituximab; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Treatment Outcome

2006
Successful autologous hematopoietic stem cell transplantations for severe multiple sclerosis with fludarabine and cyclophosphamide conditioning.
    International journal of hematology, 2006, Volume: 83, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multiple Sclerosis, Chronic Progressive; Myeloablative Agonists; Podophyllotoxin; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Vidarabine

2006
Palifermin for oral mucositis in the high-dose chemotherapy and stem cell transplant setting: the Royal Adelaide Hospital Cancer Centre experience.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2006, Volume: 14, Issue:6

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cancer Care Facilities; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Drug Eruptions; Female; Fibroblast Growth Factor 7; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Melphalan; Middle Aged; Podophyllotoxin; Primary Prevention; Severity of Illness Index; South Australia; Stomatitis; Time Factors; Transplantation Conditioning; Treatment Outcome

2006
Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma.
    Annals of hematology, 2006, Volume: 85, Issue:10

    Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Neutropenia; Podophyllotoxin; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous

2006
Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma.
    Transfusion, 2006, Volume: 46, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Transplantation, Autologous; Treatment Outcome

2006
Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation.
    Leukemia & lymphoma, 2006, Volume: 47, Issue:8

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Male; Melphalan; Middle Aged; Morbidity; Mortality; Podophyllotoxin; Transplantation Conditioning; Transplantation, Autologous

2006
Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chlorambucil; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Germany; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Prospective Studies; Survival Rate; Treatment Outcome; Vincristine

2007
Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma.
    British journal of haematology, 2007, Volume: 136, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Celiac Disease; Combined Modality Therapy; Cytarabine; Enteral Nutrition; Epirubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Immunosuppressive Agents; Lymphoma, T-Cell, Peripheral; Male; Melphalan; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2007
High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation.
    Bone marrow transplantation, 2007, Volume: 39, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma; Male; Melphalan; Remission Induction; Transplantation Conditioning; Transplantation, Homologous

2007
Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma.
    Experimental hematology, 2007, Volume: 35, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Salvage Therapy; Stem Cell Transplantation; Transplantation Conditioning; Treatment Outcome

2007
Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jan-01, Volume: 26, Issue:1

    Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Radioimmunotherapy; Stem Cell Transplantation; Treatment Outcome; Yttrium Radioisotopes

2008
Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
    European journal of haematology, 2008, Volume: 80, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Prednisone; Prognosis; Prospective Studies; Risk Assessment; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Vincristine

2008
A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
    Haematologica, 2008, Volume: 93, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carboplatin; Carmustine; Cytarabine; Double-Blind Method; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Polyethylene Glycols; Recombinant Proteins; Transplantation, Autologous

2008
Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, T-Cell, Peripheral; Male; Melphalan; Middle Aged; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Prednisone; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine

2008
Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies.
    Blood, 2008, Jul-15, Volume: 112, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2008
Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma.
    Cancer, 2008, Nov-01, Volume: 113, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Fluorodeoxyglucose F18; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Prospective Studies; Radiopharmaceuticals; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Vincristine

2008
Treatment of oral mucositis after peripheral blood SCT with ATL-104 mouthwash: results from a randomized, double-blind, placebo-controlled trial.
    Bone marrow transplantation, 2009, Volume: 43, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Double-Blind Method; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Mouthwashes; Phytohemagglutinins; Pilot Projects; Placebos; Recombinant Proteins; Stomatitis

2009
The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology
    Cancer, 2009, May-15, Volume: 115, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Disease-Free Survival; Female; Humans; Interferon Type I; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recombinant Proteins; Survival Rate; Vincristine

2009
Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Apr-01, Volume: 27, Issue:10

    Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Female; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Radioimmunotherapy; Radiotherapy Dosage; Salvage Therapy; Transplantation, Autologous

2009
Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG.
    Bone marrow transplantation, 2010, Volume: 45, Issue:2

    Topics: Adult; Animals; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Graft Rejection; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Horses; Humans; Male; Melphalan; Middle Aged; Multiple Sclerosis; Quality of Life; Rabbits; Transplantation Conditioning

2010
Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
    Hematology (Amsterdam, Netherlands), 2010, Volume: 15, Issue:1

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Positron-Emission Tomography; Predictive Value of Tests; Prednisolone; Prednisone; Proportional Hazards Models; Radiopharmaceuticals; Rituximab; Teniposide; Tomography, X-Ray Computed; Transplantation, Autologous; Treatment Outcome; Vincristine; Young Adult

2010
Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL.
    British journal of haematology, 2010, Volume: 149, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Neoplasm Staging; Prednisolone; Prognosis; Recurrence; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vincristine; Young Adult

2010
Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma.
    Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Staging; Neutropenia; Podophyllotoxin; Polyethylene Glycols; Recombinant Proteins; Transplantation, Autologous; Young Adult

2010
BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity.
    Leukemia research, 2011, Volume: 35, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult

2011
Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary progressive multiple sclerosis in a Chinese population.
    Annals of hematology, 2011, Volume: 90, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; China; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Male; Melphalan; Middle Aged; Multiple Sclerosis, Chronic Progressive; Neuromyelitis Optica; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Spinal Cord; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult

2011
A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:7

    Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Carmustine; Combined Modality Therapy; Cytarabine; Cytoprotection; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lymphoma; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Mucositis; Pancytopenia; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Transplantation Conditioning; Transplantation, Autologous; Young Adult

2011
Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party.
    Bone marrow transplantation, 2011, Volume: 46, Issue:12

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematologic Neoplasms; Humans; Infant; Male; Melphalan; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2011
The risk factors for oral mucositis and the effect of cryotherapy in patients after the BEAM and HD-l-PAM 200 mg/m(2) autologous hematopoietic stem cell transplantation.
    European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2011, Volume: 15, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cryotherapy; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Prospective Studies; Risk Factors; Stomatitis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult

2011
High-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphoma (PTCL): analysis of prognostic factors.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, T-Cell, Peripheral; Male; Melphalan; Middle Aged; Prospective Studies; Survival Rate; Transplantation, Autologous; Whole-Body Irradiation

2011
Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.
    Annals of hematology, 2011, Volume: 90, Issue:11

    Topics: Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Etoposide; Humans; Iodine Radioisotopes; Kaplan-Meier Estimate; Lymphoma, B-Cell; Male; Melphalan; Middle Aged; Myeloablative Agonists; Prospective Studies; Radioimmunotherapy; Recurrence; Rituximab; Salvage Therapy; Stem Cell Transplantation

2011
(90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study.
    Clinical lymphoma, myeloma & leukemia, 2011, Volume: 11, Issue:2

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Melphalan; Middle Aged; Neoplasm Staging; Podophyllotoxin; Rituximab; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Young Adult

2011
Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma.
    Bone marrow transplantation, 2012, Volume: 47, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Carmustine; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Survival Rate; Time Factors; Transplantation Conditioning; Transplantation, Autologous

2012
A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation.
    Transplantation proceedings, 2011, Volume: 43, Issue:8

    Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carmustine; Cytarabine; Dexamethasone; Drug Therapy, Combination; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Melphalan; Morpholines; Nausea; Ondansetron; Palonosetron; Quinuclidines; Transplantation, Autologous; Treatment Outcome; Vomiting

2011
Efficiency of supersaturated calcium phosphate mouth rinse treatment in patients receiving high-dose melphalan or BEAM prior to autologous blood stem cell transplantation: a single-center experience.
    Transplantation proceedings, 2011, Volume: 43, Issue:8

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Calcium Phosphates; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mouthwashes; Multiple Myeloma; Stomatitis; Transplantation Conditioning; Treatment Outcome; Young Adult

2011
A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.
    Cancer, 2012, Oct-01, Volume: 118, Issue:19

    Topics: Adult; Aged; Analysis of Variance; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Odds Ratio; Prognosis; Proportional Hazards Models; Recurrence; Risk Factors; Sample Size; Stem Cell Transplantation; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2012
MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation.
    Blood, 2012, May-17, Volume: 119, Issue:20

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cytarabine; Dexamethasone; Etoposide; Female; Genes, myc; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunotherapy; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Rituximab; Salvage Therapy; Transplantation, Autologous; Treatment Failure; Young Adult

2012
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.
    British journal of haematology, 2012, Volume: 158, Issue:3

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Recurrence; Rituximab; Survival Rate; Transplantation, Autologous

2012
Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Melphalan; Middle Aged; Myeloablative Agonists; Podophyllotoxin; Recurrence; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2013
Phase II trial of 131-Iodine tositumomab with high-dose chemotherapy and autologous stem cell transplantation for relapsed diffuse large B cell lymphoma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:1

    Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Follow-Up Studies; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Recurrence; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous

2013
Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.
    Cancer biotherapy & radiopharmaceuticals, 2012, Volume: 27, Issue:9

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Humans; Iodine Radioisotopes; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Radioimmunotherapy; Rituximab; Salvage Therapy; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous

2012
Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT C
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, May-01, Volume: 31, Issue:13

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Melphalan; Middle Aged; Prospective Studies; Radioimmunotherapy; Recurrence; Rituximab; Transplantation, Autologous; Young Adult

2013
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial.
    Haematologica, 2014, Volume: 99, Issue:3

    Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Neoplasm Staging; Podophyllotoxin; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2014
Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Pyrazines; Recurrence; Remission Induction; Survival Analysis; Transplantation, Autologous

2014
Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.
    Blood, 2014, May-08, Volume: 123, Issue:19

    Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Multivariate Analysis; Neoplasm, Residual; Prognosis; Radioimmunotherapy; Stem Cell Transplantation; Time Factors; Transplantation, Autologous; Treatment Outcome

2014
Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
    British journal of haematology, 2014, Volume: 167, Issue:3

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Positron-Emission Tomography; Prednisone; Prognosis; Prospective Studies; Radiopharmaceuticals; Remission Induction; Rituximab; Transplantation, Autologous; Treatment Outcome; Vincristine

2014
A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma.
    Bone marrow transplantation, 2014, Volume: 49, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Carmustine; Cytarabine; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Pyrazines; Stem Cell Transplantation; Transplantation Conditioning

2014
Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:12

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Prospective Studies; Risk Factors; Rituximab; Stem Cell Transplantation; Survival Rate

2014
Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:12

    Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning

2014
Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study.
    British journal of haematology, 2015, Volume: 168, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell; Male; Melphalan; Middle Aged; Patient Selection; Prospective Studies; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Young Adult

2015
Zevalin and BEAM (Z-BEAM) versus rituximab and BEAM (R-BEAM) conditioning chemotherapy prior to autologous stem cell transplantation in patients with mantle cell lymphoma.
    Hematological oncology, 2016, Volume: 34, Issue:3

    Topics: Adult; Aged; Algorithms; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cytarabine; Disease-Free Survival; Female; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Podophyllotoxin; Rituximab; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning

2016
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:7

    Topics: Adult; Aged; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Drug Combinations; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; North America; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous

2016
Modified BEAM with triple autologous stem cell transplantation for patients with relapsed aggressive non-Hodgkin lymphoma.
    Annals of hematology, 2016, Volume: 95, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Prospective Studies; Salvage Therapy; Transplantation, Autologous; Young Adult

2016
Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:12

    Topics: Adolescent; Adult; Aged; Carmustine; Cytarabine; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Myeloablative Agonists; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult

2016
BEAM conditioning is well-tolerated and yields similar survival in obese and non-obese patients with lymphoma: no requirement for weight-based dose modifications.
    Bone marrow transplantation, 2017, Volume: 52, Issue:3

    Topics: Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Obesity; Podophyllotoxin; Prospective Studies; Transplantation Conditioning

2017
Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.
    Haematologica, 2017, Volume: 102, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Fluorodeoxyglucose F18; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Positron-Emission Tomography; Prednisone; Retreatment; Rituximab; Treatment Outcome; Vincristine; Young Adult

2017
Pretransplant functional imaging and outcome in pediatric patients with relapsed/refractory Hodgkin lymphoma undergoing autologous transplantation.
    Pediatric blood & cancer, 2018, Volume: 65, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Child; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Melphalan; Podophyllotoxin; Positron-Emission Tomography; Preoperative Care; Retrospective Studies; Stem Cell Transplantation; Survival Rate

2018
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:8

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Deoxycytidine; Etoposide; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Melphalan; Middle Aged; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Young Adult

2018
Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.
    Annals of hematology, 2018, Volume: 97, Issue:9

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Italy; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Invasiveness; Podophyllotoxin; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult; Yttrium Radioisotopes

2018
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:10

    Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Male; Melphalan; Middle Aged; Morpholines; Nausea; Olanzapine; Ondansetron; Podophyllotoxin; Vomiting

2018
Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:2

    Topics: Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Lymphoma; Male; Melphalan; Middle Aged; Podophyllotoxin; Sirolimus; Survival Rate; Tacrolimus; Transplantation Conditioning

2019
Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
    Journal of neurology, neurosurgery, and psychiatry, 2019, Volume: 90, Issue:5

    Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Progression-Free Survival; Prospective Studies; Transplantation, Autologous; Treatment Outcome; Young Adult

2019
Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial.
    British journal of haematology, 2020, Volume: 190, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Netherlands; Prednisone; Progression-Free Survival; Remission Induction; Rituximab; Transplantation, Autologous; Treatment Failure; Vincristine; Young Adult

2020
Impact of the Conditioning Regimen Dose Intensity Before Autologous Stem Cell Transplantation on the Pulmonary Function Test Abnormalities in Patients With Lymphoma and Multiple Myeloma: Single Center Experience.
    Clinical lymphoma, myeloma & leukemia, 2020, Volume: 20, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Lung; Lymphoma; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Respiratory Function Tests; Retrospective Studies; Survival Rate; Transplantation Conditioning

2020
A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trial.
    British journal of haematology, 2021, Volume: 192, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Burkitt Lymphoma; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; HIV Infections; Humans; Lymphoma, B-Cell; Male; Melphalan; Middle Aged; Transplantation, Autologous

2021
Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years.
    Journal of cancer research and clinical oncology, 2022, Volume: 148, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etoposide; Follow-Up Studies; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy

2022

Other Studies

449 other study(ies) available for carmustine and melphalan

ArticleYear
Cell-based screen for identification of inhibitors of tubulin polymerization.
    Journal of natural products, 1996, Volume: 59, Issue:12

    Topics: Animals; Brain Neoplasms; Bucladesine; Cell Differentiation; Drug Screening Assays, Antitumor; Formazans; Glioma; Rats; Tubulin; Tumor Cells, Cultured

1996
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Discovery of antiglioma activity of biaryl 1,2,3,4-tetrahydroisoquinoline derivatives and conformationally flexible analogues.
    Journal of medicinal chemistry, 2006, Sep-21, Volume: 49, Issue:19

    Topics: Animals; Antineoplastic Agents; Astrocytes; Biphenyl Compounds; Cell Line, Tumor; Cells, Cultured; Drug Screening Assays, Antitumor; Glioma; Humans; Isoquinolines; Molecular Conformation; Rats; Structure-Activity Relationship; Tetrahydroisoquinolines

2006
Chemical genetics reveals a complex functional ground state of neural stem cells.
    Nature chemical biology, 2007, Volume: 3, Issue:5

    Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells

2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
    Journal of medicinal chemistry, 2008, Nov-13, Volume: 51, Issue:21

    Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship

2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
    Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3

    Topics:

2008
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
    European journal of medicinal chemistry, 2010, Volume: 45, Issue:4

    Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water

2010
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
    Bioorganic & medicinal chemistry, 2010, Mar-15, Volume: 18, Issue:6

    Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics

2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs.
    The New England journal of medicine, 1978, Jun-15, Volume: 298, Issue:24

    Topics: Antineoplastic Agents; Bleomycin; Carmustine; Clone Cells; Doxorubicin; Drug Resistance; Female; Hematopoietic Stem Cells; Humans; Melphalan; Methotrexate; Multiple Myeloma; Ovarian Neoplasms; Prognosis; Prospective Studies; Retrospective Studies; Vinblastine

1978
[Interim results of the combination of M2 polychemotherapy with calcitonin and synthetic anabolic agents in the treatment of plasmacytoma].
    Recenti progressi in medicina, 1979, Volume: 66, Issue:4

    Topics: Aged; Anabolic Agents; Antineoplastic Agents; Calcitonin; Carmustine; Cyclophosphamide; Dihydrotestosterone; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunoglobulin Light Chains; Male; Melphalan; Middle Aged; Plasmacytoma; Prednisolone; Vincristine

1979
Regression of established tumors and induction of tumor immunity by intratumor chemotherapy.
    Journal of the National Cancer Institute, 1976, Volume: 56, Issue:4

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Carmustine; Dacarbazine; Dactinomycin; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Graft Rejection; Guinea Pigs; Injections; Injections, Intraperitoneal; Liver Neoplasms; Melphalan; Mercaptopurine; Methotrexate; Mitomycins; Neoplasm Transplantation; Neoplasms, Experimental

1976
Drug - resistant multiple myeloma. A trial with the M 2 cyclic alkylating agent polychemotherapy.
    Haematologica, 1978, Volume: 63, Issue:1

    Topics: Adult; Aged; Alkylating Agents; Carmustine; Cyclophosphamide; Drug Evaluation; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Vincristine

1978
Multiple myeloma: results with the M-2 protocol in a community hospital.
    The Journal of the American Osteopathic Association, 1979, Volume: 78, Issue:12

    Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Hospitals, Community; Humans; Melphalan; Multiple Myeloma; Prednisone; Vincristine

1979
Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol.
    The American journal of medicine, 1977, Volume: 63, Issue:6

    Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Remission, Spontaneous; Time Factors; Vincristine

1977
Bence Jones proteins and light chains of immunoglobulins. XV. Effect of corticosteroids on synthesis and excretion of Bence Jones protein.
    The Journal of clinical investigation, 1978, Volume: 61, Issue:1

    Topics: Adult; Aged; Bence Jones Protein; Carmustine; Cyclophosphamide; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone

1978
A new basis for treatment of multiple myeloma.
    Schweizerische medizinische Wochenschrift, 1978, Oct-14, Volume: 108, Issue:41

    Topics: Carmustine; Cell Transformation, Neoplastic; Doxorubicin; Drug Resistance; Humans; Melphalan; Multiple Myeloma; Neoplasm Staging; Prognosis

1978
Adriamycin, 1,3-bis (2-chloroethyl) 1 nitrosourea (BCNU, NSC No. 409962), cyclophosphamide plus prednisone (ABC-P) in melphalanresistant multiple myeloma.
    Cancer, 1978, Volume: 42, Issue:3

    Topics: Aged; Antineoplastic Agents; Bone Marrow; Carmustine; Cyclophosphamide; Doxorubicin; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Remission, Spontaneous; Time Factors

1978
[Effect of several chemotherapeutic agents on protein synthesis in leukemic plasma cells (author's transl)].
    Blut, 1979, Feb-19, Volume: 38, Issue:2

    Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Cytarabine; Humans; Immunoglobulins; Leukemia, Plasma Cell; Male; Melphalan; Middle Aged; Plasma Cells; Protein Biosynthesis; Vincristine

1979
Management and prognosis of multiple myeloma.
    Mayo Clinic proceedings, 1976, Volume: 51, Issue:12

    Topics: Anemia; Bacterial Infections; BCG Vaccine; Carmustine; Cyclophosphamide; Fractures, Bone; Humans; Hypercalcemia; Kidney Failure, Chronic; Melphalan; Multiple Myeloma; Mycobacterium bovis; Prognosis

1976
Treatment of plasma cell myeloma with cytotoxic agents.
    Archives of internal medicine, 1975, Volume: 135, Issue:1

    Topics: Acute Disease; Alkylating Agents; Bence Jones Protein; Bone Neoplasms; Carmustine; Cell Count; Cyclophosphamide; Drug Therapy, Combination; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Mechlorethamine; Melphalan; Multiple Myeloma; Myeloma Proteins; Prednisone; Remission, Spontaneous; Time Factors

1975
Bence Jones proteins and light chains of immunoglobulins. XI. A transient Bence Jones-related protein associated with corticosteroid therapy.
    The Journal of clinical investigation, 1975, Volume: 55, Issue:3

    Topics: Amino Acid Sequence; Antineoplastic Agents; Bence Jones Protein; Bone Marrow; Bone Marrow Cells; Carmustine; Cyclophosphamide; Electrophoresis; Electrophoresis, Starch Gel; Female; Humans; Immunodiffusion; Immunoelectrophoresis; Immunoglobulin Fragments; Melphalan; Middle Aged; Molecular Weight; Multiple Myeloma; Prednisone; Proteinuria

1975
[Results of plasmacytoma therapy of ALGB (acute leukemia group B)].
    Hamatologie und Bluttransfusion, 1976, Volume: 18

    Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Humans; Melphalan; Multiple Myeloma; Plasmacytoma; Prednisolone; Prognosis; Remission, Spontaneous; Testosterone

1976
Studies with 2,5-piperazinedione, 3,6-bis(5-chloro-2-piperidyl)-,dihydrochloride. III. Biochemical and therapeutic effects in L1210 leukemias sensitive and resistant to alkylating agents: comparison with melphalan, cyclophosphamide, and BCNU.
    Cancer treatment reports, 1976, Volume: 60, Issue:9

    Topics: Animals; Antibiotics, Antineoplastic; Carmustine; Cells, Cultured; Cyclophosphamide; DNA, Neoplasm; Dose-Response Relationship, Drug; Leukemia L1210; Melphalan; Mice; Piperazines; Piperidines

1976
The role of drug transport in resistance to nitrogen mustard and other alkylating agents in L518Y lymphoblsts.
    Cancer research, 1975, Volume: 35, Issue:7

    Topics: Alkylating Agents; Animals; Binding, Competitive; Biological Transport; Carmustine; Cell Line; Chlorambucil; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Resistance; Female; Leukemia, Experimental; Leukemia, Lymphoid; Male; Mechlorethamine; Melphalan; Mice; Mice, Inbred DBA; Mitomycins

1975
Letter: Maintenance therapy in myeloma: risk versus benefit.
    British medical journal, 1975, Jun-07, Volume: 2, Issue:5970

    Topics: Carmustine; Humans; Leukemia, Myeloid, Acute; Melphalan; Multiple Myeloma; Prednisone

1975
Evaluation of a cooperative group human myeloma protocol using the MOPC 104E myeloma model.
    Cancer research, 1975, Volume: 35, Issue:5

    Topics: Animals; Antineoplastic Agents; Carmustine; Cell Line; Cell Survival; Cyclophosphamide; Disease Models, Animal; Drug Therapy, Combination; Female; Immunoglobulin M; Melphalan; Mescaline; Mice; Mice, Inbred BALB C; Multiple Myeloma; Neoplasms, Experimental; Plasmacytoma; Prednisolone; Time Factors

1975
Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas.
    Bone marrow transplantation, 1992, Volume: 9, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion, Autologous; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukapheresis; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Salvage Therapy; Whole-Body Irradiation

1992
Combination chemotherapy for myelomatosis.
    Lancet (London, England), 1992, Aug-15, Volume: 340, Issue:8816

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Humans; Melphalan; Multiple Myeloma

1992
BEAM regimen and G-CSF in HTLV-I-associated T-cell lymphoma.
    Lancet (London, England), 1992, Jan-11, Volume: 339, Issue:8785

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug Therapy, Combination; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Humans; Leukemia-Lymphoma, Adult T-Cell; Melphalan; Middle Aged

1992
Depletion of a discrete nuclear glutathione pool by oxidative stress, but not by buthionine sulfoximine. Correlation with enhanced alkylating agent cytotoxicity to human melanoma cells in vitro.
    Biochemical pharmacology, 1992, Oct-06, Volume: 44, Issue:7

    Topics: Buthionine Sulfoximine; Carmustine; Cell Division; Cell Nucleus; Cytosol; Doxorubicin; Drug Synergism; Glutathione; Glutathione Disulfide; Humans; Melanoma; Melphalan; Methionine Sulfoximine; Oxidation-Reduction; Tumor Cells, Cultured

1992
Non-secretory multiple myeloma presenting as primary plasma cell leukaemia.
    Postgraduate medical journal, 1992, Volume: 68, Issue:800

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Humans; Leukemia, Plasma Cell; Melphalan; Multiple Myeloma; Prednisone; Vincristine

1992
Treatment of melphalan-resistant multiple myeloma with vincristine, BCNU, doxorubicin, and high-dose dexamethasone (VBAD).
    European journal of cancer (Oxford, England : 1990), 1992, Volume: 29A, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dexamethasone; Doxorubicin; Drug Resistance; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prognosis; Survival Analysis; Vincristine

1992
High-dose chemotherapy and autologous bone marrow transplantation for relapsed and refractory Hodgkin's disease.
    European journal of cancer (Oxford, England : 1990), 1992, Volume: 28A, Issue:8-9

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Transplantation, Autologous

1992
Myeloma cell resistance to melphalan, BCNU and epirubicin determined in vitro with the 3H-thymidine incorporation technique prior to chemotherapy.
    Neoplasma, 1992, Volume: 39, Issue:1

    Topics: Adult; Bone Marrow; Carmustine; Drug Resistance; Epirubicin; Humans; Immunoglobulins; Melphalan; Middle Aged; Multiple Myeloma; Thymidine; Tritium; Tumor Cells, Cultured

1992
Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma.
    Journal of the National Cancer Institute, 1992, Feb-05, Volume: 84, Issue:3

    Topics: Alkylating Agents; Animals; Antineoplastic Agents; Bone Marrow; Carmustine; Cisplatin; Cyclophosphamide; Drug Screening Assays, Antitumor; Drug Synergism; Fibrosarcoma; Male; Melphalan; Mice; Mice, Inbred C3H; Tirapazamine; Triazines

1992
A new concentrated perfluorochemical emulsion and carbogen breathing as an adjuvant to treatment with antitumor alkylating agents.
    Journal of cancer research and clinical oncology, 1992, Volume: 118, Issue:7

    Topics: Administration, Inhalation; Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Carbon Dioxide; Carmustine; Cell Survival; Cyclophosphamide; Drug Administration Schedule; Drug Synergism; Emulsions; Fibrosarcoma; Fluorocarbons; Hematopoietic Stem Cells; Hydrocarbons, Brominated; Male; Melphalan; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Oxygen; Tumor Cells, Cultured

1992
Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease.
    British journal of haematology, 1992, Volume: 81, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Risk Factors; Time Factors

1992
Hypersensitivity to clinically useful alkylating agents and radiation in poly(ADP-ribose) polymerase-deficient cell lines.
    Cancer communications, 1990, Volume: 2, Issue:12

    Topics: Alkylating Agents; Amsacrine; Animals; Bleomycin; Carmustine; Cells, Cultured; Cricetinae; Dimethyl Sulfoxide; Doxorubicin; HEPES; In Vitro Techniques; Melphalan; Mitomycins; Poly(ADP-ribose) Polymerases; Radiotherapy; Ultraviolet Rays

1990
Effect of a bovine hemoglobin preparation on the response of the FSaIIC fibrosarcoma to chemotherapeutic alkylating agents.
    Journal of cancer research and clinical oncology, 1992, Volume: 118, Issue:2

    Topics: Alkylating Agents; Animals; Carbon Dioxide; Carmustine; Cattle; Cisplatin; Cyclophosphamide; Drug Synergism; Fibrosarcoma; Hemoglobins; Male; Melphalan; Mice; Mice, Inbred C3H; Oxygen

1992
Combination therapy of M2-protocol and interferon-alpha as remission induction in refractory multiple myeloma.
    Haematologia, 1991, Volume: 24, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Female; Humans; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Remission Induction; Vincristine

1991
[Preleukemia myelodysplastic syndrome after chemotherapy for multiple myeloma: "a new case"].
    Sangre, 1991, Volume: 36, Issue:5

    Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Humans; Male; Melphalan; Methotrexate; Multiple Myeloma; Prednisone; Risk; Vincristine

1991
Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
    Cancer research, 1991, Feb-15, Volume: 51, Issue:4

    Topics: Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carbon Dioxide; Carboplatin; Carmustine; Cell Survival; Colony-Forming Units Assay; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Etanidazole; Fibrosarcoma; Flow Cytometry; Fluorocarbons; Hydroxyethyl Starch Derivatives; Mammary Neoplasms, Experimental; Melphalan; Mice; Nitroimidazoles; Organoplatinum Compounds; Oxygen; Radiation-Sensitizing Agents; Thiotepa

1991
In vivo and in vitro evaluation of the alkylating agent carmethizole.
    Cancer research, 1991, Sep-01, Volume: 51, Issue:17

    Topics: Animals; Antineoplastic Agents; Carmustine; DNA Repair; DNA, Neoplasm; Drug Screening Assays, Antitumor; Imidazoles; Leukemia L1210; Leukemia P388; Melphalan; Tumor Cells, Cultured

1991
Myeloablative combination chemotherapy without total body irradiation for neuroblastoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:2

    Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Infant; Male; Melphalan; Neuroblastoma; Pelvic Neoplasms; Radiotherapy Dosage; Retroperitoneal Neoplasms; Survival Rate; Thiotepa; Whole-Body Irradiation

1991
Waldenström's macroglobulinemia.
    Cancer investigation, 1991, Volume: 9, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Humans; Male; Melphalan; Prednisone; Vincristine; Waldenstrom Macroglobulinemia

1991
High-dose cytostatic agents in allogeneic bone marrow transplantation: comparison of the engraftment promoting potential.
    British journal of haematology, 1991, Volume: 78, Issue:3

    Topics: Animals; Antineoplastic Agents; Bone Marrow Transplantation; Carboplatin; Carmustine; Cyclophosphamide; Graft Rejection; Ifosfamide; Immunosuppression Therapy; Male; Melphalan; Nimustine; Rats; Rats, Inbred Lew; Thiotepa

1991
Modulation of resistance to alkylating agents in cancer cell by gossypol enantiomers.
    Cancer letters, 1991, Volume: 56, Issue:1

    Topics: Alkylating Agents; Animals; Breast Neoplasms; Buthionine Sulfoximine; Carcinoma 256, Walker; Carmustine; Cell Division; Cell Line; Chlorambucil; Cisplatin; Drug Antagonism; Drug Resistance; Glutathione Transferase; Gossypol; Humans; In Vitro Techniques; Isomerism; Melphalan; Methionine Sulfoximine; Rats

1991
Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo.
    International journal of cancer, 1991, Jun-19, Volume: 48, Issue:4

    Topics: Alkylating Agents; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Cisplatin; Colony-Forming Units Assay; Cyclophosphamide; Etoposide; Fibrosarcoma; Hematopoietic Stem Cells; Indazoles; Male; Melphalan; Mice; Mice, Inbred C3H; Pentoxifylline; Sarcoma, Experimental

1991
Sensitization of human melanoma cells to melphalan cytotoxicity by adriamycin and carmustine.
    Journal of cancer research and clinical oncology, 1991, Volume: 117, Issue:4

    Topics: Carmustine; Cell Cycle; Doxorubicin; Drug Interactions; Glutathione; Humans; Melanoma; Melphalan; Tumor Cells, Cultured

1991
High-dose thiotepa alone and in combination regimens with bone marrow support.
    Seminars in oncology, 1990, Volume: 17, Issue:1 Suppl 3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Carboplatin; Carmustine; Cisplatin; Cyclophosphamide; Drug Evaluation; Female; Humans; Melphalan; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Thiotepa

1990
BEAM protocol and autologous bone marrow transplantation in first chemosensitive relapse of non-Hodgkin's lymphomas.
    European journal of cancer (Oxford, England : 1990), 1990, Volume: 26, Issue:7

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Cytarabine; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Retrospective Studies

1990
Autopsy-documented cure of multiple myeloma 14 years after M2 chemotherapy.
    Cancer, 1990, Oct-01, Volume: 66, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Carmustine; Cyclophosphamide; Female; Humans; Melphalan; Multiple Myeloma; Prednisone; Remission Induction; Vincristine

1990
Therapy of multiple myeloma. Italian Multiple Myeloma Study Group.
    Pathologie-biologie, 1990, Volume: 38, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Humans; Interferon alpha-2; Interferon-alpha; Melphalan; Multiple Myeloma; Prednisone; Recombinant Proteins; Vincristine

1990
Pharmacokinetics of very high-dose oral melphalan in cancer patients.
    American journal of clinical oncology, 1990, Volume: 13, Issue:1

    Topics: Adenocarcinoma; Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Bone Marrow Transplantation; Carmustine; Etoposide; Female; Humans; Injections, Intravenous; Lymphoma; Male; Melanoma; Melphalan; Middle Aged; Time Factors

1990
Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease.
    Bone marrow transplantation, 1990, Volume: 5, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Chi-Square Distribution; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Epirubicin; Etoposide; Evaluation Studies as Topic; Hodgkin Disease; Humans; Male; Melphalan; Prednisone; Premedication; Remission Induction; Vincristine

1990
Platelets acquire a secretion defect after high-dose chemotherapy.
    Cancer, 1990, Apr-15, Volume: 65, Issue:8

    Topics: Adenosine Triphosphate; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Platelet Disorders; Blood Platelets; Bone Marrow Transplantation; Breast Neoplasms; Carmustine; Cisplatin; Cyclophosphamide; Female; Hemorrhage; Humans; Male; Melanoma; Melphalan; Middle Aged; Myocarditis; Platelet Aggregation

1990
[Combination chemotherapy of multiple myeloma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:8 Pt 1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Drug Evaluation; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Nitrosourea Compounds; Prednisolone; Procarbazine; Remission Induction; Survival Rate

1990
Recombinant human granulocyte-macrophage colony-stimulating factor plus the beam regimen instead of autologous bone marrow transplantation.
    Lancet (London, England), 1989, Jun-24, Volume: 1, Issue:8652

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Colony-Stimulating Factors; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Recombinant Proteins

1989
High dose chemotherapy with autologous hematopoietic stem cell support in the treatment of refractory stage IV breast carcinoma.
    Bone marrow transplantation, 1989, Volume: 4, Issue:4

    Topics: Adult; Breast Neoplasms; Carmustine; Cell Survival; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cells; Humans; Melphalan; Middle Aged; Neoplasm Staging; Thiotepa

1989
Treatment of multiple myeloma by high dose chemotherapy, total body irradiation and autologous blood stem cell autograft.
    Nouvelle revue francaise d'hematologie, 1989, Volume: 31, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Etoposide; Evaluation Studies as Topic; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Remission Induction; Transplantation, Autologous; Whole-Body Irradiation

1989
High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease.
    British journal of cancer, 1989, Volume: 59, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Etoposide; Female; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged

1989
High-dose chemotherapy with autologous bone marrow support in advanced malignant melanoma.
    Onkologie, 1989, Volume: 12, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Humans; Male; Melanoma; Melphalan; Middle Aged; Neoplasm Metastasis; Skin Neoplasms

1989
[Complete double remission and prolonged survival of a patient diagnosed with plasma cell leukemia].
    Sangre, 1989, Volume: 34, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Humans; Leukemia, Plasma Cell; Male; Melphalan; Middle Aged; Prednisone; Remission Induction; Time Factors; Vincristine

1989
Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.
    Cancer research, 1989, Nov-15, Volume: 49, Issue:22

    Topics: Alkylating Agents; Antineoplastic Agents; Blotting, Northern; Carmustine; Cell Line; Cell Survival; Clone Cells; Cyclophosphamide; Drug Resistance; Glutathione Transferase; Humans; Melanoma; Melphalan; RNA, Neoplasm; Tumor Cells, Cultured

1989
[High-doses chemotherapy followed by bone marrow autograft in the treatment of small cell bronchial cancer].
    Bulletin du cancer, 1987, Volume: 74, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carcinoma, Small Cell; Carmustine; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Melphalan; Procarbazine

1987
Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies.
    Cancer chemotherapy and pharmacology, 1988, Volume: 22, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematologic Diseases; Humans; Leukemia, Lymphoid; Lymphoma; Male; Melphalan; Middle Aged; Recurrence; Remission Induction; Thymoma; Thymus Neoplasms

1988
Diffuse well-differentiated lymphocytic lymphoma: chemotherapy with BCNU, cyclophosphamide, vincristine, melphalan and prednisone.
    Oncology, 1988, Volume: 45, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Melphalan; Middle Aged; Prednisone; Vincristine

1988
Combination chemotherapy for multiple myeloma with melphalan, ifosfamide, prednisolone, nitrosourea and vincristine.
    Acta medica Okayama, 1988, Volume: 42, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Female; Humans; Ifosfamide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Nimustine; Nitrosourea Compounds; Prednisolone; Prognosis; Vincristine

1988
Tumoricidal and immunomodulatory activities of drugs and implications for therapy of mice bearing a late stage MOPC-315 plasmacytoma.
    International journal of immunopharmacology, 1988, Volume: 10, Issue:7

    Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents; Carmustine; Cell Division; Cyclophosphamide; Female; Hydroxyurea; Immunity; Melphalan; Methylnitrosourea; Mice; Mice, Inbred BALB C; Plasmacytoma; Spleen

1988
[Metastatic neuroblastoma: consolidation treatment with 2 courses of high-dose chemotherapy followed by a bone marrow autograft].
    Bulletin du cancer, 1988, Volume: 75, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Infant; Male; Melphalan; Neoplasm Staging; Neuroblastoma; Prognosis; Teniposide; Transplantation, Autologous

1988
[Monoclonal gammapathy of indeterminate origin and myeloma].
    Revue medicale de Liege, 1988, Apr-15, Volume: 43, Issue:8

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Diagnosis, Differential; Doxorubicin; Drug Therapy, Combination; Humans; Hypergammaglobulinemia; Interferon Type I; Melphalan; Methylprednisolone; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Prednisone; Vincristine

1988
Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support.
    Archives of dermatology, 1988, Volume: 124, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Melphalan; Middle Aged; Pelvic Neoplasms; Remission Induction

1988
Ifosfamide and VP-16213 combination chemotherapy combined with ablative chemotherapy and autologous marrow transplantation as salvage treatment for malignant lymphoma.
    European journal of cancer & clinical oncology, 1988, Volume: 24, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Ifosfamide; Lymphoma; Melphalan; Methotrexate; Middle Aged; Mitoguazone; Podophyllotoxin

1988
Repeated high-dose chemotherapy followed by purged autologous bone marrow transplantation as consolidation therapy in metastatic neuroblastoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:8

    Topics: Abdominal Neoplasms; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Gastrointestinal Diseases; Humans; Infant; Infections; Melphalan; Neuroblastoma; Teniposide; Thoracic Neoplasms; Transplantation, Autologous; Vincristine

1987
M-2 protocol for melphalan-resistant and relapsing multiple myeloma.
    European journal of haematology, 1988, Volume: 40, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Marrow; Carmustine; Cyclophosphamide; Drug Resistance; Hemoglobins; Humans; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pain; Prednisone; Time Factors; Vincristine

1988
VBAMDex chemotherapy in advanced multiple myeloma.
    European journal of haematology, 1988, Volume: 40, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dexamethasone; Doxorubicin; Follow-Up Studies; Humans; Melphalan; Multiple Myeloma; Remission Induction; Vincristine

1988
Very high dose chemotherapy with autologous bone marrow rescue in adult patients with resistant relapsed lymphoma.
    Cancer chemotherapy and pharmacology, 1986, Volume: 16, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Cytarabine; Female; Hodgkin Disease; Humans; Lymphoma; Male; Melphalan; Methotrexate; Middle Aged; Podophyllotoxin

1986
High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:5

    Topics: Adult; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carcinoma; Carmustine; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Evaluation; Drug Tolerance; Female; Humans; Male; Melphalan; Middle Aged; Neoplasm Metastasis; Sarcoma

1986
Bone marrow transplantation in multiple myeloma.
    Scandinavian journal of haematology, 1986, Volume: 36, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Female; Humans; Male; Melphalan; Multiple Myeloma; Whole-Body Irradiation

1986
Recovery of blood and bone marrow stem cells following intense chemotherapy and autologous bone marrow transplantation.
    Oncology, 1986, Volume: 43, Issue:5

    Topics: Agranulocytosis; Bone Marrow Transplantation; Carmustine; Colony-Forming Units Assay; Hematopoietic Stem Cells; Humans; Melanoma; Melphalan; Platelet Count; Time Factors

1986
High-dose chemotherapy without autologous bone marrow transplantation in melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:12

    Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Carmustine; Central Nervous System Diseases; Drug Administration Schedule; Female; Humans; Lung Diseases; Male; Melanoma; Melphalan; Middle Aged; Thrombocytopenia; Vincristine

1986
High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
    Cancer treatment reports, 1987, Volume: 71, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Drug Evaluation; Female; Hematologic Diseases; Humans; Melanoma; Melphalan; Middle Aged; Neoplasm Metastasis; Neoplasms; Statistics as Topic

1987
Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy.
    Cancer research, 1987, May-01, Volume: 47, Issue:9

    Topics: Alkylating Agents; Animals; Antineoplastic Agents; Biological Assay; Carmustine; Cisplatin; Cyclophosphamide; Drug Resistance; Leukemia L1210; Melphalan; Mice; Mice, Inbred BALB C; Mice, Inbred DBA

1987
Complete remission in plasma cell leukaemia.
    British journal of haematology, 1987, Volume: 66, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Humans; Leukemia, Plasma Cell; Melphalan; Middle Aged; Prednisone; Remission Induction; Vincristine

1987
N-methylformamide-mediated enhancement of in vitro tumor cell chemosensitivity.
    Cancer chemotherapy and pharmacology, 1986, Volume: 17, Issue:3

    Topics: Animals; Antineoplastic Agents; Carmustine; Cell Differentiation; Cell Survival; Cisplatin; Drug Synergism; Formamides; Humans; Liver Neoplasms, Experimental; Melphalan; Mice; Sister Chromatid Exchange; Tumor Stem Cell Assay

1986
Pseudohypercalcemia and hyperviscosity with neurological manifestations in multiple myeloma.
    Israel journal of medical sciences, 1986, Volume: 22, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Viscosity; Carmustine; Cyclophosphamide; Humans; Hypercalcemia; Male; Melphalan; Multiple Myeloma; Paralysis; Plasmapheresis; Prednisone; Seizures; Serum Globulins; Vincristine

1986
[Results with the use of the M-2 protocol in plasmacytoma].
    Deutsche medizinische Wochenschrift (1946), 1986, May-30, Volume: 111, Issue:22

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Drug Evaluation; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Vincristine

1986
Melphalan-resistant multiple myeloma: results of treatment according to the M-2 protocol.
    Cancer chemotherapy and pharmacology, 1985, Volume: 14, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Drug Administration Schedule; Drug Resistance; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Vincristine

1985
[Treatment of multiple myeloma in stages II and III with melphalan, prednisone, cyclophosphamide, vincristine and BCNU (M-2 protocol)].
    Revista clinica espanola, 1985, Volume: 176, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Humans; Male; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Prognosis; Vincristine

1985
Combination chemotherapy for multiple myeloma with BCNU, cyclophosphamide, vincristine, melphalan, and prednisone (M-2 protocol).
    Oncology, 1985, Volume: 42, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Urea Nitrogen; Carmustine; Cyclophosphamide; Humans; Immunoglobulins; Leukemia, Monocytic, Acute; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Prognosis; Time Factors; Vincristine

1985
Treatment of advanced neuroblastoma with two consecutive high-dose chemotherapy regimens and ABMT.
    Progress in clinical and biological research, 1985, Volume: 175

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Infant; Male; Melphalan; Neuroblastoma; Teniposide

1985
[Diagnosis and treatment of Waldenstrom's macroglobulinemia: 4 case reports].
    Zhonghua nei ke za zhi, 1985, Volume: 24, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Diagnostic Errors; Female; Humans; Male; Melphalan; Prednisone; Vincristine; Waldenstrom Macroglobulinemia

1985
Pharmacokinetics of high-dose melphalan in children and adults.
    Cancer chemotherapy and pharmacology, 1986, Volume: 16, Issue:2

    Topics: Adolescent; Adult; Carmustine; Child; Child, Preschool; Diuresis; Dose-Response Relationship, Drug; Furosemide; Half-Life; Humans; Kinetics; Melphalan; Middle Aged; Neoplasms; Podophyllotoxin; Procarbazine

1986
Emergence of nitrosourea resistant sublines of Lewis lung tumour following MeCCNU treatment in vivo.
    British journal of cancer, 1986, Volume: 53, Issue:2

    Topics: Animals; Carmustine; Cell Line; Cell Survival; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Resistance; Lomustine; Lung Neoplasms; Melphalan; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Nitrosourea Compounds; Semustine; Time Factors

1986
Prediction of in vivo tumor response to chemotherapeutic agents by the in vitro sister chromatid exchange assay.
    Cancer research, 1985, Volume: 45, Issue:5

    Topics: Animals; Carmustine; Cell Survival; Cisplatin; Colony-Forming Units Assay; Liver Neoplasms, Experimental; Lung Neoplasms; Male; Melphalan; Mice; Mice, Inbred C3H; Sister Chromatid Exchange; Tumor Stem Cell Assay

1985
Comparison of cytotoxicity of single dose and infusion of alkylating agents.
    Cancer drug delivery, 1985,Winter, Volume: 2, Issue:1

    Topics: Alkylating Agents; Animals; Carmustine; Cell Survival; Colony-Forming Units Assay; Infusions, Parenteral; Injections, Intravenous; Lethal Dose 50; Leukemia L1210; Male; Melphalan; Mice; Mice, Inbred DBA; Nitrogen Mustard Compounds

1985
Thermochemotherapy with cis-platinum, CCNU, BCNU, chlorambucil and melphalan on murine marrow and two tumours: therapeutic gain for melphalan only.
    The British journal of radiology, 1985, Volume: 58, Issue:685

    Topics: Animals; Antineoplastic Agents; Bone Marrow; Carmustine; Chlorambucil; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Hyperthermia, Induced; Lomustine; Melphalan; Mice; Mice, Inbred C3H; Neoplasms, Experimental

1985
Combination chemotherapy with the M-2 protocol (BCNU, cyclophosphamide, vincristine, melphalan, and prednisone) for chronic lymphocytic leukemia (stages III and IV).
    Oncology, 1985, Volume: 42, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Humans; Leukemia, Lymphoid; Melphalan; Middle Aged; Neoplasm Staging; Prednisone; Prognosis; Vincristine

1985
Comparative chemotherapy of AKR lymphoma and human hematological neoplasia.
    Cancer research, 1974, Volume: 34, Issue:1

    Topics: Animals; Antineoplastic Agents; Biological Assay; Carmustine; Cyclohexanes; Cyclophosphamide; Cytarabine; Daunorubicin; Disease Models, Animal; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Fluorouracil; Hodgkin Disease; Humans; Leukemia; Leukemia L1210; Leukemia, Experimental; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma; Male; Mechlorethamine; Melphalan; Mice; Mice, Inbred AKR; Multiple Myeloma; Nitrosourea Compounds; Prednisone; Remission, Spontaneous; Vinblastine; Vincristine

1974
Proceedings: Combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone, and BCNU.
    Cancer, 1974, Volume: 33, Issue:2

    Topics: Adult; Aged; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Vincristine

1974
Proceedings: Treatment of multiple myeloma by a quadruple chemotherapy regime.
    British journal of haematology, 1974, Volume: 27, Issue:2

    Topics: Carmustine; Cyclophosphamide; Drug Synergism; Drug Therapy, Combination; Humans; Melphalan; Multiple Myeloma; Prednisolone

1974
In vitro cloning and chemosensitivity of human myeloma stem cells.
    Clinics in haematology, 1982, Volume: 11, Issue:1

    Topics: Animals; Carmustine; Cell Transformation, Neoplastic; Clone Cells; Colony-Forming Units Assay; DNA; Doxorubicin; Drug Resistance; Humans; Hypergammaglobulinemia; Interferons; Melphalan; Mice; Mice, Inbred BALB C; Multiple Myeloma; Vinblastine; Waldenstrom Macroglobulinemia

1982
Chemosensitivity tests by a miniclone technique.
    Medical oncology and tumor pharmacotherapy, 1984, Volume: 1, Issue:1

    Topics: Antineoplastic Agents; Carmustine; Cell Survival; Cisplatin; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Doxorubicin; Humans; Melphalan; Methods; Streptozocin; Tumor Stem Cell Assay

1984
Ovarian reticular cell sarcoma of the mouse (M5076) made resistant to cyclophosphamide.
    Cancer research, 1983, Volume: 43, Issue:12 Pt 1

    Topics: Animals; Antineoplastic Agents; Carmustine; Cell Cycle; Cell Line; Cyclophosphamide; Dacarbazine; Drug Resistance; Female; Lymphoma, Large B-Cell, Diffuse; Melphalan; Mice; Mice, Inbred C57BL; Ovarian Neoplasms

1983
Autologous bone marrow transplantation for human solid tumors.
    Texas medicine, 1984, Volume: 80, Issue:6

    Topics: Bone Marrow Transplantation; Carmustine; Humans; Melphalan; Neoplasms; Transplantation, Autologous

1984
Perspectives for the use of high-dose chemotherapy in the treatment of solid malignant tumors.
    European journal of cancer & clinical oncology, 1984, Volume: 20, Issue:11

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Drug Evaluation; Etoposide; Humans; Melphalan; Neoplasms; Whole-Body Irradiation

1984
Long-term survival of patients with multiple myeloma and acute renal failure at presentation.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 1983, Volume: 2, Issue:5

    Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Humans; Long-Term Care; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Procarbazine; Renal Dialysis; Time Factors; Vincristine

1983
Serum-free light chain analysis by crossed immunoelectrophoresis: correlation with plasmapheresis in light chain disease nephropathy.
    American journal of hematology, 1983, Volume: 15, Issue:1

    Topics: Acute Kidney Injury; Aged; Allopurinol; Calcitonin; Carmustine; Counterimmunoelectrophoresis; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Immunoglobulin lambda-Chains; Immunoglobulin Light Chains; Male; Melphalan; Paraproteinemias; Peritoneal Dialysis; Plasmapheresis; Prednisone; Vincristine

1983
[Systemic light-chain disease as a complication of plasmacytoma].
    Deutsche medizinische Wochenschrift (1946), 1984, Sep-14, Volume: 109, Issue:37

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Bone Marrow Cells; Carmustine; Cyclophosphamide; Humans; Hypergammaglobulinemia; Hypertension, Renal; Immunoglobulin kappa-Chains; Immunoglobulin Light Chains; Male; Melphalan; Middle Aged; Nephrotic Syndrome; Plasma Cells; Plasmacytoma; Prednisone; Vincristine

1984
The development of a system for study of bone marrow transplantation in vitro: effects of X-irradiation dose rate and chemotherapeutic agents on the isolated bone marrow microenvironment.
    Kroc Foundation series, 1984, Volume: 18

    Topics: Animals; Bone Marrow; Bone Marrow Cells; Busulfan; Carmustine; Cell Communication; Cells, Cultured; Colony-Forming Units Assay; Culture Techniques; Doxorubicin; Female; Hematopoiesis; Hematopoietic Stem Cells; Interleukin-3; Lymphokines; Melphalan; Mice; Mice, Inbred Strains

1984
Theophylline does not reverse DNA replicon initiation inhibition in human cells resistant to alkylating agent-theophylline killing synergism.
    Chemico-biological interactions, 1984, Sep-15, Volume: 51, Issue:2

    Topics: Alkylating Agents; Burkitt Lymphoma; Carmustine; Cell Line; Cell Survival; Cisplatin; Cross-Linking Reagents; DNA, Neoplasm; Drug Resistance; Drug Synergism; Ethylnitrosourea; Humans; Melphalan; Replicon; Theophylline

1984
Comparison of M-2 protocol with COP in patients with nodular lymphoma.
    Oncology, 1984, Volume: 41, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carmustine; Cyclophosphamide; Humans; Lymphoma; Melphalan; Middle Aged; Neoplasm Staging; Prednisone; Probability; Time Factors; Vincristine

1984
[Therapy of multiple myeloma. Results of sequential treatment with melphalan-prednisolone and the M2 protocol].
    Deutsche medizinische Wochenschrift (1946), 1984, Jun-29, Volume: 109, Issue:26

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Creatinine; Cyclophosphamide; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisolone; Prednisone; Prognosis; Vincristine

1984
Efficacy of the M-2 protocol in previously untreated patients with advanced multiple myeloma.
    Blut, 1984, Volume: 49, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Remission, Spontaneous; Vincristine

1984
[Combination chemotherapy (modified M-2 protocol) for multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 1984, Volume: 25, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Vincristine

1984
Adriamycin, BCNU, and cyclophosphamide in drug-resistant adenocarcinoma of the ovary.
    Medical and pediatric oncology, 1983, Volume: 11, Issue:3

    Topics: Adenocarcinoma; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug Resistance; Drug Therapy, Combination; Female; Humans; Melphalan; Ovarian Neoplasms

1983
Treatment of multiple myeloma with M-2 protocol and without maintenance therapy.
    European journal of cancer & clinical oncology, 1983, Volume: 19, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Humans; Immunoglobulins; Male; Melphalan; Middle Aged; Multiple Myeloma; Paraproteins; Prednisone; Time Factors; Vincristine

1983
Treatment of advanced malignant melanoma with high-dose chemotherapy and autologous bone marrow transplantation. Preliminary results--Phase I study.
    American journal of clinical oncology, 1982, Volume: 5, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Agents; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Cell Survival; Colony-Forming Units Assay; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Lymphatic Metastasis; Male; Mechlorethamine; Melanoma; Melphalan; Middle Aged; Transplantation, Autologous

1982
Combination chemotherapy (M-2) protocol (BCNU, cyclophosphamide, vincristine, melphalan, and prednisone) for Waldenström macroglobulinemia: preliminary report.
    Blood, 1982, Volume: 59, Issue:5

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Immunoglobulin M; Male; Melphalan; Middle Aged; Prednisone; Prognosis; Vincristine; Waldenstrom Macroglobulinemia

1982
Combination chemotherapy with AMSA on L1210 leukaemia and B16 melanoma.
    European journal of cancer & clinical oncology, 1981, Volume: 17, Issue:9

    Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Carmustine; Dacarbazine; Drug Therapy, Combination; Leukemia L1210; Male; Melanoma; Melphalan; Mice; Mice, Inbred Strains; Neoplasms, Experimental

1981
Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
    Cancer treatment reports, 1982, Volume: 66, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Leukopenia; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prospective Studies; Thrombocytopenia; Vincristine

1982
Effects of alkylating agents on the DNA replication of cultured Yoshida sarcoma cells.
    Chemico-biological interactions, 1982, Mar-15, Volume: 39, Issue:2

    Topics: Alkylating Agents; Animals; Carmustine; Cell Division; Cell Survival; Chlorambucil; Cyclophosphamide; DNA Replication; Doxorubicin; Kinetics; Mechlorethamine; Melphalan; Mice; Sarcoma, Yoshida; Structure-Activity Relationship

1982
Misonidazole enhancement of the action of BCNU and melphalan against human melanoma xenografts.
    American journal of clinical oncology, 1982, Volume: 5, Issue:1

    Topics: Animals; Antineoplastic Agents; Bone Marrow; Carmustine; Cell Line; Drug Synergism; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Melphalan; Mice; Mice, Inbred CBA; Misonidazole; Neoplasm Transplantation; Neoplasms, Experimental; Nitroimidazoles; Transplantation, Heterologous

1982
The effect of alkylating agents and other drugs on the accumulation of melphalan by murine L1210 leukaemia cells in vitro.
    Biochemical pharmacology, 1982, Sep-01, Volume: 31, Issue:17

    Topics: Alkylating Agents; Animals; Carmustine; Cells, Cultured; Leukemia L1210; Melphalan; Mice; Time Factors

1982
Drug resistance in multiple myeloma associated with high in vitro incorporation of 3H-thymidine.
    Blood, 1981, Volume: 58, Issue:3

    Topics: Carmustine; Cell Nucleus; Cell Transformation, Neoplastic; Doxorubicin; Drug Resistance; Drug Therapy, Combination; Humans; Melphalan; Multiple Myeloma; Thymidine; Vincristine

1981
[Value of successive chemotherapy in multiple myeloma of bone. Prospective study over 4 years].
    Revue du rhumatisme et des maladies osteo-articulaires, 1980, Volume: 47, Issue:2

    Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carmustine; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Vincristine

1980
Strategic down-regulation of DNA polymerase beta by antisense RNA sensitizes mammalian cells to specific DNA damaging agents.
    Nucleic acids research, 1995, Oct-11, Volume: 23, Issue:19

    Topics: 3T3 Cells; Animals; Antineoplastic Agents; Bleomycin; Carmustine; Cell Death; Cisplatin; DNA; DNA Damage; DNA Polymerase I; Gene Expression Regulation; Humans; Mechlorethamine; Melphalan; Methyl Methanesulfonate; Mice; RNA, Antisense; Transfection; Ultraviolet Rays; Zinc

1995
Administration of three cytokines instead of bone marrow transplantation in an HIV+ patient with high-grade lymphoma.
    European journal of haematology, 1994, Volume: 53, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Cytarabine; Cytokines; Doxorubicin; Drug Therapy, Combination; Erythropoietin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lymphoma, AIDS-Related; Melphalan; Prednisolone; Vincristine

1994
Visual hallucinations following treatment with vincristine.
    Clinical and laboratory haematology, 1994, Volume: 16, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cyclophosphamide; Doxorubicin; Etoposide; Hallucinations; Humans; Lymphoma, T-Cell; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Prednisolone; Prednisone; Procarbazine; Salvage Therapy; Serotonin; Structure-Activity Relationship; Vincristine

1994
Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation.
    Blood, 1995, Jun-01, Volume: 85, Issue:11

    Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Marrow; Bone Marrow Cells; Carboplatin; Carmustine; Cell Adhesion Molecules; Cell Movement; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Epirubicin; Etoposide; Female; Fluorouracil; Gene Expression; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Ifosfamide; L-Selectin; Leukocyte Count; Male; Melphalan; Middle Aged; Neoplasms; Neutrophils; Platelet Count; Podophyllotoxin; Receptors, Very Late Antigen; Thiotepa

1995
[Pneumonia caused by Salmonella in a patient with myeloma].
    Sangre, 1995, Volume: 40, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Immunocompromised Host; Male; Melphalan; Middle Aged; Multiple Myeloma; Pneumonia, Bacterial; Prednisone; Salmonella Infections; Vincristine

1995
Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts.
    Blood, 1995, Nov-15, Volume: 86, Issue:10

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Cells; Bone Marrow; Bone Marrow Transplantation; Carmustine; Cell Survival; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Glyoxal; Graft Survival; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multivariate Analysis; Prednimustine; Prednisolone; Prednisone; Procarbazine; Radiotherapy; Retrospective Studies; Salvage Therapy; Vinblastine; Vincristine

1995
Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma.
    Blood, 1995, Oct-15, Volume: 86, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Graft Rejection; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Humans; Life Tables; Lymphoma, Follicular; Melphalan; Middle Aged; Pancytopenia; Podophyllotoxin; Prednisone; Prognosis; Teniposide; Treatment Outcome; Vincristine; Whole-Body Irradiation

1995
Functional hyperactivity of monocytes after bone marrow transplantation: possible relevance for the development of post-transplant complications or relapse.
    Bone marrow transplantation, 1995, Volume: 15, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopterins; Bone Marrow Transplantation; Busulfan; Carmustine; Cells, Cultured; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Susceptibility; Female; Graft vs Host Disease; Hepatic Veno-Occlusive Disease; Humans; Leukemia; Lymphoma; Male; Melphalan; Middle Aged; Monocytes; Neopterin; Podophyllotoxin; Respiratory Burst; Superoxides; Tumor Necrosis Factor-alpha; Whole-Body Irradiation

1995
Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
    Bone marrow transplantation, 1995, Volume: 15, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Diseases; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Leukapheresis; Lymphocyte Count; Lymphocyte Subsets; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Mesna; Middle Aged; Podophyllotoxin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Time Factors; Treatment Outcome; Vincristine

1995
Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product.
    British journal of cancer, 1993, Volume: 68, Issue:5

    Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Lymphoma; Male; Melphalan; Middle Aged; Salvage Therapy; Time Factors

1993
Induction of ovarian function by using short-term human menopausal gonadotrophin in patients with ovarian failure following cytotoxic chemotherapy for haematological malignancy.
    Leukemia & lymphoma, 1993, Volume: 10, Issue:4-5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Female; Follicle Stimulating Hormone; Hodgkin Disease; Humans; Leukemia, Myelomonocytic, Acute; Luteinizing Hormone; Melphalan; Menotropins; Ovulation Induction; Podophyllotoxin; Prednisone; Pregnancy; Pregnancy, Multiple; Primary Ovarian Insufficiency; Remission Induction; Teniposide; Thioguanine; Vincristine

1993
Prolonged impairment of hematopoiesis after high-dose therapy followed by autologous bone marrow transplantation.
    Blood, 1995, Jun-01, Volume: 85, Issue:11

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Busulfan; Carmustine; Cell Count; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoiesis; Hematopoietic Cell Growth Factors; Humans; Male; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Multivariate Analysis; Neoplasms; Prognosis; Radiation Injuries; Treatment Outcome; Vincristine; Whole-Body Irradiation

1995
Delayed neutrophil recovery after BEAM chemotherapy and autologous bone marrow transplantation for lymphoma is not associated with increased mortality from infection.
    Bone marrow transplantation, 1995, Volume: 15, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cell Count; Combined Modality Therapy; Cytarabine; Etoposide; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Neutropenia; Opportunistic Infections; Survival Analysis

1995
Cyclocreatine in cancer chemotherapy.
    Cancer chemotherapy and pharmacology, 1995, Volume: 35, Issue:5

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Small Cell; Carmustine; Cell Division; Cell Survival; Cisplatin; Creatinine; Cyclophosphamide; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Lung Neoplasms; Mammary Neoplasms, Experimental; Melphalan; Rats; Rats, Inbred F344; Tumor Cells, Cultured

1995
Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens.
    Oncology research, 1994, Volume: 6, Issue:6

    Topics: Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Aphidicolin; Camptothecin; Carmustine; Cell Cycle; Cell Death; Cell Line; Cisplatin; Cricetinae; Cricetulus; DNA Damage; DNA Repair; DNA, Neoplasm; Doxorubicin; Drug Synergism; Etoposide; Fibroblasts; Hydroxyurea; Lung; Melphalan; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan

1994
The therapeutic efficacy of VBCMP-M2 protocol in multiple myeloma.
    Haematologia, 1994, Volume: 26, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Survival; Vincristine

1994
Pregnancy after autologous bone marrow transplantation for malignant lymphomas.
    Nouvelle revue francaise d'hematologie, 1994, Volume: 36, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Infant, Newborn; Lymphoma, Large B-Cell, Diffuse; Mechlorethamine; Melphalan; Podophyllotoxin; Prednisone; Pregnancy; Pregnancy Outcome; Procarbazine; Remission Induction; Salvage Therapy; Vincristine

1994
CAI: effects on cytotoxic therapies in vitro and in vivo.
    Cancer chemotherapy and pharmacology, 1994, Volume: 34, Issue:6

    Topics: Aminoimidazole Carboxamide; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Carmustine; Cisplatin; Cyclophosphamide; Fibrosarcoma; Mammary Neoplasms, Experimental; Melphalan; Mice; Triazoles; Tumor Cells, Cultured

1994
Quality and functional capacity of the bone marrow microenvironment of autologous blood stem cell transplantation (ABSCT) recipients.
    Nouvelle revue francaise d'hematologie, 1994, Volume: 36, Issue:4

    Topics: Bone Marrow; Carmustine; Cells, Cultured; Colony-Forming Units Assay; Connective Tissue; Cyclophosphamide; Cytarabine; Etoposide; Graft Survival; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Multiple Myeloma; Transplantation, Autologous; Whole-Body Irradiation

1994
Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan.
    Cancer research, 1994, Jul-01, Volume: 54, Issue:13

    Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Camptothecin; Carmustine; DNA Polymerase I; DNA Polymerase II; DNA Topoisomerases, Type II; Drug Resistance; Drug Screening Assays, Antitumor; Female; Humans; Male; Melphalan; Mice; Mice, Inbred BALB C; Mice, Nude; Rhabdomyosarcoma; Topotecan; Transferases; Transplantation, Heterologous

1994
Germ cell failure and Leydig cell insufficiency in post-pubertal males after autologous bone marrow transplantation with BEAM for lymphoma.
    Bone marrow transplantation, 1994, Volume: 13, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Follicle Stimulating Hormone; Humans; Leydig Cells; Luteinizing Hormone; Lymphoma; Male; Melphalan; Spermatozoa; Transplantation, Autologous

1994
High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease.
    Annals of hematology, 1993, Volume: 66, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Survival Rate

1993
Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival.
    Cancer research, 1994, Apr-15, Volume: 54, Issue:8

    Topics: Animals; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Enzyme-Linked Immunosorbent Assay; Etoposide; Gangliosides; Humans; Melphalan; Mice; Neoplasm Staging; Neuroblastoma; Prognosis; Radiotherapy Dosage; Survival Analysis; Survival Rate; Thiotepa

1994
[Results of alternating treatment of multiple myeloma--cytostatics VBMCP and recombinant interferon alfa-2B].
    Polskie Archiwum Medycyny Wewnetrznej, 1993, Volume: 90, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recombinant Proteins; Survival Rate; Vincristine

1993
Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma.
    Oncology research, 1995, Volume: 7, Issue:5

    Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Carmustine; Cell Hypoxia; Cell Survival; Cisplatin; Cyclohexanes; Cyclophosphamide; DNA, Neoplasm; Drug Combinations; Male; Melphalan; Mice; Mice, Inbred C57BL; Minocycline; O-(Chloroacetylcarbamoyl)fumagillol; Platinum; Sesquiterpenes; Tumor Cells, Cultured

1995
A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation.
    Experimental hematology, 1995, Volume: 23, Issue:14

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Granulocytes; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukapheresis; Leukocyte Count; Leukocytes, Mononuclear; Lymphoma; Lymphoma, Non-Hodgkin; Macrophages; Male; Melphalan

1995
Chemotherapy-associated changes in 31P MRS spectra of sera from patients with multiple myeloma.
    NMR in biomedicine, 1995, Volume: 8, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium; Carmustine; Cholesterol; Cyclophosphamide; Female; Humans; Immunoglobulin G; Lipoproteins; Magnetic Resonance Spectroscopy; Male; Melphalan; Middle Aged; Multiple Myeloma; Phosphatidylcholines; Phosphatidylethanolamines; Phospholipids; Prednisone; Reference Values; Sphingomyelins; Vincristine

1995
Enhancement of melphalan activity by inhibition of DNA polymerase-alpha and DNA polymerase-beta.
    Cancer chemotherapy and pharmacology, 1996, Volume: 38, Issue:4

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Aphidicolin; Carmustine; DNA Polymerase I; DNA Polymerase II; Drug Synergism; Enzyme Inhibitors; Female; Guanine; Humans; Male; Melphalan; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Rhabdomyosarcoma; Zalcitabine

1996
High-dose carmustine, etoposide and melphalan ('BEM') with autologous stem cell transplantation: a dose-toxicity study.
    Bone marrow transplantation, 1996, Volume: 17, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Liver Function Tests; Lymphoma; Male; Melphalan; Middle Aged; Multiple Myeloma; Respiratory Function Tests; Retrospective Studies; Transplantation, Autologous

1996
Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines.
    Anti-cancer drugs, 1996, Volume: 7, Issue:4

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Breast Neoplasms; Carmustine; Cisplatin; Cyclophosphamide; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Melphalan; Nitrogen Mustard Compounds; Ovarian Neoplasms; Tumor Cells, Cultured

1996
Effective autologous peripheral blood stem cell transplantation in plasma cell leukemia followed by T-large granular lymphocyte expansion: a case report.
    Bone marrow transplantation, 1996, Volume: 18, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Plasma Cell; Lymphocyte Count; Male; Melphalan; Mitoxantrone; Prednisone; Remission Induction; T-Lymphocyte Subsets; Transplantation Conditioning; Vincristine; Whole-Body Irradiation

1996
Successful mobilisation of blood stem cells following previous autologous bone marrow transplantation.
    Bone marrow transplantation, 1996, Volume: 18, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Cells; Bone Marrow; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Epirubicin; Etoposide; Hematopoietic Stem Cells; Humans; Ifosfamide; Leukapheresis; Lymphoma, Follicular; Male; Melphalan; Methotrexate; Podophyllotoxin; Prednisolone; Prednisone; Transplantation Conditioning; Transplantation, Autologous; Vincristine

1996
G-CSF (filgrastim)-stimulated whole blood kept unprocessed at 4 degrees C does support a BEAM-like regimen in bad-risk lymphoma.
    Bone marrow transplantation, 1996, Volume: 18, Issue:2

    Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cold Temperature; Combined Modality Therapy; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Podophyllotoxin

1996
t(9;13)(q34;q12) chromosomal translocation persisting 4 years post autologous bone marrow transplantation for secondary AML despite morphological remission.
    Clinical and laboratory haematology, 1996, Volume: 18, Issue:2

    Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzene; Bone Marrow; Bone Marrow Transplantation; Carmustine; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 9; Combined Modality Therapy; Etoposide; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Melphalan; Myelodysplastic Syndromes; Neoplastic Stem Cells; Occupational Diseases; Occupational Exposure; Pancytopenia; Remission Induction; Solvents; Translocation, Genetic; Transplantation, Homologous

1996
Improved priming for mobilization of and optimal timing for harvest of peripheral blood stem cells.
    Journal of hematotherapy, 1996, Volume: 5, Issue:4

    Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Blood Transfusion, Autologous; Bone Marrow; Carmustine; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Drug Synergism; Epirubicin; Etoposide; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cells; Humans; Injections, Subcutaneous; Leukapheresis; Leukocyte Count; Male; Melphalan; Middle Aged; Neoplasms; Recombinant Proteins

1996
Peripheral blood stem cell support does not accelerate haemopoietic recovery from miniBEAM chemotherapy.
    Bone marrow transplantation, 1996, Volume: 18, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged

1996
Conventional induction treatments do not influence overall survival in multiple myeloma.
    British journal of haematology, 1997, Volume: 96, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Humans; Melphalan; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Prednisone; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome; Vincristine

1997
Treatment of relapsed non-Hodgkin's lymphoma after BEAM chemotherapy and autologous transplantation by BU/CY chemotherapy and salvage transplantation.
    Bone marrow transplantation, 1997, Volume: 19, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Epirubicin; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Injections, Spinal; Lymphoma, B-Cell, Marginal Zone; Male; Melphalan; Methotrexate; Prednisone; Recurrence; Remission Induction; Retreatment; Salvage Therapy; Stomach Neoplasms; Transplantation Conditioning; Tumor Lysis Syndrome; Vincristine

1997
Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:2

    Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leucovorin; Leukapheresis; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Pilot Projects; Prednisone; Risk; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vincristine

1997
Long-term haematological reconstitution following BEAM and autologous transplantation of circulating progenitor cells in non-Hodgkin's lymphoma.
    British journal of haematology, 1997, Volume: 96, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hemoglobins; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neutrophils; Platelet Count; Transplantation Conditioning

1997
Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin's lymphomas.
    Annals of hematology, 1997, Volume: 74, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cytarabine; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Methylprednisolone; Middle Aged; Myeloproliferative Disorders; Neutropenia; Salvage Therapy; Survival Rate; Time Factors

1997
Dementia improvement with cytotoxic chemotherapy. A case of Alzheimer disease and multiple myeloma.
    Archives of neurology, 1997, Volume: 54, Issue:4

    Topics: Alzheimer Disease; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Vincristine

1997
Multifocal plasmacytoma of hand and foot bones.
    Leukemia & lymphoma, 1996, Volume: 21, Issue:5-6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carmustine; Combined Modality Therapy; Cyclophosphamide; Female; Fingers; Foot Diseases; Hand Deformities, Acquired; Humans; Melphalan; Metacarpus; Plasmacytoma; Prednisone; Vincristine

1996
[Hemopoietic stem cell transplantation in lymphogranulomatosis].
    Voprosy onkologii, 1997, Volume: 43, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Carmustine; Child; Cytarabine; Female; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Length of Stay; Male; Melphalan; Podophyllotoxin; Recurrence; Treatment Outcome

1997
Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Etoposide; Humans; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Recurrence; Salvage Therapy; Treatment Outcome

1997
BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.
    Bone marrow transplantation, 1997, Volume: 20, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Cytarabine; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Treatment Outcome

1997
Hypersensitivity to DNA cross-linking agents associated with up-regulation of glucose-regulated stress protein GRP78.
    Cancer research, 1997, Nov-15, Volume: 57, Issue:22

    Topics: 6-Aminonicotinamide; Animals; Antimetabolites; Antineoplastic Agents, Alkylating; Carmustine; Carrier Proteins; Cell Line; Cisplatin; Cricetinae; Deoxyglucose; DNA Repair; DNA, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Heat-Shock Proteins; Melphalan; Molecular Chaperones; Teratogens; Up-Regulation

1997
BEAM chemotherapy and autologous haemopoietic progenitor cell transplantation as front-line therapy for high-risk patients with diffuse large cell lymphoma.
    British journal of haematology, 1997, Volume: 99, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leucovorin; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Methotrexate; Middle Aged; Prednisone; Survival Rate; Treatment Outcome; Vincristine

1997
[Autologous transplant with BEAM protocol in lymphoma].
    Sangre, 1997, Volume: 42 Suppl 1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Remission Induction; Transplantation Conditioning; Transplantation, Autologous

1997
[Superhigh-dosage chemotherapy with the transplantation of autologous hemopoietic precursor cells in patients with a prognostically unfavorable relapse and resistant course of lymphogranulomatosis].
    Terapevticheskii arkhiv, 1997, Volume: 69, Issue:10

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Prognosis; Radiotherapy, Adjuvant; Recurrence; Remission Induction; Transplantation, Autologous

1997
[The influence of verapamil on platelet function in patients with multiple myeloma].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 1997, Volume: 2, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Platelet Aggregation; Platelet Aggregation Inhibitors; Prednisone; Verapamil; Vincristine

1997
Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:4

    Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Transfusion; Bone Marrow; Carmustine; Combined Modality Therapy; Cryopreservation; Cyclophosphamide; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Neoplasms; Podophyllotoxin; Treatment Failure

1998
Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation.
    Cancer, 1998, Apr-15, Volume: 82, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Female; Heart; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lung; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neutropenia; Neutrophils; Podophyllotoxin; Respiratory Function Tests; Retrospective Studies; Ventricular Function, Left

1998
[Intensive treatment of T-cell-rich B lymphoma].
    Sangre, 1998, Volume: 43, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Lymphoma, B-Cell; Male; Melphalan; Podophyllotoxin; Prednisone; Remission Induction; T-Lymphocyte Subsets; Vincristine

1998
Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Bone marrow transplantation, 1998, Volume: 21, Issue:9

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Mitoguazone; Salvage Therapy; Time Factors

1998
Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study.
    Bone marrow transplantation, 1998, Volume: 21, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Pilot Projects; Prednisone; Survival Rate; Transplantation, Autologous; Vincristine

1998
High-dose chemotherapy and autologous transplantation in lymphomatous polyposis in second remission: three case reports and literature review.
    Bone marrow transplantation, 1998, Volume: 22, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Intestinal Polyps; Lymphoma, B-Cell; Male; Melphalan; Middle Aged; Prednisone; Transplantation, Autologous; Vincristine

1998
Melanin content and downregulation of glutathione S-transferase contribute to the action of L-buthionine-S-sulfoximine on human melanoma.
    Chemico-biological interactions, 1998, Apr-24, Volume: 111-112

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Buthionine Sulfoximine; Carmustine; Down-Regulation; Drug Resistance; Enzyme Inhibitors; Female; Glutamate-Cysteine Ligase; Glutathione Transferase; Humans; Melanins; Melanoma; Melphalan; Ovarian Neoplasms; Tumor Cells, Cultured

1998
Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy.
    Blood, 1998, Aug-01, Volume: 92, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Chromosomes, Human, Pair 17; Cyclophosphamide; Dexamethasone; Female; Gene Deletion; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Interphase; Karyotyping; Life Tables; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Survival Analysis; Treatment Outcome; Vincristine

1998
Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation--results of a retrospective analysis on 120 patients autografted in a single institution.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:8

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prognosis; Recurrence; Remission Induction; Retrospective Studies

1998
Modulation of erythrocyte photohemolysis rate by glutathione reductase inactivating alkylating agents.
    Biochemistry and molecular biology international, 1998, Volume: 45, Issue:4

    Topics: Alkylating Agents; Carmustine; Glutathione Reductase; Hemolysis; Humans; Kinetics; Light; Melphalan; Oxidation-Reduction; Oxygen; Oxygen Consumption; Phenylacetates; Photolysis; Photosensitizing Agents; Singlet Oxygen; Thioctic Acid

1998
Mobilizing peripheral blood stem cells with high-dose G-CSF alone is as effective as with Dexa-BEAM plus G-CSF in lymphoma patients.
    British journal of haematology, 1998, Volume: 102, Issue:4

    Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colony-Forming Units Assay; Cytarabine; Dexamethasone; Etoposide; Female; Filgrastim; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hospitalization; Humans; Lymphoma; Male; Melphalan; Middle Aged; Recombinant Proteins; Retrospective Studies

1998
Clonal myelodysplastic cells present in apheresis product before transplantation.
    Leukemia, 1998, Volume: 12, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chromosome Aberrations; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 7; Cyclophosphamide; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Lymphoma, B-Cell; Lymphoma, Follicular; Melphalan; Middle Aged; Podophyllotoxin; Retrospective Studies

1998
Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system.
    Bone marrow transplantation, 1998, Volume: 22, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Neoplasms; Predictive Value of Tests; Transplantation, Autologous

1998
Haemopoietic cell transplantation activity and results: a single institution experience.
    Bone marrow transplantation, 1998, Volume: 22 Suppl 4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Hungary; Leukemia; Melphalan; Podophyllotoxin; Recurrence; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation

1998
Non-secretory solitary plasmacytoma of the spleen.
    Medical oncology (Northwood, London, England), 1998, Volume: 15, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Humans; Male; Melphalan; Middle Aged; Plasmacytoma; Prednisone; Splenectomy; Splenic Neoplasms; Vincristine

1998
The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients.
    Bone marrow transplantation, 1999, Volume: 23, Issue:1

    Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carmustine; Combined Modality Therapy; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Lomustine; Male; Mechlorethamine; Melphalan; Middle Aged; Transplantation, Autologous

1999
Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
    Bone marrow transplantation, 1999, Volume: 23, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Bone Marrow; Carmustine; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease Progression; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Life Tables; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Neoplasm Proteins; Plasmacytoma; Prednisone; Salvage Therapy; Survival Analysis; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine

1999
Increased sensitivity of human colon cancer cells to DNA cross-linking agents after GRP78 up-regulation.
    Biochemical and biophysical research communications, 1999, Apr-13, Volume: 257, Issue:2

    Topics: 6-Aminonicotinamide; Blotting, Western; Carmustine; Carrier Proteins; Cell Survival; Cisplatin; Colonic Neoplasms; Cross-Linking Reagents; DNA Damage; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Heat-Shock Proteins; Humans; Melphalan; Molecular Chaperones; NAD; Poly Adenosine Diphosphate Ribose; Time Factors; Tumor Cells, Cultured; Up-Regulation

1999
Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option.
    Bone marrow transplantation, 1999, Volume: 23, Issue:6

    Topics: Adult; Ambulatory Care; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Neutropenia; Podophyllotoxin; Retrospective Studies

1999
Amyloidosis: recognition, confirmation, prognosis, and therapy.
    Mayo Clinic proceedings, 1999, Volume: 74, Issue:5

    Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Diagnosis, Differential; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Prednisone; Prognosis; Vincristine

1999
Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Podophyllotoxin; Survival Rate; Transplantation Conditioning; Transplantation, Homologous

1999
[Acute and chronic renal failure in patients with myeloma].
    Terapevticheskii arkhiv, 1999, Volume: 71, Issue:7

    Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Hemodiafiltration; Hemofiltration; Humans; Kidney Failure, Chronic; Male; Melphalan; Middle Aged; Multiple Myeloma; Peritoneal Dialysis; Prednisone; Renal Dialysis; Time Factors; Vincristine

1999
High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy.
    Bone marrow transplantation, 1999, Volume: 24, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Life Tables; Melphalan; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Survival Analysis; Treatment Outcome

1999
High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    British journal of cancer, 1999, Volume: 81, Issue:3

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Chlorambucil; Cohort Studies; Combined Modality Therapy; Cytarabine; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Incidence; Infant; Leukemia, Myeloid; Life Tables; Lomustine; Male; Mechlorethamine; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Podophyllotoxin; Prednisolone; Prednisone; Procarbazine; Retrospective Studies; Risk; Salvage Therapy; Vinblastine; Vincristine

1999
Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD 20 mono- clonal antibody) and interleukin-2.
    Leukemia & lymphoma, 1999, Volume: 35, Issue:5-6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Idarubicin; Ifosfamide; Immunization, Passive; Interleukin-2; Male; Melphalan; Middle Aged; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Vinblastine; Vincristine

1999
Stem cell transplantations in patients with malignant lymphoma: costs in a Dutch university hospital in the period 1984-1995.
    Journal of hematotherapy & stem cell research, 1999, Volume: 8, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Transfusion; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Hematopoietic Stem Cell Transplantation; Hospital Costs; Hospital Units; Hospitalization; Humans; Length of Stay; Lymphoma, Non-Hodgkin; Melphalan; Netherlands; Parenteral Nutrition; Patient Isolation; Podophyllotoxin; Prednisone; Retrospective Studies; Transplantation, Autologous; Vincristine

1999
Double high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - effect of sequence.
    Cancer chemotherapy and pharmacology, 2000, Volume: 45, Issue:3

    Topics: Alkylating Agents; Animals; Antineoplastic Agents; Breast Neoplasms; Carmustine; Cell Survival; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Mechlorethamine; Melphalan; Mice; Neoplasms, Experimental; Tumor Cells, Cultured

2000
Comparative effects of (SBE)7m-beta-CD and HP-beta-CD on the stability of two anti-neoplastic agents, melphalan and carmustine.
    Journal of pharmaceutical sciences, 2000, Volume: 89, Issue:2

    Topics: 2-Hydroxypropyl-beta-cyclodextrin; Antineoplastic Agents, Alkylating; beta-Cyclodextrins; Binding Sites; Carmustine; Cyclodextrins; Drug Stability; Excipients; Kinetics; Melphalan; Nuclear Magnetic Resonance, Biomolecular; Solubility; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Structure-Activity Relationship

2000
Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2000, Volume: 6, Issue:1

    Topics: Adjuvants, Pharmaceutic; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Breast Neoplasms; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Infections; Melphalan; Middle Aged; Mitoxantrone; Paclitaxel; Survival Rate; Thiotepa; Time Factors; Transplantation, Autologous

2000
Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity.
    British journal of haematology, 2000, Volume: 108, Issue:4

    Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclosporine; Cytarabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoproliferative Disorders; Male; Melphalan; Methotrexate; Middle Aged; Podophyllotoxin; Transplantation Conditioning; Transplantation, Homologous

2000
Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT).
    Bone marrow transplantation, 2000, Volume: 25, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Prognosis; Recurrence; Transplantation, Autologous

2000
Automated immature reticulocyte counts are early markers of engraftment following autologous PBSC transplantation in patients with lymphoma.
    Journal of hematotherapy & stem cell research, 2000, Volume: 9, Issue:2

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Automation; Biomarkers; Carmustine; Cytarabine; Female; Flow Cytometry; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Neutrophils; Podophyllotoxin; Predictive Value of Tests; Reticulocyte Count; Reticulocytes; Time Factors; Transplantation, Autologous

2000
Oxidative burst measurement in patients treated with cytostatics: influence of G-CSF and role as a prognostic factor.
    Annals of hematology, 2000, Volume: 79, Issue:4

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Escherichia coli; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; N-Formylmethionine Leucyl-Phenylalanine; Prognosis; Respiratory Burst; Tetradecanoylphorbol Acetate

2000
High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:6

    Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; L-Lactate Dehydrogenase; Male; Melphalan; Middle Aged; Prognosis; Recurrence; Transplantation, Autologous

2000
Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
    Haematologica, 2000, Volume: 85, Issue:8

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Carmustine; Cell Lineage; Combined Modality Therapy; Cytarabine; Disease Susceptibility; Female; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infections; Lymphocyte Count; Lymphocyte Subsets; Lymphopenia; Male; Melphalan; Middle Aged; Podophyllotoxin; Sweden; Transplantation Conditioning; Transplantation, Autologous

2000
[The 1st results of the combined therapy of recurrent and refractory forms of lymphogranulomatosis (polychemotherapy, radiation therapy and the removal of the residual mediastinal formation)].
    Terapevticheskii arkhiv, 2000, Volume: 72, Issue:7

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cytarabine; Dexamethasone; Etoposide; Female; Hodgkin Disease; Humans; Male; Mediastinal Neoplasms; Melphalan; Middle Aged; Neoplasm, Residual; Prognosis; Radiotherapy, Adjuvant; Recurrence; Salvage Therapy

2000
Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma.
    Blood, 2000, Oct-15, Volume: 96, Issue:8

    Topics: Adult; Aged; Alkaline Phosphatase; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Remodeling; Bone Resorption; Carmustine; Clodronic Acid; Combined Modality Therapy; Cytarabine; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Isoenzymes; Male; Melphalan; Middle Aged; Multiple Myeloma; Osteoclasts; Peptide Fragments; Podophyllotoxin; Procollagen; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2000
Patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation.
    Bone marrow transplantation, 2000, Volume: 26, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation

2000
Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol.
    Bone marrow transplantation, 2000, Volume: 26, Issue:7

    Topics: Adolescent; Adult; Age Factors; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease Progression; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Infections; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Survival Rate; Time Factors; Transplantation Conditioning

2000
Two-step immunoablative treatment with autologous peripheral blood CD34(+) cell transplantation in an 8-year-old boy with autoimmune haemolytic anaemia.
    British journal of haematology, 2000, Volume: 110, Issue:4

    Topics: Anemia, Hemolytic, Autoimmune; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cyclophosphamide; Cytarabine; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Male; Melphalan; Methylprednisolone; Plasmapheresis; Podophyllotoxin; Prednisolone; Splenectomy; Stem Cells; Transplantation, Autologous; Treatment Outcome

2000
[High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Harefuah, 2000, Volume: 139, Issue:5-6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Combined Modality Therapy; Cytarabine; Dacarbazine; Doxorubicin; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Middle Aged; Podophyllotoxin; Prednisone; Procarbazine; Recurrence; Retrospective Studies; Survival Rate; Time Factors; Vinblastine; Vincristine

2000
Rescue of haemopoiesis by a combination of growth factors including stem-cell factor.
    Lancet (London, England), 2000, Oct-14, Volume: 356, Issue:9238

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carmustine; Cytarabine; Epoetin Alfa; Erythrocyte Transfusion; Erythropoietin; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Cell Growth Factors; Humans; Lymphoma, Non-Hodgkin; Melphalan; Platelet Transfusion; Recombinant Proteins; Treatment Outcome

2000
Recurrent penicillin-resistant pneumococcal sepsis after matched unrelated donor (MUD) transplantation for refractory T cell lymphoma.
    Bone marrow transplantation, 2000, Volume: 26, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bone Marrow Transplantation; Carmustine; Cefotaxime; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Cytomegalovirus Infections; Doxorubicin; Drug Therapy, Combination; Etoposide; Humans; Idarubicin; Immunocompromised Host; Immunosuppressive Agents; Levofloxacin; Lymphoma, T-Cell; Male; Melphalan; Ofloxacin; Penicillin Resistance; Pneumococcal Infections; Prednisone; Recurrence; Rifampin; Splenectomy; Streptococcus pneumoniae; Transplantation Conditioning; Vincristine

2000
Complete remission of generalized relapsed extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type of the gastrointestinal tract after high-dose chemotherapy and autologous peripheral stem cell transplantation.
    Annals of hematology, 2000, Volume: 79, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Gastrointestinal Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Melphalan; Middle Aged; Remission Induction; Transplantation, Autologous

2000
[Role of high-dose BEAM-chemotherapy and autologous hemopoietic stem cell transplantation in the treatment of drug-resistant Hodgkin disease].
    Voprosy onkologii, 2000, Volume: 46, Issue:5

    Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Retrospective Studies; Risk Factors; Survival Analysis; Transplantation, Autologous; Treatment Outcome

2000
Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease.
    British journal of haematology, 2001, Volume: 113, Issue:1

    Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Blood Sedimentation; Carmustine; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Recurrence; Salvage Therapy; Sex Factors; Survival Analysis; Transplantation, Autologous

2001
Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant?
    Annals of hematology, 2001, Volume: 80, Issue:7

    Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Analysis; Time Factors; Transplantation, Autologous; Treatment Outcome

2001
[Autograft and multiple myeloma: experience of the Intergroupe Français du Myélome].
    Bulletin du cancer, 2001, Volume: 88, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; France; Humans; Melphalan; Multiple Myeloma; Prednisone; Prognosis; Randomized Controlled Trials as Topic; Transplantation, Autologous; Vincristine

2001
Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease.
    Blood, 2001, Nov-15, Volume: 98, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Diagnosis, Differential; Disease-Free Survival; Doxorubicin; Etoposide; False Negative Reactions; False Positive Reactions; Fibrosis; Fluorodeoxyglucose F18; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Life Tables; Mediastinal Neoplasms; Melphalan; Neoplasm Recurrence, Local; Predictive Value of Tests; Prednisone; Procarbazine; Prospective Studies; Radiopharmaceuticals; Radiotherapy, Adjuvant; Remission Induction; Salvage Therapy; Tomography, Emission-Computed; Transplantation, Autologous; Vinblastine; Vincristine

2001
Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
    Bone marrow transplantation, 2001, Volume: 28, Issue:7

    Topics: Adjuvants, Immunologic; Adult; Aged; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cells, Cultured; Cytarabine; Cytotoxicity Tests, Immunologic; Cytotoxicity, Immunologic; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Interferon-alpha; Interleukin-2; K562 Cells; Killer Cells, Natural; Lymphocyte Count; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Time Factors; Transplantation Conditioning; Transplantation, Autologous

2001
High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells.
    Bone marrow transplantation, 2001, Volume: 28, Issue:9

    Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Infections; Male; Melphalan; Middle Aged; Neutropenia; Radiotherapy, Adjuvant; Retrospective Studies; Risk; Safety; Salvage Therapy; Survival Analysis; Survival Rate; Transplantation Conditioning; Treatment Outcome

2001
A novel type of metastatically spreading subcutaneous aspergillosis without epidermal lesions following allogeneic stem cell transplantation.
    Bone marrow transplantation, 2001, Volume: 28, Issue:9

    Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Bleomycin; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunocompromised Host; Klebsiella Infections; Klebsiella pneumoniae; Lung Diseases, Fungal; Male; Melphalan; Neoplasm Recurrence, Local; Opportunistic Infections; Pneumonia, Bacterial; Pneumonia, Pneumocystis; Prednisone; Procarbazine; Salvage Therapy; Skin; Transplantation, Homologous; Vinblastine; Vincristine

2001
Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
    Leukemia, 2002, Volume: 16, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Prognosis; Radiopharmaceuticals; Survival Analysis; Survival Rate; Tomography, Emission-Computed; Transplantation Conditioning; Treatment Outcome; Whole-Body Irradiation

2002
Point mutations of the BCL-6 gene: clinical and prognostic correlation in B-diffuse large cell lymphoma.
    Leukemia, 2002, Volume: 16, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Chromosomes, Human, Pair 3; Cyclophosphamide; Cytarabine; Disease-Free Survival; DNA Mutational Analysis; DNA-Binding Proteins; DNA, Neoplasm; Doxorubicin; Etoposide; Female; Genes, bcl-2; Humans; Life Tables; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Methotrexate; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Point Mutation; Prednisolone; Prednisone; Prognosis; Proto-Oncogene Mas; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-6; Proto-Oncogenes; Transcription Factors; Treatment Outcome; Vincristine

2002
Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia.
    The hematology journal : the official journal of the European Haematology Association, 2000, Volume: 1, Issue:4

    Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Idarubicin; Life Tables; Male; Melphalan; Mercaptopurine; Middle Aged; Neoplasm Proteins; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Retrospective Studies; Teniposide; Transplantation, Autologous; Treatment Outcome; Vincristine

2000
Unusual implantation site of a port-a-cath system via the right femoral vein.
    Journal of cancer research and clinical oncology, 2002, Volume: 128, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Catheterization, Central Venous; Catheters, Indwelling; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Mediastinal Neoplasms; Melphalan; Podophyllotoxin; Radiography; Thrombosis; Transplantation, Autologous

2002
Long-term results (12 years) of high-dose therapy in 127 patients with de novo multiple myeloma.
    Leukemia, 2002, Volume: 16, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Female; Humans; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Prednisone; Survival Rate; Time Factors; Transplantation, Autologous; Vincristine

2002
Acute myocardial ischemia after high-dose therapy with BEAM regimen.
    Bone marrow transplantation, 2002, Volume: 30, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Immunoblastic Lymphadenopathy; Melphalan; Middle Aged; Myocardial Ischemia; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous

2002
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.
    Blood, 2002, Nov-01, Volume: 100, Issue:9

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclosporine; Cytarabine; Data Collection; Etoposide; Female; Follow-Up Studies; Graft Enhancement, Immunologic; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2002
Vanishing corneal epithelial crystals following thalidomide induced resolution of myeloma related paraproteinaemia.
    The British journal of ophthalmology, 2002, Volume: 86, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Corneal Diseases; Cyclophosphamide; Doxorubicin; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Paraproteinemias; Thalidomide; Visual Acuity

2002
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
    Blood, 2002, Dec-15, Volume: 100, Issue:13

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cohort Studies; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Europe; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hodgkin Disease; Humans; Immunosuppressive Agents; Life Tables; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Proportional Hazards Models; Salvage Therapy; Survival Analysis; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2002
[High-dose chemotherapy with autologous bone marrow transplantation in children with high-risk malignant neoformations].
    Voprosy onkologii, 2002, Volume: 48, Issue:3

    Topics: Adolescent; Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carboplatin; Carmustine; Child; Child, Preschool; Cytarabine; Dacarbazine; Data Interpretation, Statistical; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Hodgkin Disease; Humans; Infant; Lymphoma, Non-Hodgkin; Male; Melphalan; Podophyllotoxin; Rhabdomyosarcoma; Sarcoma, Ewing; Sex Factors; Statistics, Nonparametric; Time Factors; Transplantation, Autologous; Vinblastine

2002
High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Cytokines; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; L-Lactate Dehydrogenase; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Prednisone; Prognosis; Radiotherapy, Adjuvant; Remission Induction; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine

2003
[Bacteremia due to Capnocytophaga spp.: two cases].
    Enfermedades infecciosas y microbiologia clinica, 2003, Volume: 21, Issue:3

    Topics: 4-Quinolones; Aged; Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Capnocytophaga; Carmustine; Combined Modality Therapy; Cytarabine; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacterial Infections; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Transplantation Conditioning

2003
[Foliculitis in a patient with Hodkins disease].
    Enfermedades infecciosas y microbiologia clinica, 2003, Volume: 21, Issue:2

    Topics: Adult; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Combined Modality Therapy; Cytarabine; Dacarbazine; Dermatomycoses; Dexamethasone; Doxorubicin; Etoposide; Folliculitis; Hodgkin Disease; Humans; Itraconazole; Malassezia; Male; Melphalan; Opportunistic Infections; Vinblastine

2003
BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2003, Volume: 9, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Etoposide; Female; Graft Survival; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome

2003
Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells.
    International journal of cancer, 2003, Jul-10, Volume: 105, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Base Pair Mismatch; Carmustine; Checkpoint Kinase 1; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA Adducts; DNA Damage; DNA Repair; DNA, Neoplasm; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; G1 Phase; Glutathione; Humans; Melphalan; Metallothionein; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Protein Kinases; Tumor Cells, Cultured

2003
A hybrid form of myeloid/NK-cell acute leukemia and myeloid/NK-cell precursor acute leukemia.
    Human pathology, 2003, Volume: 34, Issue:5

    Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; CD2 Antigens; Cytarabine; Flow Cytometry; Humans; Immunophenotyping; Killer Cells, Natural; Leukemia, Lymphoid; Male; Melphalan; Podophyllotoxin

2003
Testicular plasmacytoma with bone dissemination without medullary plasmacytosis.
    Annals of hematology, 2003, Volume: 82, Issue:8

    Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Humans; Male; Melphalan; Plasma Cells; Plasmacytoma; Prednisone; Skull Neoplasms; Testicular Neoplasms; Tomography, X-Ray Computed; Vincristine

2003
A mathematical model for reconstitution of granulopoiesis after high dose chemotherapy with autologous stem cell transplantation.
    Journal of mathematical biology, 2003, Volume: 47, Issue:2

    Topics: Adult; Algorithms; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Cell Differentiation; Cell Division; Computer Simulation; Cytarabine; Dose-Response Relationship, Drug; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Granulocytes; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Kinetics; Leukocytes, Mononuclear; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Models, Biological; Myelopoiesis; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Transplantation, Autologous

2003
Construction of a dual beam heated infrared cell.
    Journal of the Optical Society of America, 1953, Volume: 43, Issue:6

    Topics: Carmustine; Etoposide; Melphalan; Spectrophotometry

1953
[Some improvements to our technic of cross beam centering by moulded apparatus].
    Journal de radiologie, d'electrologie & archives d'electricite medicale, 1953, Volume: 34, Issue:5-6

    Topics: Carmustine; Cytarabine; Etoposide; Humans; Melphalan; Radiotherapy

1953
[Utilization of contiguous orthogonal beams in the treatment of semi-deep-seated tumors].
    Journal de radiologie, d'electrologie & archives d'electricite medicale, 1953, Volume: 34, Issue:5-6

    Topics: Carmustine; Etoposide; Humans; Melphalan; Neoplasms

1953
Influence of beam trypsin inhibitors on thromboplastic properties of trypsin and hypochlorite-treated trypsin.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1954, Volume: 86, Issue:3

    Topics: Carmustine; Etoposide; Hypochlorous Acid; Melphalan; Thromboplastin; Trypsin; Trypsin Inhibitors

1954
Convergent beam roentgen tube.
    The American journal of roentgenology, radium therapy, and nuclear medicine, 1955, Volume: 73, Issue:1

    Topics: Carmustine; Cytarabine; Etoposide; Humans; Melphalan; Radiotherapy

1955
[The principle of convergent beam irradiation and the effects of a modified spacer tube].
    Strahlentherapie, 1954, Volume: 94, Issue:4

    Topics: Carmustine; Melphalan; Radiation; Radiology

1954
[Determination of the mean guide beam in pendulum radiation].
    Strahlentherapie, 1954, Volume: 95, Issue:1

    Topics: Carmustine; Etoposide; Humans; Melphalan; Radiation; Radiotherapy

1954
[The effects of changed spacer tubes of the convergent beam irradiator].
    Strahlentherapie, 1954, Volume: 95, Issue:2

    Topics: Carmustine; Etoposide; Humans; Inhalation Spacers; Melphalan; Radiotherapy

1954
Preliminary experiences with a 50 gram converging beam radium unit.
    The American journal of roentgenology, radium therapy, and nuclear medicine, 1955, Volume: 74, Issue:4

    Topics: Carmustine; Cytarabine; Etoposide; Melphalan; Radium

1955
Some measurements of scattered radiation from roentgen diagnostic beams.
    Acta radiologica, 1956, Volume: 46, Issue:5

    Topics: Carmustine; Etoposide; Melphalan; Radiation; X-Rays

1956
[Contribution to the study of convergence beam radiotherapy].
    Journal belge de radiologie, 1956, Volume: 39, Issue:5

    Topics: Carmustine; Etoposide; Humans; Melphalan; Neoplasms; Radiotherapy

1956
Cobalt 60 beam therapy: some impressions after five years.
    Canadian Medical Association journal, 1957, Aug-15, Volume: 77, Issue:4

    Topics: Carmustine; Cobalt; Cobalt Radioisotopes; Etoposide; Humans; Melphalan; Neoplasms; Radioactivity

1957
Limitation of the primary beam in chest radiography.
    Radiography, 1957, Volume: 23, Issue:273

    Topics: Carmustine; Etoposide; Humans; Melphalan; Radiography, Thoracic

1957
[Technic of moving beam therapy in cancer of esophagus].
    Strahlentherapie, 1957, Volume: 103, Issue:2

    Topics: Carmustine; Esophageal Neoplasms; Humans; Melphalan; Neoplasms; Radiotherapy

1957
[Exact focus adjustment in moving-beam irradiation].
    Strahlentherapie, 1957, Volume: 104, Issue:2

    Topics: Adaptation, Psychological; Carmustine; Etoposide; Humans; Melphalan; Radiotherapy

1957
[Centering of the beam in pendulum cyclotherapy and in convergent pendulum cyclotherapy].
    Journal de radiologie, d'electrologie & archives d'electricite medicale, 1958, Volume: 39, Issue:4

    Topics: Carmustine; Cytarabine; Etoposide; Melphalan; Radiotherapy

1958
Cobalt beam therapy for bursitis.
    Mississippi Valley medical journal (Quincy, Ill), 1958, Volume: 80, Issue:6

    Topics: Bursitis; Carmustine; Cobalt; Cobalt Radioisotopes; Melphalan; Radioactivity

1958
The relative biological effectiveness of external beams of ionizing radiations.
    Progress in radiation therapy, 1958, Volume: 1

    Topics: Carmustine; Etoposide; Humans; Melphalan; Radiation Effects; Radiation, Ionizing; Relative Biological Effectiveness

1958
Off-focus radiation: its significance to the roentgenographic results when a narrow beam of rays is used in roentgenography.
    Annales medicinae internae Fenniae. Supplementum, 1959, Volume: 48, Issue:Supp 28

    Topics: Carmustine; Humans; Melphalan; Radiation; Radiography; Research

1959
[Stratigraphy with thick and thin layers in various changes of the beam direction].
    Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 1961, Volume: 94

    Topics: Carmustine; Cytarabine; Etoposide; Melphalan; Radiography

1961
Beam flatteners for a teletherapy unit.
    Journal of the Canadian Association of Radiologists, 1961, Volume: 12

    Topics: Carmustine; Cytarabine; Equipment and Supplies; Etoposide; Humans; Melphalan; Radiotherapy

1961
[Isodoses in moving beam therapy].
    Strahlentherapie, 1962, Volume: 117

    Topics: Carmustine; Etoposide; Humans; Melphalan; Radiotherapy

1962
Oblique variation of cross-table lateral (horizontal beam) myelography.
    Journal of neurosurgery, 1962, Volume: 19

    Topics: Carmustine; Etoposide; Intervertebral Disc Displacement; Melphalan; Myelography; Spinal Cord

1962
A method of multilead D.C. registration on the one-beam oscilloscope by the chopping technique.
    Physiologia bohemoslovenica, 1961, Volume: 10

    Topics: Carmustine; Cytarabine; Etoposide; Humans; Melphalan; Oscillometry

1961
A beam directing caliper for tangential radiation therapy.
    The American journal of roentgenology, radium therapy, and nuclear medicine, 1955, Volume: 73, Issue:5

    Topics: Carmustine; Humans; Melphalan; Radiotherapy

1955
Moving beam irradiation in orthovoltage radiotherapy.
    The Journal of the Egyptian Medical Association, 1962, Volume: 45

    Topics: Carmustine; Cytarabine; Etoposide; Humans; Melphalan; Radiotherapy

1962
Treatment of lymphoma relapses after allogeneic hematopoietic stem cell transplantation with intensive chemotherapy followed by infusion of hematopoietic stem cell from the original donor.
    Annals of hematology, 2003, Volume: 82, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Neutropenia; Recurrence; Remission Induction; Thrombocytopenia; Tomography, X-Ray Computed; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome

2003
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Nov-15, Volume: 21, Issue:22

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Safety; Salvage Therapy; Survival Rate; Transplantation, Autologous; Treatment Outcome

2003
A new roentgen-ray beam director for precision radiation therapy.
    The American journal of roentgenology and radium therapy, 1951, Volume: 65, Issue:1

    Topics: Carmustine; Etoposide; Melphalan; X-Ray Therapy

1951
Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy.
    British journal of haematology, 2004, Volume: 125, Issue:5

    Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Salvage Therapy; Treatment Outcome

2004
High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
    Bone marrow transplantation, 2004, Volume: 34, Issue:7

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Length of Stay; Lymphoma; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2004
A long-term follow-up of 33 patients with non-Hodgkin's lymphoma who received the BEAM high-dose intensification regimen with cytokine support only and no transplant.
    Leukemia, 2004, Volume: 18, Issue:10

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug Therapy, Combination; Erythropoietin; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Survival Rate; Time Factors

2004
Venous thromboembolism after high-dose chemotherapy in a patient with Hodgkin's lymphoma receiving the new oral contraceptive ethinylestradiol and drospirenone ("Yasmine").
    Bone marrow transplantation, 2005, Volume: 35, Issue:1

    Topics: Adult; Androstenes; Angiography; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Contraceptives, Oral, Synthetic; Cytarabine; Etoposide; Female; Hodgkin Disease; Humans; Immunotherapy; International Normalized Ratio; Lynestrenol; Melphalan; Mineralocorticoid Receptor Antagonists; Risk; Risk Factors; Time Factors; Venous Thrombosis; Warfarin

2005
Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life.
    Blood, 2005, Mar-15, Volume: 105, Issue:6

    Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Humans; Male; Melphalan; Middle Aged; Multiple Sclerosis; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Quality of Life; Radiography; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2005
Effect of pre-transplant cumulative doses of chemotherapeutic drugs on early and long-term hematological recovery after autologous bone-marrow transplantation for lymphoma.
    Haematologica, 2005, Volume: 90, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow; Bone Marrow Transplantation; Carmustine; Chemotherapy, Adjuvant; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma; Male; Melphalan; Middle Aged; Multivariate Analysis; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous

2005
[Autologous stem-cell transplantations in children with non-Hodgkin lymphomas].
    Przeglad lekarski, 2004, Volume: 61 Suppl 2

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Melphalan; Podophyllotoxin; Poland; Retrospective Studies; Survival Analysis; Time Factors; Transplantation, Autologous; Treatment Outcome

2004
[Use of dexamethasone in treatment of high- and low-grade non-Hodgkin's lymphoma].
    Voprosy onkologii, 2004, Volume: 50, Issue:6

    Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etoposide; Humans; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Treatment Outcome

2004
Mini-BEAM and autologous hematopoietic stem-cell transplant for treatment of post-transplant lymphoproliferative disorders.
    American journal of hematology, 2005, Volume: 79, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Lymphoproliferative Disorders; Male; Melphalan; Middle Aged; Salvage Therapy; Transplantation, Autologous; Transplants

2005
A phase Ib clinical trial of PV701, a milk-derived protein extract, for the prevention and treatment of oral mucositis in patients undergoing high-dose BEAM chemotherapy.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2005, Volume: 11, Issue:7

    Topics: Adult; Aged; Animals; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cattle; Complex Mixtures; Cytarabine; Dose-Response Relationship, Drug; Female; Growth Substances; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Milk; Mouth Mucosa; Mouthwashes; Podophyllotoxin; Stomatitis

2005
Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation.
    Leukemia & lymphoma, 2005, Volume: 46, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Medical Oncology; Melphalan; Middle Aged; Prednisolone; Prognosis; Recurrence; Remission Induction; Stem Cell Transplantation; Transplantation, Autologous; Vincristine

2005
Occurrence of multiple myeloma 13 years after Hodgkin's disease: chance or consequence?
    Annals of hematology, 2005, Volume: 84, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carmustine; Combined Modality Therapy; Cyclophosphamide; Female; Hodgkin Disease; Humans; Melphalan; Multiple Myeloma; Neoplasms, Second Primary; Prednisone; Procarbazine; Vincristine; Whole-Body Irradiation

2005
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
    Oncology reports, 2005, Volume: 14, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Epirubicin; Etoposide; Female; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mitoxantrone; Multiple Myeloma; Odds Ratio; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Recurrence; Remission Induction; Salvage Therapy; Time Factors; Transplantation Conditioning; Treatment Outcome

2005
Successful autologous peripheral blood stem cell harvest and transplant in a patient with cold agglutinins.
    Bone marrow transplantation, 2006, Volume: 37, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cryoglobulins; Cytarabine; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Transplantation, Autologous

2006
Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation
    Cancer, 2006, Jan-15, Volume: 106, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cytarabine; Deoxycytidine; Dexamethasone; Disease Progression; Disease-Free Survival; Etoposide; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Prognosis; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome

2006
Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-centre analysis over a 12-year period.
    Annals of hematology, 2006, Volume: 85, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Remission Induction; Retrospective Studies; Transplantation, Autologous

2006
Prophylaxis of central venous catheter-related thrombosis with minidose warfarin in patients treated with high-dose chemotherapy and peripheral-blood stem-cell transplantation: retrospective analysis of 228 cancer patients.
    American journal of hematology, 2006, Volume: 81, Issue:1

    Topics: Administration, Oral; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Catheterization, Central Venous; Cytarabine; Female; Hemorrhage; Humans; Male; Melphalan; Neoplasms; Peripheral Blood Stem Cell Transplantation; Platelet Count; Podophyllotoxin; Retrospective Studies; Risk Factors; Transplantation, Homologous; Venous Thrombosis; Warfarin

2006
Higher incidence of chemotherapy induced oral mucositis in females: a supplement of multivariate analysis to a randomized multicentre study.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2006, Volume: 14, Issue:9

    Topics: Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Humans; Incidence; Male; Melphalan; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Oral Ulcer; Peripheral Blood Stem Cell Transplantation; Predictive Value of Tests; Randomized Controlled Trials as Topic; Risk Factors; Severity of Illness Index; Sex Factors; Stomatitis; Transplantation, Autologous

2006
Treatment options in relapsed or refractory Hodgkin disease patients: the mini-BEAM regimen does exist too.
    British journal of haematology, 2006, Volume: 134, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug Administration Schedule; Etoposide; Hodgkin Disease; Humans; Melphalan; Recurrence; Salvage Therapy

2006
Prolonged remission in a case of Richter's transformation of B-cell chronic lymphocytic leukaemia following adoptive immunotherapy.
    Bone marrow transplantation, 2006, Volume: 38, Issue:6

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cell Transformation, Neoplastic; Cyclophosphamide; Cytarabine; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Transfusion; Melphalan; Podophyllotoxin; Prednisone; Remission Induction; Rituximab; Time Factors; Vincristine

2006
Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study.
    American journal of hematology, 2007, Volume: 82, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Hodgkin Disease; Humans; Ifosfamide; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Prospective Studies; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation, Autologous; Vinblastine; Vinorelbine

2007
Autologous peripheral blood stem cell transplantation for severe multiple sclerosis.
    International journal of hematology, 2006, Volume: 84, Issue:3

    Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Diarrhea; Disease-Free Survival; Female; Hematopoietic Stem Cell Mobilization; Humans; Liver Diseases; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Mucositis; Multiple Sclerosis; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous

2006
Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus I.V. melphalan.
    Annals of hematology, 2007, Volume: 86, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carmustine; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Infusions, Intravenous; Male; Melphalan; Mexico; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation, Autologous; Treatment Outcome

2007
Fatal leukoencephalopathy after reduced-intensity allogeneic stem cell transplantation.
    Onkologie, 2007, Volume: 30, Issue:1-2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclosporine; Demyelinating Diseases; Fatal Outcome; Female; Humans; Immunosuppressive Agents; Melphalan; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risk Assessment; Stem Cell Transplantation; Vidarabine

2007
Factors influencing engraftment in autologous peripheral hematopoetic stem cell transplantation (PBSCT).
    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2007, Volume: 36, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Component Removal; Carmustine; Cytarabine; Disease-Free Survival; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Humans; Kinetics; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Retrospective Studies; Time Factors; Transplantation Conditioning; Transplantation, Autologous

2007
[What is your diagnosis? Neutropenic colitis (neutropenic typhlitis)].
    Praxis, 2007, Jan-24, Volume: 96, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cecum; Colon; Combined Modality Therapy; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Tomography, X-Ray Computed; Typhlitis

2007
Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma.
    Pediatric blood & cancer, 2008, Volume: 50, Issue:3

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biliary Atresia; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunocompromised Host; Immunosuppressive Agents; Liver Transplantation; Lymphoma, T-Cell, Peripheral; Lymphoproliferative Disorders; Melphalan; Mesna; Postoperative Complications; Prednisone; Radiotherapy, Adjuvant; Transplantation, Autologous; Vidarabine; Vincristine

2008
Dexa-BEAM as salvage therapy in patients with primary refractory aggressive non-Hodgkin lymphoma.
    Leukemia & lymphoma, 2007, Volume: 48, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Survival Rate; Transplantation, Autologous

2007
Palifermin and palmar-plantar erythrodysesthesia.
    British journal of haematology, 2007, Volume: 136, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug Hypersensitivity; Female; Fibroblast Growth Factor 7; Foot Dermatoses; Hand Dermatoses; Humans; Lymphoma, B-Cell; Melphalan; Middle Aged; Mitogens; Podophyllotoxin

2007
High-dose therapy and autologous stem cell transplantation for Hodgkin's lymphoma in relapse or failure after initial chemotherapy : results of the Centre National de Greffe de Moelle Osseuse de Tunis.
    La Tunisie medicale, 2007, Volume: 85, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cytarabine; Data Interpretation, Statistical; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Follow-Up Studies; Hodgkin Disease; Humans; Melphalan; Neoplasm Staging; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2007
[Transdermal fentanyl in treating severe painful mucositis caused by autologous hematopoietic stem cell transplantation].
    Ai zheng = Aizheng = Chinese journal of cancer, 2007, Volume: 26, Issue:4

    Topics: Administration, Cutaneous; Adolescent; Adult; Analgesics, Opioid; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Fentanyl; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mucositis; Pain; Pain Measurement; Podophyllotoxin; Quality of Life; Transplantation, Homologous; Young Adult

2007
A second autologous transplant may be efficacious in selected patients with Hodgkin's lymphoma relapsing after a previous autograft.
    Leukemia & lymphoma, 2007, Volume: 48, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Podophyllotoxin; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous

2007
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
    Haematologica, 2007, Volume: 92, Issue:5

    Topics: Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Data Collection; Disease-Free Survival; Etoposide; Female; France; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2007
Refractory multiple myeloma treated with homoharringtonine: report of two cases.
    Annals of hematology, 2007, Volume: 86, Issue:12

    Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carmustine; Cyclophosphamide; Dexamethasone; Doxorubicin; Harringtonines; Homoharringtonine; Humans; Male; Melphalan; Multiple Myeloma; Oxides; Prednisone; Remission Induction; Salvage Therapy; Thalidomide; Vincristine; Vindesine

2007
Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients.
    Bone marrow transplantation, 2007, Volume: 40, Issue:7

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cohort Studies; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Multivariate Analysis; Neoplasm Staging; Podophyllotoxin; Prognosis; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Survival Analysis; Treatment Outcome

2007
BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.
    Annals of hematology, 2008, Volume: 87, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Retrospective Studies; Survival Rate; Transplantation, Autologous

2008
[Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
    Deutsche medizinische Wochenschrift (1946), 2007, Volume: 132, Issue:33

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Lymph Nodes; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Prednisone; Procarbazine; Remission Induction; Rituximab; Treatment Outcome; Vinblastine; Vincristine

2007
High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jan-10, Volume: 26, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease Progression; Etoposide; Female; Humans; Immunoblastic Lymphadenopathy; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Transplantation Conditioning; Treatment Outcome

2008
Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Europe; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Lymphoma, Non-Hodgkin; Male; Medical Audit; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Prospective Studies; Research Design; Risk Assessment; Risk Factors; Stomatitis; Transplantation Conditioning; Transplantation, Autologous

2008
Transient global amnesia associated with the infusion of DMSO-cryopreserved autologous peripheral blood stem cells.
    Haematologica, 2008, Volume: 93, Issue:3

    Topics: Adult; Alkalosis, Respiratory; Amnesia, Retrograde; Amnesia, Transient Global; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Confusion; Cryoprotective Agents; Cytarabine; Dacarbazine; Dexamethasone; Dimethyl Sulfoxide; Doxorubicin; Etoposide; Hippocampus; Hodgkin Disease; Humans; Hyperventilation; Ifosfamide; Magnetic Resonance Imaging; Male; Melphalan; Paresthesia; Peripheral Blood Stem Cell Transplantation; Salvage Therapy; Vinblastine; Vision Disorders

2008
Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma.
    British journal of haematology, 2008, Volume: 141, Issue:2

    Topics: Acute Disease; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Retrospective Studies; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome

2008
Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Disease Progression; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Time Factors; Transplantation, Autologous; Treatment Outcome

2008
Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Female; Graft Survival; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Retrospective Studies; Severity of Illness Index; Stem Cell Transplantation; Transplantation, Autologous

2008
Keratinocyte growth factor is effective in the prevention of intestinal mucositis in patients with hematological malignancies treated with high-dose chemotherapy and autologous hematopoietic SCT: a video-capsule endoscopy study.
    Bone marrow transplantation, 2008, Volume: 42, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capsule Endoscopy; Carmustine; Cytarabine; Female; Fibroblast Growth Factor 7; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Intestinal Diseases; Male; Melphalan; Middle Aged; Mucositis; Podophyllotoxin; Transplantation, Autologous

2008
Heterogeneity of human glioblastoma: glutathione-S-transferase and methylguanine-methyltransferase.
    Cancer investigation, 2008, Volume: 26, Issue:6

    Topics: Alkylating Agents; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Proliferation; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; DNA Replication; Dose-Response Relationship, Drug; Enzyme Inhibitors; Ethacrynic Acid; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioblastoma; Glutathione S-Transferase pi; Glutathione Transferase; Guanine; Humans; Melphalan; Promoter Regions, Genetic; Tumor Suppressor Proteins

2008
Myelomatous meningitis.
    European journal of haematology, 2008, Volume: 81, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Female; Humans; Melphalan; Meningoencephalitis; Multiple Myeloma; Supratentorial Neoplasms

2008
Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
    British journal of haematology, 2008, Volume: 143, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carmustine; Chi-Square Distribution; Cohort Studies; Cytarabine; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Length of Stay; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Mucositis; Recurrence; Risk; Statistics, Nonparametric; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2008
The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT.
    Bone marrow transplantation, 2009, Volume: 43, Issue:2

    Topics: Adult; Aged; Analgesics, Opioid; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Humans; Length of Stay; Lymphoma, Non-Hodgkin; Male; Medical Audit; Melphalan; Middle Aged; Multiple Myeloma; Prospective Studies; Risk Factors; Stem Cell Transplantation; Stomatitis; Transplantation Conditioning

2009
Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT.
    Bone marrow transplantation, 2009, Volume: 43, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Carmustine; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Lymphoproliferative Disorders; Male; Melphalan; Middle Aged; Neutropenia; Prospective Studies; Risk Factors; Rituximab; Vidarabine; Young Adult

2009
The development of a beam-walking test and its use in measuring development of balance in children.
    Research quarterly, 1947, Volume: 18, Issue:4

    Topics: Carmustine; Child; Cytarabine; Etoposide; Growth and Development; Melphalan; Walking

1947
High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma.
    Leukemia & lymphoma, 2008, Volume: 49, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Drug Evaluation; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Retrospective Studies; Thiotepa; Transplantation, Autologous

2008
Pseudo-bowel obstruction due to varicella zoster virus infection after autologous stem cell transplantation.
    American journal of hematology, 2009, Volume: 84, Issue:2

    Topics: Acyclovir; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Carmustine; Cisplatin; Colitis; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Herpes Zoster; Herpesvirus 3, Human; Humans; Immunocompromised Host; Immunoglobulins, Intravenous; Intestinal Pseudo-Obstruction; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Postoperative Complications; Prednisolone; Rituximab; Transplantation, Autologous; Vincristine; Virus Activation

2009
delta-Aminolevulinate dehydratase activity and oxidative stress during melphalan and cyclophosphamide-BCNU-etoposide (CBV) conditioning regimens in autologous bone marrow transplantation patients.
    Pharmacological research, 2009, Volume: 59, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Biomarkers; Bone Marrow Transplantation; Carmustine; Case-Control Studies; Cyclophosphamide; Etoposide; Humans; Lipid Peroxidation; Male; Melphalan; Middle Aged; Oxidative Stress; Porphobilinogen Synthase; Reactive Oxygen Species; Sulfhydryl Compounds; Transplantation Conditioning; Transplantation, Autologous

2009
Mass selection of ions from beams using waveform isolation in radiofrequency quadrupoles.
    Analytical chemistry, 2009, Mar-01, Volume: 81, Issue:5

    Topics: Carmustine; Cytarabine; Ions; Mass Spectrometry; Mathematics; Melphalan; Radio Waves; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry

2009
Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2009, Volume: 17, Issue:10

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mucositis; Multiple Myeloma; Neoplasms; Severity of Illness Index; Whole-Body Irradiation; Young Adult

2009
Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.
    Leukemia & lymphoma, 2009, Volume: 50, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Neoplasms, Second Primary; Retrospective Studies; Risk Factors; Salvage Therapy; Transplantation, Autologous; Whole-Body Irradiation; Young Adult

2009
pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation.
    Leukemia & lymphoma, 2009, Volume: 50, Issue:8

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Neoplasm Proteins; Phosphorylation; Phosphotyrosine; Podophyllotoxin; Prednisone; Prognosis; Prospective Studies; Protein Processing, Post-Translational; STAT3 Transcription Factor; Transplantation, Autologous; Tumor Suppressor Protein p53; Vincristine

2009
Autologous stem cell transplantation for Hodgkin's lymphoma: results and prognostic factors in 51 high-risk patients.
    Advances in clinical pathology : the official journal of Adriatic Society of Pathology, 2002, Volume: 6, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Italy; Lymph Nodes; Male; Melphalan; Middle Aged; Prognosis; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult

2002
The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.
    European journal of haematology, 2010, Volume: 84, Issue:3

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Organoplatinum Compounds; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Topotecan; Transplantation, Autologous; Vidarabine; Vinblastine; Vincristine

2010
Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian society of hematology.
    American journal of hematology, 2010, Volume: 85, Issue:2

    Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Hematology; Humans; Italy; Lymphoma, Non-Hodgkin; Melphalan; Podophyllotoxin; Practice Guidelines as Topic; Recurrence; Societies, Medical; Time Factors

2010
Immunomagnetic selection of CD34(+) cells carried out in cryopreserved cell concentrates from a paediatric patient affected with non-Hodgkin lymphoma.
    Transfusion medicine (Oxford, England), 2010, Aug-01, Volume: 20, Issue:4

    Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Preservation; Carmustine; Cell Count; Child, Preschool; Combined Modality Therapy; Cryopreservation; Cyclophosphamide; Cytarabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunomagnetic Separation; Leukapheresis; Lymphoma, Large-Cell, Anaplastic; Melphalan; Podophyllotoxin; Recurrence; Transplantation, Autologous

2010
Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma.
    International journal of radiation oncology, biology, physics, 2010, Oct-01, Volume: 78, Issue:2

    Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Dose Fractionation, Radiation; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Manitoba; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Radiation Pneumonitis; Retrospective Studies; Survival Rate; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation; Young Adult

2010
Absorption measurements for broad beams of 1 and 2 megavolt roentgen rays.
    The American journal of roentgenology and radium therapy, 1946, Volume: 56, Issue:6

    Topics: Carmustine; Etoposide; Melphalan; Radiation; X-Rays

1946
A double-beam, percent transmission recording infra-red spectrophotometer.
    Journal of the Optical Society of America, 1947, Volume: 37, Issue:3

    Topics: Carmustine; Etoposide; Humans; Melphalan; Spectrophotometry

1947
High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2010, Volume: 16, Issue:6

    Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Kaplan-Meier Estimate; Male; Melphalan; Multiple Sclerosis; Treatment Outcome

2010
Simultaneous bilateral spontaneous pneumothorax following high-dose chemotherapy and bone marrow transplantation for mantle cell lymphoma without evidence of pulmonary disease.
    International journal of clinical oncology, 2010, Volume: 15, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Humans; Lung Diseases; Lymphoma, Mantle-Cell; Melphalan; Middle Aged; Pneumothorax; Prognosis

2010
Association of HSV reactivation and pro-inflammatory cytokine levels with the severity of stomatitis after BEAM chemotherapy and autologous SCT.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2011, Volume: 19, Issue:8

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Cytokines; Female; Herpesvirus 1, Human; Herpesvirus 2, Human; Hodgkin Disease; Humans; Inflammation; Interleukin-1; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Saliva; Severity of Illness Index; Statistics as Topic; Stem Cell Transplantation; Stomatitis; Transplantation, Autologous; Tumor Necrosis Factor-alpha; Young Adult

2011
Further interferometric studies with mica; new multiple-beam fringes and their application.
    Proceedings of the Royal Society of Medicine, 1946, Jul-09, Volume: 186, Issue:Ser A

    Topics: Aluminum Silicates; Carmustine; Humans; Interferometry; Melphalan

1946
Absorption measurements for broad beams of 1- and 2-million-volt X-rays.
    Journal of research of the National Bureau of Standards, 1946, Volume: 37, Issue:2

    Topics: Carmustine; Cytarabine; Etoposide; Melphalan; X-Rays

1946
Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation.
    Oncology, 2010, Volume: 79, Issue:1-2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hodgkin Disease; Humans; Length of Stay; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neutropenia; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Polyethylene Glycols; Recombinant Proteins; Severity of Illness Index; Thrombocytopenia; Time Factors; Transplantation, Autologous; Treatment Outcome; Young Adult

2010
Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Carmustine; Clinical Trials, Phase I as Topic; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Immunoconjugates; Lymphoma, Large-Cell, Anaplastic; Maintenance Chemotherapy; Male; Melphalan; Prednisone; Remission Induction; Stem Cell Transplantation; Transplantation, Autologous; Vincristine

2012
[Pulmonary Langerhans histiocytosis and Hodgkin's lymphoma].
    Revue des maladies respiratoires, 2011, Volume: 28, Issue:7

    Topics: Accidents, Traffic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bronchioles; Carmustine; Cytarabine; Dacarbazine; Doxorubicin; Etoposide; Female; Histiocytosis, Langerhans-Cell; Hodgkin Disease; Humans; Ifosfamide; Incidental Findings; Lung Diseases; Lymphatic Diseases; Marijuana Smoking; Melphalan; Methylprednisolone; Mitoguazone; Remission Induction; Smoking; Tomography, X-Ray Computed; Vinblastine; Vindesine; Vinorelbine; Young Adult

2011
Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy.
    Haematologica, 2012, Volume: 97, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation, Autologous; Young Adult

2012
Improving survival in patients with transformed B cell non Hodgkin lymphoma: consolidation with ⁹⁰Yttrium ibritumomab tiuxetan-BEAM and autologous stem cell transplantation.
    British journal of haematology, 2012, Volume: 157, Issue:3

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Melphalan; Radioimmunotherapy; Treatment Outcome; Yttrium Radioisotopes

2012
Single-dose pegylated-filgrastim versus daily filgrastim after high-dose chemotherapy and autologous stem cell transplantation for lymphoid malignancies: delayed platelets recovery?
    Blood transfusion = Trasfusione del sangue, 2012, Volume: 10, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Carmustine; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Platelet Count; Podophyllotoxin; Polyethylene Glycols; Recombinant Proteins; Recovery of Function; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous

2012
Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL.
    British journal of haematology, 2012, Volume: 157, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Recurrence; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Young Adult

2012
[Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transp
    Vnitrni lekarstvi, 2012, Volume: 58, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cladribine; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Histiocytosis, Langerhans-Cell; Humans; Lenalidomide; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Thalidomide; Transplantation, Autologous

2012
[First case in Spain of bacteremia by Methylobacterium thiocyanatum from Hickmann catheter in an immunosuppressed patient with Hodgkin's lymphoma].
    Medicina clinica, 2012, Dec-01, Volume: 139, Issue:13

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Biofilms; Bleomycin; Carmustine; Catheter-Related Infections; Central Venous Catheters; Cisplatin; Cross Infection; Cytarabine; Dacarbazine; Deoxycytidine; Doxorubicin; Drug Resistance, Multiple, Bacterial; Equipment Contamination; Etoposide; Female; Gemcitabine; Gram-Negative Bacterial Infections; Hodgkin Disease; Humans; Immunocompromised Host; Melphalan; Methylobacterium; Prednisone; Ribotyping; Spain; Vinblastine

2012
Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation.
    Annals of hematology, 2013, Volume: 92, Issue:1

    Topics: Adult; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Carmustine; Cisplatin; Combined Modality Therapy; Compassionate Use Trials; Crizotinib; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Humans; Immunoconjugates; Lymphocyte Transfusion; Lymphoma, Large-Cell, Anaplastic; Male; Melphalan; Molecular Targeted Therapy; Neoplasm Proteins; Peripheral Blood Stem Cell Transplantation; Prednisone; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Remission Induction; Respiration, Artificial; Respiratory Insufficiency; Transplantation, Homologous; Vincristine

2013
Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphoma.
    British journal of haematology, 2012, Volume: 159, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Carmustine; Cytarabine; Female; HIV Seropositivity; Humans; Male; Melphalan; Middle Aged; Podophyllotoxin; Stem Cell Transplantation; Transplantation, Autologous

2012
Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse.
    Haematologica, 2013, Volume: 98, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Time Factors; Transplantation, Autologous; Treatment Outcome

2013
Long-term clinical and molecular remissions in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Podophyllotoxin; Remission Induction; Stem Cell Transplantation; Time Factors; Transplantation, Autologous; Treatment Outcome

2013
DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
    Annals of hematology, 2013, Volume: 92, Issue:8

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Disease-Free Survival; Drug Evaluation; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphoma, T-Cell, Peripheral; Male; Melphalan; Middle Aged; Mucositis; Peripheral Blood Stem Cell Transplantation; Preoperative Care; Retrospective Studies; Salvage Therapy; Transplantation, Autologous; Treatment Outcome; Young Adult

2013
Contribution of involved-field radiotherapy to survival in patients with relapsed or refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
    American journal of clinical oncology, 2015, Volume: 38, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Carmustine; Chemoradiotherapy; Cisplatin; Cohort Studies; Cytarabine; Dacarbazine; Dexamethasone; Doxorubicin; Etoposide; Female; Hodgkin Disease; Humans; Ifosfamide; Male; Mediastinal Neoplasms; Melphalan; Methylprednisolone; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome; Vinblastine; Young Adult

2015
Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte ant
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:8

    Topics: Adult; Age Factors; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Retrospective Studies; Risk Factors; Survival Analysis; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2013
Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience.
    Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Risk Factors; Transplantation, Autologous; Young Adult

2013
Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma.
    Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Prognosis; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult

2013
Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:11

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, T-Cell; Male; Melphalan; Middle Aged; Remission Induction; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous

2013
Impact of palifermin on intestinal mucositis of HSCT recipients after BEAM.
    Bone marrow transplantation, 2014, Volume: 49, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; C-Reactive Protein; Carmustine; Case-Control Studies; Cytarabine; Etoposide; Febrile Neutropenia; Female; Fibroblast Growth Factor 7; Hematopoietic Stem Cell Transplantation; Humans; Inflammation; Intestinal Mucosa; Male; Melphalan; Middle Aged; Mucositis; Neutropenia; Young Adult

2014
Seven-year follow-up of allogeneic transplant using BCNU, etoposide, cytarabine and melphalan chemotherapy in patients with Hodgkin lymphoma after autograft failure: importance of minimal residual disease.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease Progression; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Neoplasm Recurrence, Local; Neoplasm, Residual; Prognosis; Transplantation, Autologous; Transplantation, Homologous; Treatment Failure; Treatment Outcome

2014
Conditioning regimen with BCNU, etoposide, cytarabine and melphalan plus amifostine for outpatient autologous stem cell transplant: feasibility and outcome in 97 patients with lymphoma.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:7

    Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Outpatients; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2014
Single-agent rituximab for primary CNS lymphoma during pregnancy as a bridge to definitive management.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Mar-01, Volume: 32, Issue:7

    Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain; Carmustine; Central Nervous System Neoplasms; Cesarean Section; Cytarabine; Dexamethasone; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Magnetic Resonance Imaging; Melphalan; Methotrexate; Podophyllotoxin; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Rituximab; Transplantation, Autologous; Treatment Outcome

2014
Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:11

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult

2014
Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure.
    British journal of haematology, 2014, Volume: 165, Issue:3

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Rituximab; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2014
The lymphoma-like polychemotherapy regimen "Dexa-BEAM" in advanced and extramedullary multiple myeloma.
    Annals of hematology, 2014, Volume: 93, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Disease-Free Survival; Drug Therapy, Combination; Etoposide; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Registries; Retrospective Studies

2014
Radium beam therapy.
    The Journal of the Faculty of Radiologists. Faculty of Radiologists (Great Britain), 1951, Volume: 3, Issue:2

    Topics: Carmustine; Etoposide; Humans; Melphalan; Neoplasms; Radium

1951
Radium beam therapy at the Western Infirmary of Glasgow, 1938-48.
    The Journal of the Faculty of Radiologists. Faculty of Radiologists (Great Britain), 1951, Volume: 3, Issue:2

    Topics: Carmustine; Etoposide; Humans; Melphalan; Neoplasms; Radium

1951
Cobalt 60 beam therapy.
    The Journal of the Faculty of Radiologists. Faculty of Radiologists (Great Britain), 1954, Volume: 5, Issue:4

    Topics: Carmustine; Cobalt; Cobalt Radioisotopes; Etoposide; Melphalan; Radioactivity; Radiotherapy

1954
Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial.
    Leukemia & lymphoma, 2015, Volume: 56, Issue:1

    Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Consolidation Chemotherapy; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Etoposide; Female; Humans; Induction Chemotherapy; Lymphoma, B-Cell; Male; Melphalan; Methylprednisolone; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Podophyllotoxin; Prednisone; Prognosis; Rituximab; Treatment Outcome; Vincristine; Young Adult

2015
Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
    British journal of haematology, 2014, Volume: 165, Issue:4

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Child; Chlorambucil; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Disease-Free Survival; Doxorubicin; Epirubicin; Etoposide; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Kaplan-Meier Estimate; Melphalan; Multicenter Studies as Topic; Neoplasm Staging; Prednisolone; Prednisone; Procarbazine; Prognosis; Radiotherapy, Adjuvant; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vinblastine; Vincristine

2014
ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma.
    Annals of hematology, 2014, Volume: 93, Issue:10

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cisplatin; Combined Modality Therapy; Cytarabine; Drug Evaluation; Etoposide; Febrile Neutropenia; Female; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Male; Melphalan; Methylprednisolone; Middle Aged; Radionuclide Imaging; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome; Young Adult

2014
BEAM-conditioned autologous SCT improves the quality of response in Waldenström's macroglobulinaemia and lymphoplasmacytic lymphoma: a single centre's 10-year experience.
    Bone marrow transplantation, 2014, Volume: 49, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Humans; Lymphoma; Male; Melphalan; Middle Aged; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Waldenstrom Macroglobulinemia

2014
Palifermin reduces infection rate and hyperfibrinogenemia in patients treated with high-dose chemotherapy based on beam or BU-thiothepa.
    Bone marrow transplantation, 2014, Volume: 49, Issue:9

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Female; Fibrinogen; Fibroblast Growth Factor 7; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infection Control; Male; Melphalan; Middle Aged; Podophyllotoxin; Retrospective Studies; Thiotepa; Transplantation Conditioning; Young Adult

2014
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
    Journal of the National Cancer Institute, 2014, Volume: 106, Issue:8

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melphalan; Nitriles; Nitrogen Mustard Compounds; Prednisone; Primary Myelofibrosis; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Rituximab; Vincristine

2014
Risk of premature menopause after treatment for Hodgkin's lymphoma.
    Journal of the National Cancer Institute, 2014, Volume: 106, Issue:9

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Child; Child, Preschool; Cytarabine; Dacarbazine; Doxorubicin; England; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Infant; Melphalan; Menopause, Premature; Ovary; Poisson Distribution; Proportional Hazards Models; Radiotherapy Dosage; Risk Assessment; Surveys and Questionnaires; Vinblastine; Wales; Young Adult

2014
The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:11

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Remission Induction; Rituximab; Stem Cell Transplantation; Transplantation, Autologous; Whole-Body Irradiation; Young Adult

2014
Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma.
    Hematological oncology, 2016, Volume: 34, Issue:1

    Topics: Allografts; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Carmustine; Combined Modality Therapy; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Lenalidomide; Liposomes; Male; Melphalan; Polyethylene Glycols; Recurrence; Remission Induction; Salvage Therapy; Thalidomide; Transplantation, Autologous; Young Adult

2016
Carmustine, etoposide, cytarabine, and melphalan (BEAM)-campath allogeneic stem cell transplantation for aggressive non-hodgkin lymphoma: an analysis of outcomes from the British Society of Blood and Marrow Transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:3

    Topics: Adolescent; Adult; Alemtuzumab; Allografts; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Autografts; Bone Marrow Transplantation; Carmustine; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Registries; Societies, Medical; Survival Rate; Transplantation Conditioning; United Kingdom

2015
High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma.
    Leukemia & lymphoma, 2015, Volume: 56, Issue:8

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease Progression; Etoposide; Female; France; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Prognosis; Recurrence; Retrospective Studies; Survival Analysis; Transplantation, Autologous; Treatment Outcome

2015
Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myeloablative Agonists; Registries; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Whole-Body Irradiation

2015
Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgk
    Leukemia & lymphoma, 2015, Volume: 56, Issue:11

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Matched-Pair Analysis; Melphalan; Middle Aged; Neoplasm Staging; Podophyllotoxin; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult

2015
Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's Witnesses.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, May-20, Volume: 33, Issue:15

    Topics: Adult; Aged; Aminocaproic Acid; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Carmustine; Combined Modality Therapy; Cyclophosphamide; Erythropoietin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hemoglobins; Humans; Iron; Jehovah's Witnesses; Lymphoma; Male; Melphalan; Middle Aged; Multiple Myeloma; Recurrence; Stem Cell Transplantation; Transplantation, Autologous; Vitamin K 1; Young Adult

2015
Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2016, Volume: 22, Issue:3

    Topics: Aged; Antiemetics; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Morpholines; Nausea; Podophyllotoxin; Prospective Studies; Retrospective Studies; Transplantation Conditioning; Vomiting

2016
Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:11

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cytarabine; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Risk; Rituximab; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous

2015
BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
    Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous

2015
Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA).
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Carmustine; Creatinine; Cytarabine; Disease-Free Survival; Etoposide; Female; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prognosis; Proportional Hazards Models; Prospective Studies; Risk Assessment; Serum Albumin; Transplantation, Autologous; Treatment Outcome; Young Adult

2015
Recovery of mucosal-associated invariant T cells after myeloablative chemotherapy and autologous peripheral blood stem cell transplantation.
    Clinical and experimental medicine, 2016, Volume: 16, Issue:4

    Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carmustine; Cytarabine; Female; Hematologic Neoplasms; Humans; Male; Melphalan; Middle Aged; Mucosal-Associated Invariant T Cells; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Transplantation Conditioning; Transplantation, Autologous

2016
Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT.
    Bone marrow transplantation, 2016, Volume: 51, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cytarabine; Disease-Free Survival; Female; Humans; Lymphoma; Male; Melphalan; Middle Aged; Podophyllotoxin; Registries; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Thiotepa

2016
LACE versus BEAM conditioning in relapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy.
    International journal of hematology, 2016, Volume: 103, Issue:3

    Topics: Adolescent; Adult; Autografts; Carmustine; Child; Child, Preschool; Cohort Studies; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lomustine; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multicenter Studies as Topic; Retrospective Studies; Survival Rate; Transplantation Conditioning; Young Adult

2016
Fertility in premenopausal women post autologous stem cell transplant with BEAM conditioning.
    European journal of haematology, 2016, Volume: 97, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Fertility; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Podophyllotoxin; Premenopause; Retrospective Studies; Transplantation Conditioning; Young Adult

2016
Thymic Activity and T Cell Repertoire Recovery after Autologous Hematopoietic Stem Cell Transplantation Preceded by Myeloablative Radiotherapy or Chemotherapy.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cyclophosphamide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Podophyllotoxin; Thymus Gland; Transplantation Conditioning; Whole-Body Irradiation

2016
Clinical assessment of 252Californium neutron intracavitary brachytherapy using a two-channel Y applicator combined with external beam radiotherapy for endometrial cancer.
    Clinics (Sao Paulo, Brazil), 2016, Volume: 71, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Californium; Carmustine; Combined Modality Therapy; Cytarabine; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Melphalan; Middle Aged; Podophyllotoxin; Survival Rate; Treatment Outcome

2016
Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis.
    Journal of cancer research and clinical oncology, 2016, Volume: 142, Issue:6

    Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Graft vs Host Disease; Hodgkin Disease; Humans; Male; Melphalan; Recurrence; Transplantation Conditioning; Young Adult

2016
Long-term follow-up of (90)Y-ibritumomab-tiuxetan ((90)YIT) in the conditioning of autologous hematopoietic transplantation for indolent and mantle cell lymphomas in a single French center.
    Bone marrow transplantation, 2016, Volume: 51, Issue:8

    Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Follow-Up Studies; France; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Radioimmunotherapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Yttrium Radioisotopes

2016
A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM.
    Bone marrow transplantation, 2016, Volume: 51, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lomustine; Lymphoma; Male; Melphalan; Middle Aged; Retrospective Studies; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous

2016
Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 66

    Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Hodgkin Disease; Humans; Male; Melphalan; Neoplasm Metastasis; Podophyllotoxin; Programmed Cell Death 1 Receptor; Remission Induction; Salvage Therapy

2016
Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective.
    Cancer medicine, 2016, Volume: 5, Issue:11

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cost-Benefit Analysis; Cytarabine; Female; Follow-Up Studies; Health Care Costs; Hematopoietic Stem Cell Transplantation; Humans; Infections; Kaplan-Meier Estimate; Lymphoma; Male; Melphalan; Middle Aged; Outpatients; Podophyllotoxin; Transplantation Conditioning; Transplantation, Autologous; Young Adult

2016
Cryptococcus laurentii diarrhea post hematopoietic stem cell transplant.
    Transplant infectious disease : an official journal of the Transplantation Society, 2017, Volume: 19, Issue:2

    Topics: Administration, Intravenous; Administration, Oral; Adult; Antibiotic Prophylaxis; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carmustine; Cryptococcosis; Cryptococcus; Cytarabine; Diarrhea; Etoposide; Feces; Fluconazole; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Melphalan; Microbial Sensitivity Tests; Transplantation Conditioning; Transplantation, Autologous; Voriconazole

2017
Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party.
    Bone marrow transplantation, 2017, Volume: 52, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Case-Control Studies; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Radioimmunotherapy; Retrospective Studies; Rituximab; Survival Analysis; Transplantation, Autologous; Young Adult

2017
Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation

2018
High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma.
    Bone marrow transplantation, 2018, Volume: 53, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous

2018
Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome.
    Bone marrow transplantation, 2018, Volume: 53, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Comorbidity; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Neoplasm Staging; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2018
A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Case-Control Studies; Cytarabine; Diarrhea; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Young Adult

2018
Abdominal computed tomography angiography in post-transplantation sinusoidal obstruction syndrome associated with R-DHAOX/BEAM toxicity.
    British journal of haematology, 2018, Volume: 180, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Computed Tomography Angiography; Cytarabine; Dexamethasone; Etoposide; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Organoplatinum Compounds; Syndrome

2018
Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Gene Rearrangement; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Melphalan; Middle Aged; Prednisone; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Rituximab; Transplantation, Autologous; Treatment Outcome; Vincristine

2018
Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens.
    Annals of hematology, 2018, Volume: 97, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Carmustine; Cost-Benefit Analysis; Cyclophosphamide; Cytarabine; Etoposide; Female; HIV Infections; Humans; Ifosfamide; Male; Melphalan; Methotrexate; Middle Aged; Neoplasm Staging; Retrospective Studies; Rituximab; Survival Analysis

2018
BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant.
    Bone marrow transplantation, 2018, Volume: 53, Issue:8

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Young Adult

2018
Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant.
    Annals of hematology, 2018, Volume: 97, Issue:7

    Topics: Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brentuximab Vedotin; Carmustine; Cisplatin; Combined Modality Therapy; Cytarabine; Dacarbazine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Kaplan-Meier Estimate; Male; Melphalan; Methylprednisolone; Middle Aged; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Vinblastine; Young Adult

2018
Systematic patient involvement for homebased outpatient administration of complex chemotherapy in acute leukemia and lymphoma.
    British journal of haematology, 2018, Volume: 181, Issue:5

    Topics: Acute Disease; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Humans; Infusion Pumps; Leukemia; Lymphoma; Male; Melphalan; Middle Aged; Outpatients; Podophyllotoxin

2018
Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis.
    Bone marrow transplantation, 2019, Volume: 54, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Carmustine; Chimerism; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Primary Myelofibrosis; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2019
High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity.
    European journal of haematology, 2018, Volume: 101, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult

2018
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Italy; Lymphoma; Male; Melphalan; Middle Aged; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous

2018
High-dose Benda-EAM versus BEAM in patients with relapsed/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation.
    Bone marrow transplantation, 2019, Volume: 54, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Recurrence; Transplantation Conditioning; Transplantation, Autologous; Young Adult

2019
Nasoethmoidal Intestinal-Type Adenocarcinoma Treated with Cetuximab: Role of Liquid Biopsy and BEAMing in Predicting Response to Anti-Epidermal Growth Factor Receptor Therapy.
    The oncologist, 2019, Volume: 24, Issue:3

    Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cetuximab; Cytarabine; ErbB Receptors; Etoposide; Genotype; Humans; Intestinal Neoplasms; Liquid Biopsy; Male; Melphalan; Paranasal Sinus Neoplasms

2019
BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Podophyllotoxin; Transplantation Conditioning; Young Adult

2019
BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas.
    Bone marrow transplantation, 2019, Volume: 54, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous; Young Adult

2019
Severe renal insufficiency is not an absolute pitfall to autologous stem cell transplantation with BeEAM (bendamustine, etoposide, cytarabine, melphalan) conditioning regimen.
    Bone marrow transplantation, 2019, Volume: 54, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cytarabine; Humans; Lymphoma, B-Cell; Male; Melphalan; Podophyllotoxin; Renal Insufficiency; Severity of Illness Index; Stem Cell Transplantation; Transplantation Conditioning

2019
A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma.
    Hematological oncology, 2019, Volume: 37, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease Progression; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Induction Chemotherapy; International Cooperation; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies; Transplantation Conditioning; Treatment Outcome

2019
Herpes zoster after autologous haematopoietic stem cell transplantation without antiviral prophylaxis.
    British journal of haematology, 2019, Volume: 186, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Herpes Zoster; Humans; Melphalan; Middle Aged; Podophyllotoxin

2019
Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia.
    Annals of hematology, 2019, Volume: 98, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Podophyllotoxin; Survival Rate; Transplantation, Autologous; Waldenstrom Macroglobulinemia

2019
Does a neutropenic diet reduce adverse outcomes in patients undergoing chemotherapy?
    European journal of cancer care, 2020, Volume: 29, Issue:1

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bacterial Infections; Carmustine; Chemotherapy-Induced Febrile Neutropenia; Cytarabine; Diet Therapy; Enterocolitis, Neutropenic; Female; Hematologic Neoplasms; Humans; Idarubicin; Male; Melphalan; Middle Aged; Neutropenia; Podophyllotoxin; Retrospective Studies; South Australia

2020
BEAM-Modified Conditioning Therapy with Cisplatin+Dexamethasone Instead of Carmustine Prior to Autologous Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Hodgkin and Non-Hodgkin Lymphoma.
    Annals of transplantation, 2019, Oct-22, Volume: 24

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cytarabine; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Podophyllotoxin; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Young Adult

2019
Hemophagocytic relapsed intramedullary plasmacytoma.
    International journal of hematology, 2020, Volume: 111, Issue:6

    Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Bortezomib; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Magnetic Resonance Imaging; Melphalan; Neoplasm Recurrence, Local; Oligopeptides; Plasmacytoma; Positron Emission Tomography Computed Tomography; Pubic Bone; Rare Diseases; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome

2020
Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma.
    American journal of hematology, 2020, Volume: 95, Issue:4

    Topics: Adrenal Cortex Hormones; Allografts; Anemia, Aplastic; Antibodies, Monoclonal, Humanized; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Deoxycytidine; Doxorubicin; Etoposide; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Oxaliplatin; Prednisone; Recurrence; Rituximab; Salvage Therapy; Transplantation, Autologous; Vincristine

2020
Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers.
    Bone marrow transplantation, 2020, Volume: 55, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Melphalan; Prospective Studies; Retrospective Studies; Transplantation, Autologous

2020
Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation.
    Cancer, 2020, 05-15, Volume: 126, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Multivariate Analysis; Registries; Rituximab; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Failure; Treatment Outcome; Young Adult

2020
Intravascular Large B-Cell Lymphoma: Clinical and Histopathologic Findings.
    The Yale journal of biology and medicine, 2020, Volume: 93, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Blood Vessels; Carmustine; Cyclophosphamide; Cytarabine; Delayed Diagnosis; Diagnosis, Differential; Doxorubicin; Early Detection of Cancer; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Podophyllotoxin; Prednisone; Rituximab; Skin; Skin Neoplasms; Treatment Outcome; Vincristine

2020
BEAM conditioning regimen ensures better progression-free survival compared with TEAM but not with FEAM in lymphoma patients undergoing autologous stem cell transplant.
    Leukemia & lymphoma, 2020, Volume: 61, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Progression-Free Survival; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous

2020
Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation.
    Bone marrow transplantation, 2021, Volume: 56, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Retrospective Studies; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2021
Substituting carmustine for lomustine is safe and effective in the treatment of relapsed or refractory Lymphoma-a retrospective study from the BSBMT (BEAM versus LEAM).
    Bone marrow transplantation, 2021, Volume: 56, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Humans; Lomustine; Lymphoma; Melphalan; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous

2021
Comparison of Mitoxantrone-Melphalan and BEAM Conditioning Regimens in Patients with Lymphoma.
    Hematology/oncology and stem cell therapy, 2022, Dec-23, Volume: 15, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Mitoxantrone; Transplantation Conditioning; Transplantation, Autologous

2022
Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma.
    Blood advances, 2021, 06-22, Volume: 5, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Transplantation, Autologous

2021
BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy.
    Scientific reports, 2021, 07-07, Volume: 11, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Neoplasms; Outcome Assessment, Health Care; Podophyllotoxin; Transplantation Conditioning

2021
Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma.
    Bone marrow transplantation, 2022, Volume: 57, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cytarabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Rituximab; Transplantation Conditioning; Transplantation, Autologous; Young Adult

2022
Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study.
    Bone marrow transplantation, 2022, Volume: 57, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Melphalan; Retrospective Studies; Transplantation, Autologous

2022
B-Cell Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.
    Neurology(R) neuroimmunology & neuroinflammation, 2022, Volume: 9, Issue:6

    Topics: Antilymphocyte Serum; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin G; Immunoglobulin Heavy Chains; Melphalan; Multiple Sclerosis

2022
Impact of Implementing a Bendamustine-Based Conditioning Regimen on Outcomes of Autologous Stem Cell Transplantation in Lymphoma while Novel Cellular Therapies Emerge.
    Transplantation and cellular therapy, 2023, Volume: 29, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Retrospective Studies; Transplantation, Autologous

2023
Bridging advanced myeloma patients to subsequent treatments and clinical trials with classical chemotherapy and stem cell support.
    Bone marrow transplantation, 2023, Volume: 58, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multiple Myeloma; Transplantation, Autologous

2023
Long-Term Results with Thiotepa-Containing Conditioning Regimens for Autologous Stem Cell Transplantation.
    Transplantation and cellular therapy, 2023, Volume: 29, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Retrospective Studies; Thiotepa; Transplantation, Autologous

2023